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ABSTRACT 
Public health strategies to tackle HIV-1 epidemics in a variety of national settings need to be 
aware of the factors involved in transmission of infections. There is support in the literature 
for the hypothesis that individuals with recent infection may contribute disproportionately to 
onward transmission due to the high viral load and lack of infection status associated with 
this stage. This thesis sets out to further explore this risk group, and to develop methods to 
monitor its impact on epidemics.  
Two epidemic settings, the United Kingdom and Kumasi, Ghana, were investigated 
using molecular epidemiological techniques to assess the role of individuals with recent 
infection in the formation of transmission clusters. A classifier of HIV-1 infection length was 
developed based upon the proportion of mixed nucleotides within consensus pol gene 
sequences and applied to phylogenies constructed using viral sequences obtained from each 
cohort. In the Ghanaian setting, the performance of the nucleotide ambiguity classifier was 
compared to an antibody avidity based measure of infection length, to gauge the usefulness of 
both approaches in a sub-Saharan setting. In order to more fully explore the complexity of 
intra-host HIV-1 quasi-species dynamics in the early phase of infection, a well defined cohort 
of UK-based individuals, some with multiple pre-treatment time points, had their virus deep-
sequenced and analysed using a subpopulation reconstruction approach. 
The proportion of recent infections identified within the UK HIV-1 epidemic by the 
classifier agreed well with previous studies. Application of the classifier to UK-wide 
phylogenies revealed disproportionate linkage of recently infected individuals to clusters 
across subtypes. Phylogenetic analysis of the Kumasi cohort did not reveal a highly clustered 
epidemic. Transmitted drug resistance was present at a level consistent with reports 
elsewhere in West Africa. Comparison of the antibody avidity based measure of infection 
length with the nucleotide ambiguity classifier indicated both markers co-segregate together, 
but produced differing estimates of the proportion of recent infections in the cohort. Deep-
sequencing of recently infected individuals revealed some individuals may have been 
infected with more than one viral subpopulation, whilst others appeared to have been infected 
with a single subpopulation. 
This work supports the utility of a consensus sequence based measure of infection 
length in assessing the role of recently infected individuals in driving epidemics on a large 
scale. Such a measure will need further refinement and validation depending on the setting 
used, but presents a potentially useful biomarker that could be used in conjunction with other 
clinical parameters. Deep-sequencing of HIV-1 in recently infected individuals points to the 
quasi-species complexity that exists between and within individuals, and the subpopulation 
reconstruction approach taken in this work reveals dynamics at play which have the potential 
to impact on vaccine design and molecular epidemiological monitoring of epidemics.  
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General introduction 
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1 General introduction 
1.1 HIV 
In mid-1981 a number of homosexual men in New York and Los Angeles presented with 
unusual opportunistic infections such as Pneumocystis carinii pneumonia and aggressive 
Kaposi’s sarcoma (Friedman-Kien, Laubenstein et al. 1981; Gottlieb, Schroff et al. 1981). All 
individuals were found to have a deficit in the CD4
+
 T cell subset of their immune system. 
Similar presentations in previously healthy individuals were reported in other risk groups and 
in other countries around the world, particularly in the Caribbean, Western Europe and Africa 
(Masur, Michelis et al. 1982; Rozenbaum, Coulaud et al. 1982; Vilaseca, Arnau et al. 1982; 
Clumeck, Mascart-Lemone et al. 1983; Harris, Small et al. 1983; Pitchenik, Fischl et al. 
1983). By late 1982 the term Acquired Immune Deficiency Syndrome (AIDS) was being 
used to describe the condition, and by 1983, evidence that the condition was linked to a 
retrovirus was published (Barré-Sinoussi, Chermann et al. 1983). The virus we now refer to 
as Human Immunodeficiency Virus was finally linked to AIDS in 1984 (Levy, Hoffman et al. 
1984). 
The Human Immunodeficiency Virus can be divided into two major types, HIV-1 and 
HIV-2. HIV-2, although spread in the same way as HIV-1, seems to be less virulent and 
transmissible, and hence is not as widespread as HIV-1 in the global epidemic (De Cock, 
Adjorlolo et al. 1993). HIV-1 and HIV-2 are lentiviruses within the retrovirus family that 
infects human immune system cells such as T-helper cells, macrophages and dendritic cells, 
and if left untreated lead to Acquired Immune Deficiency Syndrome (AIDS) through 
destruction of the adaptive immune system, making the body vulnerable to opportunistic 
infections such as tuberculosis, and cancers such as Kaposi's sarcoma and AIDS-related non-
Hodgkin's lymphoma (Embretson, Zupancic et al. 1993; Fauci 1993). Perhaps circulating in 
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humans as early as 1910 (Sharp and Hahn 2011), an estimated 35.3 million people were 
living with HIV (type 1 and 2) world-wide in 2012, with AIDS related deaths having reached 
an estimated 36 million deaths over that period (UNAIDS 2013; UNAIDS 2013). 
1.2 Biology of HIV-1 
1.2.1 Structure of the virion 
Mature HIV-1 virions are variable in size, and have been shown to have diameters ranging 
between 125 and 145nm (Briggs, Wilk et al. 2003; Briggs, Grünewald et al. 2006). They are 
comprised of an envelope of host cell derived lipid bi-layer containing an average of 14 
(range 4-35) trimer molecules of the transmembrane gp41 and gp120 glycoproteins used for 
host cell binding and fusion (Klein and Bjorkman 2010). Within the envelope is a capsid 
(p24) core organised into a fullerene-type cone structure made up of a sheet of ~1500 capsid 
molecules organised into a hexagonal lattice comprised of approximately 250 hexameric 
rings organised into a cylindrical conformation, capped at the wide end by 7 pentameric 
rings, and at the narrow end by 5 rings (Arhel 2010; Jiang, Ablan et al. 2011). The core 
contains further structural proteins derived from the Gag and Gag-Pol polyproteins, namely: 
matrix (p17), associated with the inner virion membrane; nucleocapsid (p7), which coats the 
RNA molecules and has a role in RNA dimerization and packaging (Kafaie, Song et al. 
2008); and p6, which enables Vpr incorporation into the mature virion (Kondo, Mammano et 
al. 1995); together with the accessory proteins Vif, Vpr and Nef, and the protease, reverse 
transcriptase and integrase enzymes proteins and two positive strands of the HIV-1 RNA 
genome (Fig 1.1.). 
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Figure 1.1. Taken from (Frankel and Young 1998). The genomic and virion structure of 
HIV-1. 
 
1.2.2 Genome 
The HIV-1 genome is an RNA positive strand genome of approximately 9.7kb in length, 
containing 15 genes. Six of these genes encode structural proteins (Table 1.1), four of which 
are derived from the Gag polyprotein p55 to form the core structural proteins: matrix (p17), 
capsid (p24), nucleocapsid (p7) and p6; with the remaining two being derived from the Env 
gp160 polyprotein to form the envelope structural proteins: surface (gp120) and 
transmembrane (gp41) (Frankel and Young 1998) (Fig 1.2.). Three enzymes are derived from 
the Gag-Pol precursor polyprotein; protease, reverse transcriptase and integrase. The 
remaining six genes encode accessory proteins: three of which are found in the HIV-1 virion 
(Vif, Vpr, Nef), two of which are the regulatory proteins Tat and Rev, and one of which is 
Vpu, which has an indirect role in virion assembly. The HIV-1 genome is flanked at both 
ends by Long Terminal Repeat (LTR) regions approximately 640bp in length, which are 
essential for integration of the viral genome into the host DNA, and contain elements that 
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interact with a variety of potential host cell transcription factors (Berkhout, Gatignol et al. 
1990; Pereira, Bentley et al. 2000). 
 
Table 1.1. List of HIV-1 genes, gene products, and functions.  
GAG
MAtrix p17 Targets Gag and Gag-Pol precursor polyproteins to the plasma membrane prior to viral 
Aids incorporation of env glycoproteins with long cytoplasmic tails into viral particles
Facilitates infection of nondividing cell types, principally macrophages
CApsid p24 Forms the core of the virus particle
NucleoCapsid p7 Coats the genomic RNA inside the virion core (protects it from nucleases and compacts it within 
the core)
p6 p6 Important for incorporation of Vpr during viral assembly
POL
PRotease PR Cleaves polyprotein at several sites to produce MA, CA, NC, and p6 proteins from Gag and PR, 
RT, and IN proteins from Pol
Reverse Transcriptase RT Catalyzes both RNA-dependent and DNA-dependent DNA polymerization reactions and 
contains an RNase H domain that cleaves the RNA portion of RNA-DNA hybrids generated 
during the reaction
INtegrase IN Catalyzes a series of reactions to integrate the viral genome into a host chromosome
ENV
SUrface gp120 Binds CD4 with high affinity and plays key role in attachment to specific cell surface receptors 
(three gp120s and gp41s combine in a trimer of heterodimers to form the envelope spike)
TransMembrane gp41 Mediates fusion between the viral and cellular membranes following receptor binding
Regulatory
Trans-Activator of 
Transcription
TAT Binds to TAR RNA element and activates transcription initiation and elongation from the LTR 
promoter
Regulator of Expression 
of Virion proteins
REV Binds to Rev Responsive Element and promotes nuclear export, stabilization, and utilization of 
the viral mRNAs containing RRE
Accessory
Viral Infectivity Factor VIF Promotes infectivity but not production of viral particles by disrupting the antiviral activity of 
the human virus restriction factor APOBEC
Viral Protein R VPR Incorporated into the virion and may aid in targeting nuclear import of preintegration 
complexes, cell growth arrest, transactivation of cellular genes, and induction of cellular 
Viral Protein U VPU Plays a role in i) degradation of CD4 in the endoplasmic reticulum, and ii) enhancement of 
virion release from the plasma membrane of HIV-1-infected cells
NEgative Factor NEF Downregulates CD4, the primary viral receptor, and MHC class I molecules, increases viral 
infectivity
HIV Genomic Structural 
Elements
Long Terminal Repeat LTR DNA sequence flanking the genome of integrated proviruses that contains important 
regulatory regions, such as transcription initiation and polyadenylation sites
TransActivation 
Response element
TAR Target sequence for viral transactivation, the binding site for Tat protein and cellular proteins
Rev Responsive Element RRE RNA element encoded within the env region of HIV-1 which contains a high affinity site for REV
HIV Genes and Gene Products
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1.2.3 Replication cycle 
HIV-1 targets three main host immune cell types: CD4
+
 T-lymphocytes, macrophages and 
dendritic cells (Boggiano and Littman 2007; Lackner and Veazey 2007). This somewhat 
limited tropism may be due to the cell surface receptors that are targeted by the virion – the 
CD4 receptor and a co-receptor that is usually the chemokine receptor CCR5 in early 
infection, although the CXCR4 co-receptor is often targeted later in HIV-1 infection as the 
virus evolves. Each trimer on the surface of the virion is comprised of three heterodimers of 
the surface gp120 glycoprotein non-covalently linked to the transmembrane gp41 
glycoprotein, which is in turn anchored to the viral envelope membrane. 
 
 
Fig 1.2. Taken from (Rambaut, Posada et al. 2004). Life-cycle of HIV-1. 
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Binding: The CD4 receptor binds between the inner and outer domains of the gp120 molecule 
(Briz, Poveda et al. 2006) and leads to a conformational change involving the V1/V2 and V3 
variable loops, which leads to the exposure of the co-receptor binding site (Clapham and 
McKnight 2001; Engelman and Cherepanov 2012) (Fig 1.2.).  
Fusion: Once the co-receptor has been bound, the N-terminal domain of gp41 is exposed, and 
the hydrophobic fusion peptide is inserted into the host cell membrane (Briz, Poveda et al. 
2006) and a series of conformational rearrangements between trimerized N-terminal and C-
terminal heptad repeat motifs generates a six helix bundle, which causes a hairpin structure in 
the gp41 molecules and the virion and host cell membranes to be brought into contact and 
fuse (Melikyan, Markosyan et al. 2000; Engelman and Cherepanov 2012). 
Uncoating: Once virion-cell fusion has occurred, the viral core is released into the cell 
interior and uncoating occurs (Fig 1.2.). The precise timing of the uncoating is still to be fully 
elucidated, with several competing models being proposed (Arhel 2010; Fassati 2012). There 
is evidence to suggest that uncoating can begin as little as 30-45 minutes post-fusion, when 
the core is released into the cytoplasm. However, there is also evidence to suggest that if 
uncoating occurs too early, reverse transcription is inhibited (Forshey, von Schwedler et al. 
2002). It also appears that initiation of reverse transcription itself has an influence on the 
timing of the uncoating process (Hulme, Perez et al. 2011). Other evidence suggests that 
uncoating does not occur close to the cell surface but takes place in a gradual, stepwise 
manner during transport of the core to the nucleus, in a process possibly instigated by 
conformational changes in the core complex as a result of the initiation of reverse 
transcription together with interactions with the host cell machinery. Another model proposes 
that uncoating does not initiate until the core has reached the nuclear membrane and reverse 
transcription is complete, whereupon the capsid lattice is disassembled and the pre-
8 
 
integration complex (PIC) is transferred across a nuclear pore into the interior of the nucleus 
(Arhel 2010). 
Integration: The pre-integration complex is made up of the double stranded reverse 
transcribed viral genomic DNA and integrase. Other proteins have also been shown to 
aggregate with the PIC, such as matrix and reverse transcriptase, but there is good evidence 
that integrase alone is necessary and sufficient to integrate viral DNA into the host genome 
(Farnet and Haseltine 1991; Bukrinsky, Sharova et al. 1993). Inside the nucleus, the PIC must 
become associated with host genomic DNA in order to integrate, and the efficiency of this 
process appears to be increased by association with the host cell transcriptional co-activator 
Lens-Epithelial-Derived Growth Factor (LEDGF/p75) (Christ and Debyser 2013), which 
helps to target the viral DNA to active transcription units within the host genome, an 
evolutionary strategy that may enable a more rapid production of viral RNA before the host 
cell is targeted for destruction by the immune system, which can occur as quickly as a few 
days after the cell is infected (Craigie and Bushman 2012). The integration reaction proceeds 
in a series of steps starting with removal of two nucleotides from the 3′ ends of the viral 
DNA, which then react with phosphodiester bonds on opposing strands of the host 
chromosomal DNA and bond with the 5′-phosphates (Craigie and Bushman 2012; Engelman 
and Cherepanov 2012). The 3′ ends of the viral DNA are subsequently joined to the host 
DNA covalently and the remaining nucleotide gaps and overhangs are repaired by host DNA 
repair machinery (Craigie and Bushman 2012). 
Transcription: The 5′ LTR region of the HIV-1 integrated provirus contains a number of 
potential transcription binding sites that can be targeted by a number of cellular transcription 
factors such as NF-κB, Sp1, and TBP (Jones and Peterlin 1994). Transcription is carried out 
by the host RNA polymerase II, but requires the trans-activator of transcription (Tat) 
accessory protein to drive elongation of the transcript. Tat binds to a highly conserved RNA 
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hairpin structure, termed the transactivation response (TAR) element, and recruits cellular 
host factors such as the human Positive Transcription Elongation Factor b (P-TEFb), which 
acts to recruit further host factors to the RNA polymerase II in order to modulate 
transcription elongation (Ott, Geyer et al. 2011). The Regulator of Expression of Virion 
proteins (Rev) protein is required to enable transport of singly spliced and unspliced HIV-1 
mRNA transcripts out of the nucleus. Initially, the first viral mRNAs produced by 
transcription are predominantly doubly spliced and code for the Tat, Rev, and Nef proteins. 
The production of the Rev protein allows singly and unspliced mRNA to be exported from 
the nucleus and translated into the additional polyproteins required for virion formation, or 
packaged into the immature virion as the complete HIV-1 genome. Export mediated by Rev 
requires the mRNA to contain a Rev Response Element (RRE), which is present as a 351bp 
sequence within the Env coding region of partially and unspliced viral mRNA (Malim, 
Hauber et al. 1989; Mann, Mikaélian et al. 1994). 
Assembly and budding: Assembly takes place at the host cell plasma membrane once all 
virion components have been translated and transported to the membrane along with the two 
capped and polyadenylated RNA genomes to be packaged inside the virion. The Gag 
structural proteins are present as the unprocessed Gag polyprotein, but this is sufficient for 
virion assembly to begin and for budding to occur. Assembly of an immature virion particle 
takes ~10 minutes on average, and budding is enabled by interaction of Gag with the 
Endosomal Sorting Complexes Required for Transport (ESCRT) machinery normally used 
during mitosis and vesicle formation (Usami, Popov et al. 2009). Once budding has occurred, 
the virion particle can mature through proteolysis of the Gag and Gag-Pol polyproteins by 
protease to form the full complement of proteins and enzymes required by the virion. The 
production of these proteins leads to major conformational changes in the virion, to produce a 
mature, fully infectious particle (Sundquist and Kräusslich 2012). 
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1.2.4 Latency and reactivation 
Even if viral replication is suppressed to below detectable levels through antiretroviral 
therapy, HIV-1 persists in the resting CD4
+
 T-cell reservoir of infected individuals as proviral 
DNA integrated into the cellular genome (Siliciano, Kajdas et al. 2003; Laird, Eisele et al. 
2013). This reservoir can remain in the body for the remainder of an infected individual’s 
lifetime because of the natural function of this immune cell subset, and can be reactivated 
into fully replication competent virus when antiretroviral drug pressure is removed (Wong, 
Hezareh et al. 1997; Chun and Fauci 2012). 
1.2.5 Cell-cell and cell-free intra-host transmission 
HIV-1 can make contact and infect host cells via two mechanisms: cell-free transmission, and 
cell-to-cell transmission. Transmission of virions across virological synapses formed between 
infected and uninfected CD4
+
 T-cells have been observed (Jolly and Sattentau 2004; Piguet 
and Sattentau 2004), and this mode of transmission could represent a more efficient 
transmission mechanism than cell-free transmission, as it leads to a concentrated targeting of 
multiple virions at one site on a donor cell, which occurs in close proximity to cell membrane 
receptors on the target cell, as opposed to diffusion of cell-free virions, with no certainty of 
encountering a suitable target cell-type (Sundquist and Kräusslich 2012). Indeed, it may be 
the case that host antiretroviral restriction factors reduce the ability of HIV-1 virions to be 
released from the host cell, instead anchoring them to the membrane in a manner which 
further promotes cell-to-cell transfer (Jolly, Booth et al. 2010). 
1.3 Natural history of infection 
1.3.1 Founding virus theory, quasi-species 
To infect a new host, HIV-1 virions must gain access and entry to the relevant target cells of 
the host immune system. The major routes for this to occur are penile-vaginal and penile-
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rectal sex, mother to child transmission, and injecting drug use. Of these, the primary route 
worldwide is vaginal-penile sex (Hladik and McElrath 2008; UNAIDS 2013). As such, it is 
the genital epithelia that present the first line of defence HIV-1 must circumvent in the 
majority of transmissions so as to establish infection. Transmission can occur both from male 
to female and female to male during vaginal-penile sex, and hence the epithelia of both the 
penis and vagina/cervix have been investigated in terms of target cell availability and 
infection rates (Haase 2010; Anderson, Politch et al. 2011). It is predominantly investigations 
of vaginal transmission using non-human primate models, together with work on individuals 
with recent infection, that has provided convincing evidence for a genetic bottleneck at the 
mucosal barrier, or soon after passing through the mucosal barrier, that results in the infection 
in the new host being founded by in some cases as few as one or two virions from the donor 
inoculum (Zhang, MacKenzie et al. 1993; Zhu, Mo et al. 1993; Keele, Li et al. 2009) (Fig 
1.3.). This may be a direct result of the mucosal barrier acting to block virion passage, or a 
consequence of other factors once the virions have overcome this initial hurdle (Boeras, 
Hraber et al. 2011; Parrish, Gao et al. 2013), although recent work casts doubt on the cervical 
mucosa being the barrier that generates the transmission bottleneck (Shen, Ding et al. 2012). 
Evidence from follow up of individuals diagnosed with early infection supports the 
hypothesis that this initially highly homogenous virus goes on to increase in diversity in a 
relatively linear manner over the first years of infection (prior to initiation of therapy) through 
host immune system pressure and the high replication and error rate of replication in HIV-1 
infection (Zhang, MacKenzie et al. 1993; Zhu, Mo et al. 1993; Shankarappa, Margolick et al. 
1999; Keele, Giorgi et al. 2008). There is limited data on the extent to which this increase in 
diversity occurs equally across the genome, and the impact co-infection and subsequent 
recombination may have on genetic diversity. The latter consideration may be important in 
the context of infections founded by multiple virions, particularly in penile-rectal sex and 
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injecting drug use associated infections, where there is good evidence the majority of 
infections are founded by more than one virion (Bar, Li et al. 2010; Li, Bar et al. 2010). In 
chapter five of this thesis, this topic is investigated using deep-sequencing (see section 1.8) in 
a cohort of patients diagnosed with early infection. 
The increase in diversity of the founding virus in early infection generates a cloud, or 
‘quasi-species’, of related but distinct viruses, These viruses can be thought of as occupying – 
and continuously exploring – a sequence space, where viruses with different mutations 
occupy different parts of this space, and have corresponding differences in fitness (Lauring 
and Andino 2010). Formal mathematical definitions of quasi-species do exist, and although it 
is debatable the extent to which these definitions are applicable to viral populations, the 
concept of a diverse but interacting swarm of viruses, under constant selective pressure by the 
host immune system and/or drug pressure, may still provide useful insights into intra-host 
viral evolution (Eigen 1971; Domingo 2002; Moya, Holmes et al. 2004; Lauring and Andino 
2010). 
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Figure 1.3. Taken from (Cohen, Shaw et al. 2011). Model for HIV-1 transmission which 
illustrates the theoretical process behind single/limited founder viruses in HIV-1 
infection. (R0 for an infection is the number of onward cases one infection generates on 
average during its infectious period in a totally susceptible population. Where R0 < 1, 
the infection tends to die out over time, where R0 > 1, the infection may become 
widespread in the population). 
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1.3.2 Viral load in blood, GALT and genital compartments 
Regardless of the route of entry into the new host, there is a period of ~10 days, termed the 
‘eclipse’ phase, when the virus replicates in the individual in the absence of symptoms, and 
no virus is detectable in the blood (Palmer, Wiegand et al. 2003; Sickinger, Jonas et al. 2008). 
HIV-1 RNA levels (“viral load”) in plasma peak in the second to third week after infection 
and then start to decline with the emergence of HIV-specific immune responses. The key 
processes and sites of initial infection and replication during this eclipse phase are still not 
completely understood. Vaginal transmission offers the most sophisticated human tissue 
explant and non-human primate models available, and it is therefore the model that is the best 
understood (Miller, Alexander et al. 1989; Miller, Li et al. 2005; Hladik and Hope 2009; 
Keele, Li et al. 2009). CD4
+
 and Langerhans cells are highly likely to be the primary targets 
of infection and replication upon immediate incursion by the virus, in both vaginal and penile 
submucosa (Cohen, Shaw et al. 2011). Replication and further infection of these target cells 
leads to rapid dissemination of the virus to lymph nodes and the gut associated lymphoid 
tissue (GALT), before spreading to other compartments and tissues. The GALT is the focus 
of the main CD4
+
 T cell loss in the initial stages of infection and throughout infection prior to 
therapy, and this loss is predominantly from the CCR5
+
 CD4
+
 T cell subset (Brenchley, 
Schacker et al. 2004). In terms of within-host compartmentalisation of the virus and onward 
transmission, there is good evidence that in early stages of infection the viral load in the male 
genital compartment lags behind the viral load in the blood, and peaks around 4 weeks post-
infection, but is controlled by around week 10, and then displays stable levels as the patient 
moves to chronic infection. In general, the viral load in the semen is lower than in the blood, 
and together with other evidence, such as discordant viral phenotype distributions and the 
lack of a strong correlation between viral RNA level in semen and CD4
+
 cell count in blood, 
points to compartmentalisation of the virus (Coombs, Speck et al. 1998; Pilcher, Shugars et 
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al. 2001), a process which is likely to be occurring in the female genital tissues also (Craigo 
and Gupta 2006). 
1.3.3 Recent and established infection 
The dynamics of early infection lead to large changes in viral load within the infected 
individual prior to reaching the relatively stable levels seen in chronic infection. Evidence 
suggests that the time taken for virions to penetrate the mucosal barrier, reach relevant cells 
and gain entry can be short, but that it may be up to a week later before the infection begins 
to spread through the lymphatic system and reach the lymph nodes and GALT (Hladik and 
McElrath 2008; Cohen, Shaw et al. 2011). Beyond this time scale the virus begins to 
disseminate through the body and to lay down the reservoir of proviral DNA that will remain 
with the patient through infection, whether viral replication is suppressed through therapy or 
not (Chun, Engel et al. 1998). The initial phase of infection can usefully be divided up into 
stages defined by various biological markers (Fiebig, Wright et al. 2003) (Fig 1.4.), although 
these stages are open to adaptation to new, more sensitive assays as they become available 
(Ananworanich, Fletcher et al. 2013). 
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Figure 1.4. Taken from (Cohen, Shaw et al. 2011). Natural history of HIV-1 infection, 
showing the Fiebig infection staging system in terms of the results of standard clinical 
laboratory tests. 
After the initial eclipse phase, the first detectable signs of HIV-1 infection, the time point 
termed Fiebig stage I, can be obtained by carrying out sensitive viral RNA detection methods 
on patient blood, generally from day 11 after infection (Fig 1.4.). Fiebig stage II is defined by 
the detectability of the p24 gag protein antigen, associated with a rise of viral load to 10000 
copies/ml and above. It is around this point in infection that peak viremia is reached, which 
can be as high as 10
7
copies/ml (Pilcher, Joaki et al. 2007), and can be linked to the severity of 
seroconversion symptoms experienced around this time (Lavreys, Baeten et al. 2002; Kelley, 
Barbour et al. 2007). Approximately 5 days later, Enzyme-Linked Immunosorbent Specific 
Assays (ELISA) can begin to detect immunoglobulin M antibodies against recombinant HIV 
antigens. Fiebig stages IV and V are defined by the results of a Western blot assay (protein 
immunoblots) that detects antibody reactivities against individual viral proteins (typically p24 
(from gag), p31 (from pol) and gp41 or gp120/160 (from env). Stage IV is defined by an 
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equivocal/indeterminate Western blot result, with stage V being an unequivocally positive 
Western blot result but p31 integrase antibody negative. The final, open-ended stage, Fiebig 
stage VI, is defined as Western blot positive and p31 integrase antibody positive (Fig 1.4.). 
The initial immune response to HIV-1 infection may be mediated by detection of viral 
specific markers by receptors evolved to detect Pathogen Associated Molecular Patterns 
(PAMPs) such as double or single stranded RNA and particular viral proteins (Mogensen, 
Melchjorsen et al. 2010). Activation of molecular pattern specific receptors, such as the Toll-
like receptors (TLR) 7 and 8, can prompt the production of immunomodulatory cytokines 
such a interferon-α and interleukin-15 (Chang and Altfeld 2010). There is also a detectable 
increase in molecular markers of cell apoptosis (Gasper-Smith, Crossman et al. 2008). The 
cytokine and chemokine surge can play a role in speeding up the dissemination of HIV-1 
infection by i) summoning immune cells to the site of infection, thereby increasing the 
number of target cells available for virion entry, and by ii) increasing inflammation in the 
infected locale, leading to a breakdown of tight junctions between epithelial cells (Chang and 
Altfeld 2010; Nazli, Chan et al. 2010). The chemokine response is likely to play a role in 
increasing the natural killer (NK) cell response in the region of infection. This cell type is 
highly heterogeneous in terms of its ability to target specific pathogens, due to differences in 
its killer-cell immunoglobulin-like receptors (KIRs), and there is evidence that individuals 
with more favourable KIRs seem to have a better ability to control HIV-1 infection (Martin, 
Gao et al. 2002; Martin, Qi et al. 2007). Initial antibodies within the adaptive immune 
response primarily target gp41, the trunk of the envelope trimer, but in a non-neutralising 
manner. CD8
+
 T cell response peaks around 1-2 weeks after peak viremia, and immediately 
leads to exploration of CTL escape mutants at various key epitope sites along the HIV-1 
genome, primarily in env and nef (McMichael, Borrow et al. 2009). 
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1.3.4 Detecting recent infection 
Of major importance in terms of onward transmission of HIV-1 within a population is the 
high viral load associated with acute HIV-1 infection prior to being brought under partial 
immune control, both in blood and genital compartments (Pilcher, Joaki et al. 2007; 
Morrison, Demers et al. 2010). This elevated viral titre, together with other factors such as 
lack of awareness of infection status, may mean that acute/recent infections account for a 
disproportionate number of onward transmissions compared to the established phase of 
infection (Jacquez, Koopman et al. 1994; Koopman, Jacquez et al. 1997; Hollingsworth, 
Anderson et al. 2008). To gain a better understanding of the incidence of HIV-1 and the role 
of recent infection in epidemics, a number of assays have been developed to detect recent 
infection in newly diagnosed individuals. These are primarily based upon measuring 
increasing levels of antibodies, such as the branched peptide antigen (BED) based capture 
Enzyme-Immuno Assay (EIA), or measurements of antigen-antibody binding strength that 
rely upon the principle of antibody hypermutation, and the corresponding maturation of 
antibody affinity to HIV-1 antigens (Parekh, Kennedy et al. 2002; Chawla, Murphy et al. 
2007; Mastro, Kim et al. 2010). Such assays are increasingly combined together with clinical 
biomarkers such as CD4
+
 cell count, into algorithms such as the Recent Infection Testing 
Algorithm used by Public Health England (Garrett, Lattimore et al. 2012) and the Serologic 
Testing Algorithm for Recent HIV Seroconversion (STARHS), developed by the US Centers 
for Disease Control and Prevention (CDC) (Janssen, Satten et al. 1998). It is important to 
note that the majority, if not all of these assays, have been developed in Western settings, and 
have been optimised predominantly on subtype B infections. As such, it is unclear to what 
extent they are immediately appropriate for use in other settings, such as sub-Saharan Africa, 
without further validation (Sakarovitch, Rouet et al. 2007). 
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A number of groups have also investigated the utility of HIV-1 sequence information 
in estimating infection length, be it using Sanger pol sequences obtained from patients as part 
of routine antiretroviral drug resistance surveillance (Kouyos, von Wyl et al. 2011; Ragonnet-
Cronin, Aris-Brosou et al. 2012; Andersson, Shao et al. 2013), or deep-sequencing data 
obtained through second-generation sequencing platforms such as 454 pyrosequencing 
(Giorgi, Funkhouser et al. 2010; Poon, McGovern et al. 2011). A further investigation of the 
use of HIV-1 sequence information to determine infection length forms chapter three of this 
thesis. 
 
1.4 Epidemiology of HIV-1 
1.4.1 Subtypes 
HIV-1 can be divided into 4 major groups, each representing a separate zoonotic transmission 
event from chimpanzees or gorillas to humans, probably in the course of bushmeat trade and 
consumption (Buonaguro, Tornesello et al. 2007; Sharp and Hahn 2011; Vallari, Holzmayer 
et al. 2011). Group M, for ‘main’, is the major group, which is responsible for the majority of 
HIV infections worldwide (Ariën, Abraha et al. 2005). Group M itself contains a diverse 
collection of HIV-1 strains, which cluster together into related clades. These 9 clades, 
labelled A–D, F–H, J and K, maintain their distinct branching patterns on phylogenetic trees 
regardless of which section of the genome is used for analysis, and have been termed 
subtypes (Fig 1.5.).  
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Figure 1.5. Group M subtype pol phylogenetic tree generated using Los Alamos Group 
M sequence reference alignment (http://www.hiv.lanl.gov/). Sub-subtypes are also 
shown. Scale bar is in nucleotide substitutions per site. 
 
Further circulating strains of HIV-1 group M have been identified that have been found to 
map to different subtype clades depending on which part of the genome is used to draw 
phylogenies (Robertson, Sharp et al. 1995) – these appear to be the result of recombination 
between different strains of virus, made possible by co-infection with two or more different 
subtypes or recombinants of HIV-1, together with the process of template swapping between 
the two RNA genomes packaged in the HIV-1 virion during reverse transcription (Onafuwa-
Nuga and Telesnitsky 2009). The HIV-1 nomenclature has been modified to take these strains 
into account, and they are termed circulating recombinant forms (CRFs) if they fulfil the 
criteria of being identified in three or more individuals not directly epidemiologically 
connected. To date, over 50 CRFs have been identified (Li, Ning et al. 2013; Foster, Ambrose 
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et al. 2014), and many more unique recombinant forms (URFs, recombinants that have only 
been identified in one or two epidemiologically unconnected individuals).  
1.4.2 Origins of HIV-1 
In terms of the diversity of HIV-1 and the distribution of URFs, Cameroon, the Republic of 
Congo, and the Democratic Republic of Congo have been found to have the highest number 
of complex forms of the virus. This fits with phylogenetic analysis of the relatedness of HIV-
1 and Simian Immunodeficiency Viruses isolated from chimpanzees and gorillas from a 
variety of locations throughout central and West Africa, that suggests the origin of the 
different HIV-1 groups is likely to be Cameroon, the Republic of Congo, and/or the 
Democratic Republic of Congo (Van Heuverswyn and Peeters 2007; Sharp and Hahn 2011). 
Further evidence suggests that the zoonotic transmission event responsible for the group M 
pandemic took place sometime around the early 1900s (Korber, Muldoon et al. 2000). It is 
possible that zoonotic transmissions of SIV to humans had taken place many times prior to 
this through exposure to chimpanzee blood products during slaughter and consumption of 
bushmeat, but that the virus was not able to replicate and transmit itself to a sufficient extent 
to allow adaptation to its new host before being removed by the host immune system 
(Peeters, Courgnaud et al. 2002; Sharp and Hahn 2011). It has been speculated that the 
development of cities such as Léopoldville/Kinshasa, and the concomitant large influx of 
works and sex workers, may have been the factor that enabled a simian immunodeficiency 
virus to be serially passed through several human hosts in quick succession, giving it the 
opportunity to adapt to the new host immune system (Locatelli and Peeters 2012). Other 
theories propose that iatrogenic practises occurring through sleep-sickness and syphilis 
vaccination programs may have been the crucial factor in enabling transmission of the 
nascent pathogen between individuals (Marx, Alcabes et al. 2001). In comparison to the 
complexity of viral forms around the geographic cradle of HIV-1 group M virus, the global 
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HIV-1 group M subtype distribution is relatively simple in its major trends, and is largely 
geographical, probably due to a combination of founder effects and differences in 
transmissibility/fitness between subtypes (Sharp and Hahn 2011) (Fig 1.6.). 
 
 
Figure 1.6. Taken from (Hemelaar, Gouws et al. 2011). Global HIV-1 subtype/CRF 
distribution 2004-2007. The surface areas of the pie charts correspond to the relative 
numbers of people living with HIV-1 in each particular region. 
 
Of importance, HIV-1 subtype B predominates in Europe and North America, where the 
resources are available to spend on research and development, but subtype B is not the most 
globally prevalent in terms of the number of individuals infected worldwide (Fig 1.6.), 
potentially leading to a mismatch in terms of the effectiveness of diagnostic assays, 
antiretroviral treatments, and vaccine designs (Apetrei, Loussert-Ajaka et al. 1996; Peeters, 
Toure-Kane et al. 2003; Geretti 2006; Geretti, Harrison et al. 2009). Some of these issues are 
encountered in chapter six of this thesis, which deals with HIV in a West African setting. 
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1.4.3 Risk groups within the UK epidemic 
In the early 1980s in the United Kingdom, the virus was initially spread within the men who 
have sex with men (MSM) community, and within networks of people who inject drugs 
(PWID), both initially subtype B virus epidemics (Robertson, Bucknall et al. 1986; 
Anonymous 1988; Brown, Lobidel et al. 1997). However, even as early as the mid 1990s, 
additional subtypes were circulating, and the epidemic was clearly involving heterosexual 
sex, and import of infections from outside of the United Kingdom (Clewley, Arnold et al. 
1996; Brown, Lobidel et al. 1997). The proportion of non-B subtypes, and the contribution to 
the epidemic from different risk groups, continued to develop in the United Kingdom, and by 
the early 2000s the majority of new diagnoses or AIDS deaths were in the heterosexual risk 
group, and of these, over three-quarters were in individuals who were probably infected in 
Africa with non-B subtypes (The UK Collaborative Group for HIV and STI Surveillance 
2007). Several lines of evidence demonstrate that the UK epidemic has experienced crossover 
between the different risk group ‘sub-epidemics’, with potential implications for clinical 
management and evolution of novel forms of the virus through recombination (Aggarwal, 
Smith et al. 2006; Fox, Castro et al. 2010), which could mirror the global increase in the 
contribution of recombinant forms to the pandemic (Hemelaar, Gouws et al. 2011). 
 
1.5 Antiretroviral management of HIV-1 infections 
1.5.1 History of drug development 
The first clinical trial of an antiretroviral drug to combat HIV-1 infection, Zidovudine, was 
carried out in 1987 (Fischl, Richman et al. 1987), followed by investigations into Didanosine, 
Stavudine and other antiretroviral compounds that all acted by inhibiting action of the reverse 
transcriptase by mimicking nucleotides and terminating synthesis of the cDNA strand of the 
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HIV-1 genome (Balzarini, Herdewijn et al. 1989; Yarchoan, Mitsuya et al. 1989). The 
effectiveness of administering these drugs individually or in dual combinations was also 
investigated (Hammer, Katzenstein et al. 1996). However, it was the addition of a third drug, 
with a different mechanism of action, that was found to have major effects on the disease 
progression of individuals infected with HIV-1 (Collier, Coombs et al. 1996; D'Aquila, 
Hughes et al. 1996; Staszewski, Miller et al. 1996; Gulick, Mellors et al. 1997; Hammer, 
Squires et al. 1997). These results introduced the era of highly active antiretroviral therapy 
(HAART), which has continued to evolve as new drugs have been developed, but the 
principle of which is to target HIV-1 with drugs that have at least two distinct mechanisms of 
action, so as to more effectively contain the ability of HIV-1 to evolve mutations that would 
allow it to escape suppression by one or two drugs (Perelson 2002; Arts and Hazuda 2012). 
1.5.2 Drug classes and mechanisms of action 
There are currently 25 drugs for the treatment of HIV-1 licensed in the European Union 
(NAM 2013). 7 of these are combination pills, containing three or more drugs, whilst the 
remainder fall into 6 categories of mechanisms, each targeting different aspects of the HIV-1 
replication cycle: Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-
nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion 
Inhibitors, CCR5 Co-receptor Antagonists, and Integrase Strand Transfer Inhibitors (INSTIs). 
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors: 
This class of antiretrovirals was the first to be developed, and acts by termination of viral 
DNA elongation (Mitsuya, Weinhold et al. 1985; Yarchoan, Weinhold et al. 1986). 
Nucleoside or nucleotide analogues enter the host cell and undergo phosphorylation by host 
kinases. These nucleotide analogues then compete with the host nucleotides for incorporation 
into the DNA chain. When a nucleotide analogue is incorporated it terminates elongation of 
25 
 
the chain due to its lack of a 3′-hydroxyl group on the deoxyribose portion of the molecule 
(Fig 1.7). Chain termination can occur during both RNA- or DNA-dependent DNA synthesis, 
interfering with production of either the forward or reverse strand of proviral DNA (Clavel 
and Hance 2004; Arts and Hazuda 2012). 
 
 
Figure 1.7. Taken from (Clavel and Hance 2004). Nucleoside or Nucleotide Reverse 
Transcriptase Inhibitor mechanism of action. 
 
Non-nucleoside Reverse Transcriptase Inhibitors: 
This class of molecule also targets the reverse transcription step of viral replication, but acts 
to inhibit the reverse transcriptase enzyme by non-competitive binding to a pocket close to 
the active site, thereby producing a conformational change in structure that reduces the 
activity of the enzyme (de Béthune 2010). 
Protease Inhibitors: 
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This class of drug aims to block cleavage of the HIV-1 polyproteins (predominantly gag-pol), 
and thereby prevent production of mature virions, by competitive binding to the protease 
enzyme. 
Entry Inhibitors: 
These can be subdivided into Fusion Inhibitors and CCR5 Co-receptor Antagonists. The 
former, of which enfuvirtide is the only currently approved member of the class, are peptide-
like molecules that block the conformational change of gp41 required to bring together and 
allow fusion of the viral envelope with the host cell membrane. The drug mimics specific 
sites within the gp41 structure (Kilby, Hopkins et al. 1998). The latter, of which maraviroc is 
the only currently approved class member, are small molecule inhibitors of CCR5 co-receptor 
binding that bind to the transmembrane region of the co-receptor causing allosteric inhibition 
of the interaction between the extracellular region of the co-receptor and the V3 region of the 
viral gp120 envelope protein. As HIV-1 can also use the CXCR4 co-receptor and 
occasionally other co-receptors for entry, it is necessary to determine the absence of CXCR4 
tropic virus prior to administering CCR5 co-receptor antagonists (Soriano, Perno et al. 2009; 
Vandekerckhove, Wensing et al. 2011). 
Integrase Strand Transfer Inhibitors: 
These compounds act to target the strand transfer reaction involved in HIV-1 proviral DNA 
integration by binding to the complex formed between integrase and the pre-integrated viral 
DNA and interfering with the integrase active site binding to the DNA molecule (Pommier, 
Johnson et al. 2005). 
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1.5.3 Triple therapy 
It is now standard to administer antiretroviral drugs to patients in combinations of usually 
three drugs, from at least two different classes. This was found early on to be more likely to 
result in long term suppression of the virus (Hammer, Katzenstein et al. 1996; Gulick, 
Mellors et al. 1997; Hammer, Squires et al. 1997). The basis for this lies in the high turnover 
of HIV-1 replication within a patient, together with the error prone nature of viral replication. 
Studies of viral populations, in combination with mathematical models of viral turnover and 
mutation rate, lead to the conclusion that the quasi-species of HIV-1 in an untreated 
individual is large enough that, statistically speaking, viral genomes with mutations 
conferring resistance to specific drugs already pre-exist in the patient prior to treatment 
(Coffin 1995), although many of these variants are likely to be non-viable. These mutants 
generally display reduced fitness in the absence of drug selective pressure, and are therefore 
often present at a low level within the quasi-species as usually single and less commonly 
double mutants (triple mutants are rare). Once drug pressure is introduced, if viral replication 
is not effectively suppressed, these pre-existing drug-resistant variants have the potential to 
become the dominant species as they outgrow other quasi-species members who lack such an 
evolutionary advantage (Coffin 1995; Nowak, Bonhoeffer et al. 1997). The presence of three 
drugs, requiring a much more unlikely combination of pre-existing mutations on the same 
viral genome, is the theoretical basis for combination therapy – particularly as some classes 
require multiple mutations to occur in the viral genome before they become ineffective 
(Clavel and Hance 2004). 
1.5.4 Drug resistance 
Even amongst antiretroviral drugs of the same class, there are differences in the type and 
number of mutations required by the virus to confer resistance – differences in the genetic 
barrier to resistance, with some drugs requiring only one mutation in the virus for them to 
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become ineffective whist others need a combination of mutations to occur in a specific order 
(Clavel and Hance 2004) (Table 1.2.). Viral load testing, where resources are available, 
allows monitoring of the effectiveness of viral suppression by the therapy being offered to a 
particular individual. When virological failure occurs, often through adherence issues (Yerly, 
Kaiser et al. 1999), it may lead to a switch in therapy, where one or two components of the 
therapy are replaced by other drugs with differing resistance profiles. Careful monitoring of 
potential drug resistance is required to ensure the correct therapy is initiated, and that any 
resistance that may have formed during virological failure to the previous regimen is unlikely 
to impact upon the effectiveness of the new regimen (Tang and Pillay 2004; Booth, Garcia-
Diaz et al. 2007). Where drug resistance has developed in an individual, this can often be 
archived within viral reservoirs, which poses a long term risk of drug resistance if the patient 
is switched back to particular components of the previous regimen. It can also lead to the 
transmission of drug resistant virus to treatment naive individuals, which may limit treatment 
options available to them (Booth and Geretti 2007; Li, Paredes et al. 2013). Where such cases 
of transmitted drug resistance are picked up, suboptimal therapies can be avoided in 
preference of antiretrovirals to which the virus does not have any resistance, however, such 
genotypic screening for resistance is not available in all settings where antiretroviral therapy 
is available. More cross-sectional epidemiological monitoring of particular populations could 
give indications of the general level of circulating drug resistant virus, particularly in more 
resource limited populations where antiretrovirals are becoming more available, but where 
routine monitoring of drug resistance in patients failing therapy is not available (Ji, Li et al. 
2011; Dudley, Chin et al. 2012; Gupta, Jordan et al. 2012). 
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Table 1.2. Adapted from (Clavel and Hance 2004). Antiretroviral agents used in the 
treatment of HIV-1 infection and their associated pathways of resistance. 
  
Drugs Mechanisms of Action Mechanisms of Resistance
Nucleoside analogues
Zidovudine
Stavudine
Lamivudine
Didanosine
Zalcitabine
Abacavir
Nucleotide analogues Same as nucleoside analogues 
Tenofovir
Non-nucleoside reverse-transcriptase 
inhibitors
Nevirapine
Efavirenz
Delavirdine
Protease inhibitors
Saquinavir
Ritonavir
Indinavir
Nelfinavir
Amprenavir
Lopinavir
Fusion inhibitors
Enfuvirtide
36-Amino-acid peptide derived from the 
HR2 domain of glycoprotein 41
Interferes with glycoprotein 
41–dependent membrane fusion
Mutations affect HR1, a domain of 
glycoprotein 41 whose interaction with 
HR2 promotes membrane fusion
Analogues of normal nucleosides
Active as triphosphate derivatives
Incorporated into nascent viral DNA
Prematurely terminate HIV DNA synthesis
Thymidine analogue mutations promote 
ATP-mediated and pyrophosphate-
mediated excision of the incorporated 
terminator
M184V or Q151M complex mutations 
impair incorporation of nucleoside 
analogues
K65R impairs incorporation of tenofovir 
into DNA
Thymidine analogue mutations often 
associated with cross-resistance to 
tenofovir
Bind a hydrophobic pocket of HIV type 1 
reverse transcriptase
Block polymerization of viral DNA
Inactive against HIV type 2
Mutations reduce affinity of the inhibitors 
for the enzyme
Single mutations generally sufficient to 
induce high level of resistance
Structure derived from natural peptidic 
substrates of the HIV type 1 protease
Bind the active site of the protease
Mutations reduce affinity of the inhibitors 
for the enzyme
High-level resistance requires 
accumulation of mutations
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1.6 Molecular epidemiology 
1.6.1 Background theory: models of nucleotide evolution, maximum 
likelihood/Bayesian approaches  
Information contained in viral sequences can provide useful insights into the timing of 
disease emergence and the composition of ancestral strains of the pathogen that can be 
obtained using molecular epidemiological tools (Leitner and Albert 1999; Korber, Muldoon 
et al. 2000; Lewis, Hughes et al. 2008; Hué, Gifford et al. 2009; Sharp and Hahn 2011). The 
principle of phylogenetic analysis of genetic sequences is that as replication and propagation 
of the genetic information occurs, mutation and evolution generates genetic differences in the 
progeny of originally highly similar sequences that increase over time with ever-increasing 
rounds of replication and propagation of the genetic material. This assumption is the basic 
principle behind reconstruction of phylogenetic trees, and at its heart is the concept that the 
further away two genetic sequences are from their most recent common ancestor, the more 
genetic differences will have accrued between them. If the assumption of a molecular clock is 
made then the number of differences between two sequences is treated as directly 
proportional to the time since the two sequences diverged (Ho 2008). This assumption 
encounters a numbers of issues when faced with real data: firstly, the rates of nucleotide 
evolution across sequences are not equal, which is not surprising given different regions of a 
nucleotide sequence may be under different evolutionary pressures (Yang 1996; 
Huelsenbeck, Larget et al. 2000). In addition, the approach of simply counting differences 
between two sequences is confounded by the redundant nature of the genetic code (Yang 
1994; Yang and Rannala 2012); for example, the observed distance between two nucleotide 
sequences may be at a single position, where there is an A in one sequence, and a C in the 
other, so there initially appears to be a single substitution event that has taken place between 
the two sequences. However, the possibility that the second sequence initially underwent 
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substitution to a G or T at that location, and subsequently a second substitution to a C cannot 
be ruled out, but cannot be directly discovered by observation of the final sequences. If the 
second sequence underwent an additional substitution back to an A, then the sequences would 
appear to have remained identical, despite the second sequence having actually gone through 
three substitution events. To address these issues a variety of models of nucleotide evolution 
have been developed to try to more realistically model the process of substitution (Yang and 
Rannala 2012). These models are based upon the principle of Markov chains, where the next 
step in the chain only depends upon the current state of the chain, and is not influenced by the 
state of the chain prior to the current state. Transition matrices are set up with differing 
probabilities attending to different substitutions depending on the model being used. Such 
probabilities may reflect differences in the likelihood of a substitution being a transition 
versus a transversion. 
There are several approaches to constructing phylogenetic trees, broadly falling into i) 
those that rely upon distance measures between sequences, involving conversion sequences 
into matrices of genetic distances, and ii) those termed discrete methods, which act upon the 
sequences themselves (Whelan, Liò et al. 2001; Yang and Rannala 2012). Of the first 
approach, the neighbor-joining method is widely used. This distance-based method starts off 
with a completely unresolved tree, and then proceeds to cluster the most closely related 
sequences together first, using a matrix of computed distances, which are then replaced by 
their common ancestral node. The process continues to cluster pairs of taxa and recompute 
the overall distance matrix of the tree until the whole tree has been reconstructed. This 
approach is fast, but can be inaccurate, as it depends upon the order in which branches were 
added to the tree, and in the end the final tree that is computed cannot be compared to other 
trees that may better represent the underlying genetic relatedness of the sequences. This latter 
issue is a strength of the discrete method maximum-likelihood approach, which tries to 
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explore as many different tree topologies as possible, in order to find the tree that explains the 
sequence data best (i.e. the tree with the highest likelihood given the data). For this reason, 
maximum-likelihood approaches can identify much more accurate tree topologies, but require 
greater computational effort, especially if a large number of sequences are involved (Whelan, 
Liò et al. 2001; Yang and Rannala 2012). Both neighbor-joining and maximum-likelihood 
methods produce a single tree at the end of the process, which contains no information on the 
confidence of any particular sequence relationship within the tree. This information is 
typically obtained using non-parametric bootstrapping. This approach randomly samples, 
with replacement, columns from the original alignment in order to build up a new alignment 
that contains a subsample of the genetic information contained in the original sequence 
alignment (Felsenstein 1985). 100 or 1000 bootstrap replicates are used, depending on the 
size of the alignment, and new trees are constructed, ideally using the same process as the 
original tree-construction if computationally feasible. Support for a particular grouping of 
sequences within the original tree is obtained by observing the frequency at which this 
grouping appears in the bootstrap tree. 
An additional approach to phylogeny reconstruction is to use a Bayesian statistical 
approach combined with a Markov Chain Monte Carlo algorithm (Yang and Rannala 1997; 
Whelan, Liò et al. 2001) to generate a sample of trees from which an overall consensus tree 
can be constructed. Each iteration of the algorithm proposes a new tree and set of parameters 
by altering the current tree and model parameters following a set of rules. The new tree may 
be accepted or rejected on the basis of particular criteria specified within the algorithm. A 
tree and parameter space of accepted proposals is built up until it is judged that the chain has 
generated a sufficient sample of trees, which can result in very long chain runs being 
required. The confidence in any one tree, or a cluster of sequences within a tree, is based 
upon the number of times it was proposed during the chain (Yang and Rannala 2012). 
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1.6.2 Practical issues: alignments, programs, trees 
In terms of practical issues surrounding the construction of phylogenetic trees, it is crucial to 
use a sequence alignment of good quality, particularly if the sequences are likely to have 
regions containing gaps, such as in alignments of the variable loops in the HIV-1 envelope 
region. A number of alignment algorithms and tools exist, such as ClustalW and MUSCLE, 
but manual curation of alignments is also advisable where feasible, prior to inputting 
sequences into phylogenetic reconstruction tools (Yang and Rannala 2012). 
A number of tree construction algorithms specialised for extremely large alignments 
have been developed, such as RAxML and FastTree. These methods use a variety of 
approximations and heuristic approaches to reduce the overall computational effort involved 
in tree construction, whilst attempting to maintain accuracy and reliability (Price, Dehal et al. 
2010; Yang and Rannala 2012; Stamatakis 2014). 
On a further practical note, it is clear that in terms of HIV-1, a virus prone to 
recombination in vivo, and where co-infection of individuals with highly unrelated viral 
subtypes can occur, that very different phylogenies may be obtained depending on the region 
of the virus used (Robertson, Sharp et al. 1995). There has been some debate as to the 
suitability of different regions of the HIV-1 genome to reconstruct epidemiological 
relationships within the epidemic (Hué, Clewley et al. 2004; Stürmer, Preiser et al. 2004; 
Hué, Clewley et al. 2005). The pol region has been at the centre of this discussion by virtue 
of the fact that the region is sequenced as part of routine drug resistance surveillance, and as 
such, there are a large number of pol sequences available in a number of countries where 
such surveillance is widely implemented, presenting a potentially highly useful resource for 
reconstruction and investigation of local or national epidemics (Lewis, Hughes et al. 2008; 
Yerly, Junier et al. 2009; Brenner, Roger et al. 2011; Foster, Ambrose et al. 2014). However, 
sequencing technologies, such as Single Molecule Real-Time (SMRT) sequencing, may 
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enable more routine whole genome sequencing in the near future, which may make such 
controversies a moot point going forward (Henn, Boutwell et al. 2012; Brown, Guo et al. 
2013). 
1.6.3 Defining transmission clusters 
A number of studies have supported the ability of molecular epidemiological techniques to 
accurately reconstruct actual epidemiological events, where such data has been available 
from cases of known infection events (Patient 1992; Hillis and Huelsenbeck 1994; Leitner 
and Albert 1999; Paraskevis, Magiorkinis et al. 2004; Brooks, Robbins et al. 2006; Scaduto, 
Brown et al. 2010; Vandamme and Pybus 2013). Key to this is the identification of clusters of 
highly related viral genomes relative to surrounding genomes, and therefore the criteria used 
to define clusters highly likely to represent networks of direct infection. It is necessary to bear 
in mind what questions are being asked when identifying such clusters, as all HIV-1 will have 
been transmitted by a donor, and to that extent a most common recent ancestor (MCRA) will 
be identifiable for all sequences on a tree (Volz, Koopman et al. 2012). However, 
identification of transmission clusters is most often in the context of analysing aspects of the 
HIV-1 epidemic that may play a significant role in the onward spread or increased 
pathogenesis of the disease, such as the role of individuals with recent infection, or the 
impact of individuals who have failed treatment and may harbour drug resistant strains of the 
virus (Brenner, Roger et al. 2007; Lewis, Hughes et al. 2008; Yerly, Junier et al. 2009). In 
these contexts it is common practice to employ some measure of cluster support, e.g. 
bootstrap or posterior probability, together with an intra-cluster genetic distance cut-off. 
There is no agreed combination of support and distance cut-off used to define clusters, and 
studies vary depending on the questions being asked (Kaye, Chibo et al. 2008; Bezemer, van 
Sighem et al. 2010; Chalmet, Staelens et al. 2010). Necessarily, altering the genetic distance 
component of the cluster identification process will result in greater or lesser average 
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pairwise genetic distances between individuals within those clusters, and may influence 
downstream inferences based upon belonging to those clusters (Volz, Koopman et al. 2012). 
It also important to be aware that phylogenies of infected individuals are unlikely to be 
complete, given the numbers of individuals infected with HIV-1 that are unaware of their 
infection, and who will therefore not have viral sequence available for analysis (Campsmith, 
Rhodes et al. 2010; Lodwick, Alioum et al. 2011; Aghaizu, Brown et al. 2013). 
 
1.7 Modelling of HIV-1 infection dynamics in populations 
1.7.1 Mathematical models of transmission 
In order to gain insight into the HIV-1 epidemic in various settings and populations, 
researchers have attempted to use mathematical models to answer questions relevant to the 
design and implementation of public health strategies to try to reduce the growth of the 
epidemic, such as the infectiousness of particular stages of HIV-1 infection or the percentage 
of individuals with undiagnosed infections (Pinkerton 2007; Hollingsworth, Anderson et al. 
2008; Granich, Gilks et al. 2009; Campsmith, Rhodes et al. 2010). Despite the high viral 
loads associated with early HIV-1 infection, modelling of the probability of transmission per 
coital act and assessment of the contribution from early infection has produced different 
results through use of different models and parameters (Miller, Rosenberg et al. 2010). This 
is partly to do with the difficulty of obtaining accurate data on the rate of transmission from 
individuals in the acute infection to uninfected individuals who then go on to seroconvert. 
Several studies have used data obtained as part of a community randomised trial of sexually 
transmitted disease (STD) control for the prevention of AIDS, in Rakai District, Uganda 
(Wawer, Gray et al. 1998; Wawer, Sewankambo et al. 1999; Wawer, Gray et al. 2005; Abu-
Raddad and Longini Jr 2008; Hollingsworth, Anderson et al. 2008). This study captured data 
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on couples where both partners were seronegative, and then one partner became seropositive, 
followed some time later by the second partner. Different treatment of the same data 
produced broadly similar agreement in their findings of increased infectiousness of the early 
and late phases of the disease, but differed in terms of the estimates of the infectiousness and 
the length of those periods, and their overall contribution to onward transmission within an 
epidemic, given that the asymptomatic period, with its lower rate of transmission, can often 
last for many years (Wawer, Gray et al. 2005; Hollingsworth, Anderson et al. 2008). A 
number of studies support the idea that the phase of the overall epidemic impacts upon the 
contribution from each phase of the disease, with early epidemics being largely driven by 
individuals in the early phases of infection, by virtue of the fact that insufficient time has 
passed for substantial numbers of individuals to have passed into the later phases of the 
infection (Abu-Raddad and Longini Jr 2008; Hollingsworth, Anderson et al. 2008). These 
and other studies also point out that other aspects of an epidemic, such as the population and 
the sexual risk behaviour of individuals, are likely to be important (Jacquez, Koopman et al. 
1994; Koopman, Jacquez et al. 1997; Abu-Raddad and Longini Jr 2008). 
1.7.2 Introduction to phylogenetic based models 
Phylogenetic approaches have also been employed to examine transmission dynamics at play 
within epidemics. Using clusters of transmissions to identify particular risk groups 
disproportionately driving onward transmission has tended to identify the recent infection 
period of infection as playing a key role (Yerly, Vora et al. 2001; Pao, Fisher et al. 2005; 
Brenner, Roger et al. 2007; Fisher, Pao et al. 2010). However, the findings of these studies 
must be considered with caution, as sampling of an infected population is often incomplete, 
and linkage of those individuals who are sampled, and whose viruses were obtained from the 
recent phase of infection, does not mean that those individuals actually transmitted from the 
recent phase of infection (Brown, Gifford et al. 2009). On top of this, phylogenetic tree 
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construction methods that incorporate genetic distance measures may introduce inherent bias 
into the process, which makes the clustering of more highly related sequences more likely 
(Volz, Koopman et al. 2012). Chapter four of this thesis investigates the utility of a 
phylogenetic approach in combination with a marker of infection length to gauge the role of 
individuals with recent HIV-1 infection in driving the UK epidemic. 
 
1.8 Ultra-deep sequencing of early HIV-1 
1.8.1 Deep-sequencing theory: current methodologies and limitations 
Until relatively recently, Sanger sequencing was the predominant way in which genetic 
information was generated for analysis (Sanger, Nicklen et al. 1977; Lander, Linton et al. 
2001). However, there are now a variety of technologies available, often generically referred 
to as ‘next-generation’ sequencing technologies, that enable the production of genetic 
information on a large scale, at ever-decreasing costs (Metzker 2009; Koboldt, Steinberg et 
al. 2013). Two main platforms, Illumina and 454, both rely upon clonal amplification of 
template DNA prior to sequencing based upon measuring incorporation of nucleotides using 
fluorescence. The clonal amplification from HIV-1 samples allows a much greater spectrum 
of the quasi-species to be captured, and therefore enables a greater depth of sampling than 
traditionally possible with Sanger sequencing, which in effect generates a consensus 
sequence from the quasi-species by collapsing the population sub-structure into an overall 
‘average’ sequence. This ‘next-generation’ technology therefore allows exploration of topics 
such as quasi-species dynamics in the presence of host immune pressure, and the impact of 
low level drug resistance on antiretroviral treatment outcomes. 
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1.8.2 454 methodology outline: tagged amplicons, MIDs 
To date, the Illumina and 454 platforms have been the main technologies offering deep-
sequencing capability useful for studying viruses. Through differences in technology, 
Illumina can produce a greater number of reads from a sample at a lower cost than 454 
pyrosequencing (Glenn 2011), but generates shorter reads, in the region of 100-150bp in 
length, whereas 454 pyrosequencing can generate read lengths of 400bp and possibly longer. 
These differences in output lend themselves to different applications, and pyrosequencing has 
generally been useful for sequencing amplicons from specific regions of the HIV-1 genome, 
the V3 loop region of HIV-1 for example, or to reconstruct subpopulations, which requires 
reads to have sufficient overlap with each other to enable confident contiguation (Zagordi, 
Bhattacharya et al. 2011; Zagordi, Däumer et al. 2012). Briefly, the principle behind 454 
pyrosequencing relies on an initial clonal amplification of individual molecules of DNA 
derived either unamplified from the original host if sufficient material is available, or from 
PCR. The clonal amplification is carried out in such a way that one individual molecule of 
DNA is clonally amplified in its own emulsion PCR reaction, which takes place on a picotitre 
plate, such that one emulsion PCR reaction of one DNA molecule takes place per well of the 
plate. The actual sequencing step is subsequently performed by breaking the emulsion PCR 
microreactor (water droplets within an oil phase) and adding additional beads with 
sulphurylase and luciferase attached. This step is followed by flowing a particular nucleotide 
across the plate and detecting incorporation events in particular wells where the nucleotide 
joins the complementary strand of a template DNA molecule. Incorporation of a nucleotide 
releases a pyrophosphate, which is detected by a high-resolution camera, thereby identifying 
every well where a nucleotide was incorporated (or more than one nucleotide in the case of 
homopolymeric regions in the template DNA) (Metzker 2009). 
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Genetic barcode systems for both Illumina and 454 allow multiple patients to be 
uniquely tagged with a short nucleotide sequence, Multiplex IDentifier (MID) tags, which 
means that all reads generated from that sample can be identified in downstream analyses and 
linked back to the patient sample, which can increase efficiency and reduce costs by 
decreasing the number of runs required to sequence large numbers of patients in parallel (454 
Life Sciences Corp. 2009; Ji, Li et al. 2011; Dudley, Chin et al. 2012). 
There are a number of limitations and potential biases that are associated with the 
different deep-sequencing technologies, and it is important to be aware of these during 
template preparation and downstream analysis steps. A major potential source of error during 
deep-sequencing is the generation of PCR errors during the sample preparation step (Hughes 
and Totten 2003; Kanagawa 2003; Jabara, Jones et al. 2011). The Taq polymerase reaction 
can incorporate 1.8 x 10
-4
 - 8.0 x 10
-6
 nucleotide errors per base pair per replication cycle 
(Terpe 2013), and can therefore introduce spurious low level variants into the results that will 
inflate estimates of true variants. The process of pyrosequencing itself encounters issues 
when dealing with homopolymer stretches of nucleotides, and can artificially elongate such 
regions (Huse, Huber et al. 2007). Though not specific to pyrosequencing, there is also the 
potential issue of low level swapping of MID tags during preparation of the sample for 
pyrosequencing, and it is necessary to take this into account when deep-sequencing in the 
context of viral quasi-species, where samples can potentially contain highly related viruses 
through transmission events, and/or can come from the same patient at multiple different time 
points (Carlsen, Aas et al. 2012). Knowledge of these issues, and strategies to ameliorate or 
correct for them, are essential in studies looking at low level variants and quasi-species 
diversity, in order to fully harness the power that these deep-sequencing technologies offer 
(Rozera, Abbate et al. 2009; Archer, Rambaut et al. 2010; Hedskog, Mild et al. 2010; Jabara, 
Jones et al. 2011; Zagordi, Bhattacharya et al. 2011).  
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Research aims 
 
1. Develop a measure of length of HIV-1 infection based upon the analysis of the proportion 
of ambiguous nucleotides in Sanger pol consensus sequences (detailed in chapter three). 
2. Construct phylogenies of Sanger pol consensus sequences from the UK HIV Drug 
Resistance Database to detect clusters of transmission, with the aim of identifying the 
extent to which individuals with recent infection are contributing to the spread of HIV-1 
in the UK and their contribution to trends in transmitted drug resistance (detailed in 
chapter four). 
3. Perform deep-sequencing of plasma HIV-1 RNA sampled from UK patients diagnosed 
with recent infection, in order to assess the complexity and evolution of viral quasi-
species, and investigate the extent to which early infections may be founded by diverse 
viral subpopulations (detailed in chapter five). 
4. Investigate the molecular epidemiology of HIV-1 infection in the Kumasi region of 
Ghana among newly diagnosed patients attending the Komfo Anokye Teaching Hospital, 
in order to identify the circulating subtypes and detect transmitted drug resistance 
(detailed in chapter six). 
5. Perform phylogenetic analyses of HIV-1 infections in the Kumasi cohort to explore the 
extent to which clusters of highly related infections exist, which may indicate high risk 
behaviours that drive the local epidemic (detailed in chapter six). 
6. Investigate the performance of methods for identifying recent HIV-1 infection (guanidine 
based avidity assay and the nucleotide ambiguity classifier) in the Kumasi cohort, with a 
view to investigating the utility of such approaches in gauging the role of individuals with 
recent (detailed in chapter six).  
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Chapter Two 
 
Materials and methods 
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2 Materials and methods 
2.1 Patient cohorts 
2.1.1 UK HIV Drug Resistance Database 
The UK HIV Drug Resistance Database (UKHIVDRD) (http://www.hivrdb.org.uk/) is a 
national repository of protease and reverse transcriptase sequences obtained by Sanger 
sequencing of HIV-1 obtained from patients undergoing drug resistance testing as part of 
routine care. At the time of the analysis, there were 43002 anonymised patients in the 
database, and a total of 55556 sequences from both antiretroviral treatment (ART)-naïve and 
ART-experienced patients. Associated clinical data for 16362 database patients was provided 
by the UK Collaborative HIV Cohort (http://www.ukchic.org.uk/). Sequences were supplied 
pre-aligned individually to a reference sequence (consensus B) using the LAP alignment 
program (Huang and Zhang 1996). 
2.1.2 UK-based cohorts for the development of the nucleotide ambiguity cut-off 
Viral sequences and clinical data were obtained from three cohorts: i) patients that attended 
the Ian Charleson Day Centre of the Royal Free Hospital (RFH), London, between 2004 and 
2010; 2) 670 patients that between 1997 and 2009 became part of the UK Register of HIV 
Seroconverters, a UK-wide database of newly diagnosed patients whose time of 
seroconversion can be reliably estimated using laboratory evidence, and; 3) patients that 
attended the HIV clinic of St Mary’s Hospital (SMH), London, between 2008 and 2010. 
Clinical data from all three cohorts was stripped of patient identifiable information prior to 
being made available to the study. 
2.1.3 Kumasi HIV new diagnosis cohort 
Serum and plasma samples were collected from randomly selected newly diagnosed patients 
attending the HIV clinic at Komfo Anokye Teaching Hospital in Kumasi, Ghana, between 
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2008 and 2012. Associated clinical and laboratory data were collected from the case records 
and anonymised. The study was approved by the Committee on Human Research 
Publications and Ethics at Kwame Nkrumah University of Science and Technology 
(KNUST), Kumasi, Ghana. 
 
2.2 Reference sequences 
HXB2 was used as a reference genome for all primer and sequence coordinates (Genbank 
Accession number K03455). 
 
2.3 HIV-1 Avidity assay 
Guanidine-based avidity assays were carried out using the Vitros ECiQ Immunodiagnostic 
System (Ortho-Clinical Diagnostics, United Kingdom) as per the Operator’s Guide. The 
machine was calibrated using the Vitros Anti-HIV 1+2 Calibrator when appropriate (e.g. 
when reagent pack lot number changed, and/or at least once every 28 days upon change of 
reagent pack and calibrator lot). Before each avidity run, a quality control step was performed 
using the Vitros Anti-HIV 1+2 Controls. Control sera were reconstituted in 1ml of de-ionized 
water. Additional high and low avidity control samples were included at the start and end of 
each run. Each sample (controls and patient samples) were run in duplicate following 
incubation for 10 min at a 1:10 (20µl sample in 180µl diluting solution) dilution in either 
phosphate-buffered saline (reference dilution) or 1M Guanidine Hydrochloride (test dilution). 
The avidity index (AI) was calculated by dividing the sample-to-cut-off ratio of the test 
dilution (mean of replicate wells) over the sample-to-cut-off ratio of the reference dilution 
(mean of replicate wells). An avidity index of ≤0.75 was taken to be indicative of the patient 
44 
 
having undergone HIV-1 seroconversion within the previous 125 days (95% confidence 
interval [CI], 85 to 164 days). 
 
2.4 Nucleic acid extraction using the NucliSENS easyMAG extraction platform 
Plasma and serum samples were extracted using the NucliSENS easyMAG (bioMerieux, 
Basingstoke, UK) for total nucleic acid extraction platform. Frozen plasma/serum samples 
stored at -80°C were brought to room temperature and vortexed for >10s to ensure 
homogenization. Depending on viral load of the sample, and the volume of material 
available, 0.2ml, 0.5ml or 1.0ml of each sample was loaded onto the NucliSENS easyMAG 
and total nucleic acid was extracted as per manufacturer guidelines, using an onboard lysis 
step and Generic 2.0.1 protocol. A negative water control was included in each extraction 
run. Elution volume was 25µl, 35µl or 65µl of easyMag elution buffer 3 depending on 
volume required for downstream applications. Eluate was transferred to ice immediately after 
extraction, prior to use in downstream applications. Any eluate remaining after downstream 
applications had been carried out was stored at -80°C. 
 
2.5 One-step Reverse Transcription PCR (RT-PCR) reaction for pol 
amplification prior to nested PCR 
HIV-1 pol in-house PCR primers (previously developed by colleagues at the Royal Free 
Hospital, London, as part of a diagnostic protocol): 
Primer (HXB2 coordinates) Sequence 
RES1 (1819-1844bp):  GAA GAA ATG ATG ACA GCA TGT CAG GG 
RES2 (4202-4173bp):  TAA TTT ATC TAC TTG TTC ATT TCC TCC AAT 
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RES3 (3585-3559bp):  ATG GYT CTT GAT AAA TTT GAT ATG TCC 
RES4 (2074-2095bp):  AGA CAG GCT AAT TTT TTA GGG A 
 
A master mix containing the following amounts of each reagent from the Qiagen OneStep 
RT-PCR Kit (Qiagen Cat. No. 210212) kit was prepared and 40µl aliquoted into each well of 
a 96-well plate: 
Reagent Amount per sample (l) 
5x buffer 10.0 
dNTPs (10mM) 2.0 
Primer RES1 (10M) 3.0 
Primer RES2 (10M) 3.0 
RT-PCR enzyme mix 2.0 
Water 20 
 
10µl of RNA was added to each well of the 96-well plate, together with appropriate negative 
controls, and the plate was transferred to a Veriti thermocycler, where the following program 
was initiated: 
Temperature (
o
C) Time Cycles 
50 35 mins 1 
95 15 mins 1 
95 30 secs 1 
65 45 secs 
72 3 mins 
95 30 secs 1 
60 45 secs 
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72 3 mins 
95 30 secs 45 
58 45 secs 
72 3 mins 
72  10 mins 1 
4 Hold (<24 hours) 1 
 
2.6 Nested PCR for pol amplification prior to cycle-sequencing 
Upon termination of the RT-PCR, a master mix of the following reagents from the Qiagen 
HotStarTaq DNA Polymerase (Qiagen Cat. No. 203205) kit was prepared, and 95µl aliquoted 
into the relevant wells of a 96-well plate: 
Reagent Amount per sample (μl) 
Buffer (10x) 10.0 
dNTPs (10mM) 2.0 
Primer RES3 (10M, note 1:10 dilution of stock) 2.0 
Primer RES4 (10M, note 1:10 dilution of stock) 2.0 
Hot start Taq (5U/µl) 0.5 
Water 78.5 
Total 95 
 
5µl of RT-PCR product was added to the relevant wells and the plate transferred to a Veriti 
thermocycler, where the following program was run: 
Temperature (
o
C) Time Cycles 
95 12 mins 1 
95 30 secs 1 
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65 45 secs 
72 3 mins 
95 30 secs 1 
60 45 secs 
72 3 mins 
95 30 secs 45 
55 45 secs 
72 3 mins 
72
o
C  10 mins 1 
4
o
C Hold (<24 hours) 1 
 
Upon termination of the nested PCR, visualisation of the DNA amplicons via gel 
electrophoresis was carried out using a 2% agarose gel with SYBR Safe DNA Gel Stain 
(Invitrogen Cat. No. S33102) and HyperLadder 1kb, formerly HyperLadder I (Bioline Cat. 
No. BIO-33053), with an expected sample amplicon size of 1511bp. A band in the negative 
control was taken to be indicative of PCR contamination. 
PCR products of the correct size were purified prior to cycle-sequencing using the QIAquick 
PCR Purification Kit (Qiagen Cat. No. 28106), as per manufacturer instructions. 65µl of 
molecular biology grade water was then added to each sample to ensure sufficient volume of 
material for cycle-sequencing with each of the 6 primers (see 2.8). 
 
2.7 Reverse transcription reaction for env prior to PCR and Sanger sequencing 
A master mix of the following amounts of each reagent from the Invitrogen SuperScript III 
First-Strand Synthesis SuperMix kit (Invitrogen Cat. No. 18080-400) together with reverse 
primer 16R (5-GGT AGC TGA AGA GGC ACA GG-3) was prepared on ice. Depending on 
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the viral load of a sample, and the downstream application, half or third volumes were used, 
in order to conserve reagents, with corresponding alterations in eluate input volume. 5µl of 
master mix was aliquoted into separate wells of a 96-well plate and kept on ice. 
Reagent Amount per sample (µl) 
Annealing buffer 2.5 
Molecular biology grade water 1.87 
16R (20uM) 0.63 
Total 5 
 
15µl of sample eluate was transferred into the corresponding well of the 96-well plate 
(including an additional well for the negative water control extract and a positive control 
where appropriate) and the plate transferred to a Veriti thermocycler, where the following 
program was initiated in order to achieve template-primer annealing: 
 
Temperature (°C) Time Cycles 
65 5 mins 1 
 
At termination of the program, the plate was immediately transferred to ice for 1 minute, 
before the following enzyme master mix was added to each sample well: 
  
Reagent Amount per sample (µl) 
SuperScript® III/RNaseOUT™ Enzyme Mix 5 
2X First-Strand Reaction Mix 25 
Total 30 
 
The plate was covered with an adhesive seal and transferred to a Veriti machine on ice, and 
the following thermocycler program initiated: 
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Temperature (°C) Time Cycles 
55 50 mins 1 
85 5 mins 1 
4 ∞ 1 
 
Once the thermocycler program has terminated, cDNA was stored at 4°C until required for 
the polymerase chain reaction amplification step. Long term storage of any remaining cDNA 
was at -20°C/-80°C. 
 
2.8 Polymerase chain reaction amplification of env prior to Sanger sequencing 
Env PCR primer sequences: 
Primer (HXB2 coordinates) Sequence 
2F (5559-5577bp) ATG GAA CAA GCC CCA GAA G 
4F (5966-5984bp) TCC TAT GGC AGG AAG AAG C 
15R (8365-8344bp) GGT GAG TAT CCC TGC CTA ACT C 
16R (8529-8510bp) GGT AGC TGA AGA GGC ACA GG 
 
A master mix containing the following amounts of each reagent from the Invitrogen Platinum 
PCR SuperMix High Fidelity (Invitrogen Cat. No. 12532-024) was prepared per sample, and 
48µl aliquoted into a 96-well plate. Depending on the viral load of a sample, and the 
downstream application, half or third volumes were used, in order to conserve reagents, with 
corresponding alterations in cDNA input volume: 
 
Reagent Amount per sample (µl) 
Platinum Taq DNA Polymerase High Fidelity 45 
50 
 
2F (10uM) 1.25 
16R (10uM) 1.25 
Molecular biology grade water 0.5 
Total 48 
 
2µl of cDNA was added to corresponding wells of the 96-well plate, together with 
appropriate positive and negative controls. 
The plate was covered with an adhesive seal and transferred to a Veriti thermocycler heating 
block, whereupon the following program was initiated: 
 
Temperature (°C) Time Cycles 
94 2 mins 1 
94 15 secs  
30 50 30 secs 
68 4 mins 
68 10 mins 1 
4 ∞ 1 
 
Upon termination of the first round PCR, a nested PCR master mix containing the following 
amounts of each reagent from the Invitrogen Platinum PCR SuperMix High Fidelity 
(Invitrogen Cat. No. 12532-024) was prepared per sample, and 48µl aliquoted into a 96-well 
plate. Depending on the viral load of a sample, and the downstream application, half or third 
volumes were used, in order to conserve reagents, with corresponding alterations in DNA 
input volume: 
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Reagent Amount per sample (µl) 
Platinum Taq DNA Polymerase High Fidelity 45 
4F (10uM) 1.25 
15R (10uM) 1.25 
Molecular biology grade water 0.5 
Total 48 
 
In a designated post-amplification ultra-violet (UV) light cabinet, 2µl of PCR product from 
the first round plate was transferred to the corresponding well of the nested PCR plate using a 
10µl multi-channel pipette, and the plate covered with an adhesive seal and transferred to a 
Veriti thermocycler heating block, whereupon the following program was initiated (the first 
round PCR plate was stored at -20°C/-80°C freezer for long term storage if necessary): 
 
Temperature (°C) Time Cycles 
94 2 mins 1 
94 15secs  
35 50 30 secs 
68 3.5 mins 
68 10 mins 1 
4 ∞ 1 
 
Upon termination of the nested PCR, visualisation of the DNA amplicons via gel 
electrophoresis was carried out using a 2% agarose gel with SYBR Safe DNA Gel Stain 
(Invitrogen Cat. No. S33102) and HyperLadder 1kb, formerly HyperLadder I (Bioline Cat. 
No. BIO-33053), with an expected sample amplicon size of 2399bp. A band in the negative 
control was taken to be indicative of PCR contamination. 
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PCR products of the correct size were purified prior to cycle-sequencing using the QIAquick 
PCR Purification Kit (Qiagen Cat. No. 28106), as per manufacturer instructions. 65µl of 
molecular biology grade water was then added to each sample to ensure sufficient volume of 
material for cycle-sequencing with each of the 12 primers (see below). 
2.9 Cycle sequencing and clean-up 
HIV-1 pol sequencing primers used in cycle-sequencing: 
Primer (HXB2 coordinates) Sequence 
SEQ1 (2149-2165bp): GAG CCA ACA GCC CCA CC 
SEQ2 (2616-2634bp): CAA TGG CCA TTG ACA GAA G 
SEQ3 (3012-3031bp): GGA TCA CCA GCA ATA TTC CA 
SEQ5 (2606-2586bp): TGG GCC ATC CAT TCC TGG CTT 
SEQ6 (2988-3007bp):  CAT CCC TGT GGA AGC ACA TT 
SEQ7_3 (3549-3569bp): TTG ATA TGT CCA TTG GCC TTG 
 
HIV-1 env sequencing primers used in cycle-sequencing:  
Primer (HXB2 coordinates) Sequence 
4F (5966-5984bp) TCC TAT GGC AGG AAG AAG C 
6F (6340-6359bp) ATT ATG GGG TAC CTG TGT GG 
ENV2 (6561-6580bp) GAT CAA AGC CTA AAG CCA TG 
6955FQ (6955-6973bp) CAG TAC AAT GYA CAC ATG G 
OFM54 (7350-7374bp) TTT AAT TGT GGA GGG GAA TTT TTC T 
TUG (7859-7879bp) GTC TGG TAT AGT GCA ACA GCA 
6582R (6582-6558bp) CAC ATG GCT TTA GGC TTT GAT CCC A 
TUE3 (7006-7028bp) TCC TTC TGC TAG ACT GCC ATT TA 
V3-2M (7371-7352bp) AAA ATT CCC CTC CAC AAT TA 
EDS8 (7648-7668bp) CAC TTC TCC AAT TGT CCC TCA 
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14R (8037-8017bp) TGC AGA TGA GTT TTC CAG AGC 
15R (8365-8344bp) GGT GAG TAT CCC TGC CTA ACT C 
 
For cycle-sequencing of either pol or env, the cycle-sequencing master mix was prepared 
with the following reagents per sequencing primer per sample, including BigDye ready 
reaction mix from the BigDye Terminator v3.1 Cycle Sequencing Kit (Invitrogen Cat. No. 
4337456): 
 
Reagent Amount per sample (µl) 
BigDye ready reaction mix 2 
Molecular biology grade water 9 
Total 12 
 
The master mix was transferred to a 96-well plate and 8µl of each sample was added to 6 or 
12 wells depending on the region being sequenced. 1µl of each of the cycle-sequencing 
primers (10uM) was added to a separate well. Once all samples had been added to the 
corresponding wells, the plate was transferred to a Veriti thermocycler for cycle sequencing 
with the following conditions: 
 
Temperature (°C) Time Cycles 
96 10 secs  
25 
 
50 5 secs 
60 4 mins 
4 ∞ 1 
 
Upon termination of the cycle-sequencing thermocycler program, a fresh solution of sodium 
acetate and ethanol was made up as follows: 
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 Per well E.g. 96-well plate (x1.2) 
Sodium Acetate 3.0M pH4.6 2 240 
100% ethanol (high grade) 50 6000 
Total 52 6240 
 
52µl of the above solution was added to each well and gently aspirated 3-4 times to mix. The 
plate was then covered with an adhesive plate seal and centrifuged at 2000g for 20 minutes at 
room temperature. 
The plate was then transferred from the centrifuge, the seal removed, and the plate inverted 
onto absorbent paper towels before centrifuging upside down at 150g for 1 minute at room 
temperature. 
150µl of 70% ethanol (freshly made up that day) was then added to each well and the plate 
covered with an adhesive seal. The plate was then centrifuged right-way-up at 2000g for 5 
minutes at room temperature. 
The plate was then transferred from the centrifuge, the seal removed, and the plate inverted 
onto absorbent paper towels before centrifuging upside down at 150g for 2 minutes at room 
temperature. The plate was then allowed to air-dry right-way-up for at least 30 minutes to 
ensure complete evaporation of residual ethanol. 
DNA pellets were then resuspended in 10-20uI of Hi-Di Formamide (Applied Biosystems 
Cat. No. 4311320) (if they were to be run on the 3730 Genetic Analyser that day) or covered 
with a plate sealer and stored at -20°C. 
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2.10 Sequence analysis in SeqScape and other tools 
Products were analysed on an Applied Biosystems 3730 DNA Analyzer and manually 
curated using SeqScape v2.6 (Applied Biosystems, Warrington, United Kingdom). 
 
2.11 454 deep-sequencing 
All samples were normalised to a viral load of 20000 copies/ml using basematrix to ensure 
approximately identical virus input. Extraction was carried out using the NucliSENS 
easyMAG total nucleic acid extraction platform into an elution volume of 35µl (in 
NucliSENS easyMAG extraction buffer 3). 
A clone control was incorporated into the experiment in order to ascertain levels of random 
errors incorporated into reads through a combination of PCR, emPCR and pyrosequencing 
errors (because the clone control was provided as DNA, it is not able to act as a control for 
the reverse transcription step). The control clone used was ARP2071 (pCRII-TOPO-SE8131-
3) plasmid DNA (a full length clade A clone (Accession Number: AF107771) in a pCRII-
TOPO vector), obtained from the National Institute for Biological Standards and Control 
(NIBSC) Centre for AIDS Reagents 
(http://www.nibsc.org/spotlight/centre_for_aids_reagents.aspx). 
 
2.11.1 RT and PCR of pol and env region of HIV-1 
A master mix was prepared on ice containing the following amounts of each reagent from the 
Invitrogen SuperScript® III First-Strand Synthesis SuperMix: 
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Reagent Amount per sample (µl) 
Annealing buffer 2.5 
Molecular biology grade water 1.87 
Reverse primer
*
 (20uM) 0.63 
Total 5 
  
*
pol and env amplicons were generated using two different primer sets, with two different 
outer reverse primers for cDNA generation: JA272 (5-GGATAAATCTGACTTGCCCART-
3) for pol and 15R (5-GGTGAGTATCCCTGCCTAACTC-3) for env (i.e. two separate 
master mixes were generated). 
5µl of each master mix was aliquoted into a 96-well plate and covered with an adhesive plate 
seal. 15µl of each eluate was transferred into corresponding wells of the 96-well plate (i.e. 
15µl into the pol well and 15µl into the env well for each sample), together with positive and 
negative controls. The plate was covered with an adhesive seal and transferred on ice to a 
Veriti thermocycler heat-block where the following program was run: 
 
Temperature (°C) Time Cycles 
65 5 mins 1 
 
Upon termination of the program, the plate was removed to ice and left for 1 minute prior to 
the addition of 30µl of the following enzyme master mix per sample well: 
 
Reagent Amount per sample (µl) 
SuperScript® III/RNaseOUT™ Enzyme Mix 5 
2X First-Strand Reaction Mix 25 
Total 30 
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The plate was then transferred to a Veriti thermocycler heat-block on ice, and the following 
program run: 
Temperature (°C) Time Cycles 
55 50 mins 1 
85 5 mins 1 
4 ∞ 1 
 
The following PCR master mix was prepared with the following reagents from the Invitrogen 
Platinum® Taq DNA Polymerase High Fidelity kit: 
 
Reagent Amount per sample (µl) 
10X High Fidelity PCR Buffer 5.5 
10mM dNTP mixture 1.1 
50mM MgSO4 2.2 
Primer outer F
‡
 (25μM each) 0.44 
Primer outer R
‡
 (25μM each) 0.44 
Platinum® Taq High Fidelity  0.22 
Autoclaved, distilled water 30.1 
Total 40 
 
‡
pol and env require two separate master mixes, each with a different primer combination: 
 
 Primer outer F Primer outer R 
Pol JA269 (5-AGGAAGGACACCARATGAARGA-3) JA272 (sequence above) 
Env 4F (5-TCCTATGGCAGGAAGAAGC-3) 15R (sequence above) 
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At this point the ARP2071 clone control was incorporated as one of the samples, and treated 
identically to patient sample cDNA. 
10µl of RT product from above was transferred to the corresponding well containing the PCR 
reaction mix, the plate sealed and transferred to a Veriti thermocycler heat-block where the 
following program was run: 
 
Temperature (°C) Time Cycles 
94 2 mins 1 
94 15 secs  
20 55 30s 
68 3 mins 
68 10 mins 1 
4 ∞ 1 
 
A nested PCR master mix was prepared using the following reagents per sample, and 49µl 
transferred to the wells of a 96-well plate: 
Reagent Amount per sample (µl) 
Platinum® PCR SuperMix High Fidelity 45 
Primer inner F
†
 (25 μM each) 0.44 
Primer inner R
†
 (25 μM each) 0.44 
Total 49 
 
†
these primers were region specific, but had GS FLX Titanium emPCR Kit LibA fusion 
adaptors attached to enable generation of amplicons that could be hybridized to the DNA 
Capture Beads prior to emulsion PCR: 
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 Primer inner F Primer inner R 
Pol NG_PinF2 NG_PinR2 
Env 6955FQ NG_EinR2 
 
16 different paired Multiplex Identifier Tags (MID) tags were used, to enable multiplexing of 
16 samples per pool (Appendix 1). 
1µl of first-round product was transferred into the nested PCR plate, the plate was sealed, and 
transferred to a Veriti thermocycler heat-block and the following program was run: 
 
Temperature (°C) Time Cycles 
94 2 mins 1 
94 15 secs  
30 48 30 secs 
68 3 mins 
68 10 mins 1 
4 ∞ 1 
 
After the nested PCR, amplicons were visualised on a 2% agarose gel, and products of the 
correct size taken forward for clean-up. The pol amplicon was expected to be 426bp in size, 
and the env amplicon was expected to be 421bp in size. 
PCR products of the correct size were purified prior to cycle-sequencing using the QIAquick 
PCR Purification Kit (Qiagen Cat. No. 28106), as per manufacturer instructions. 
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2.11.2 Measuring DNA concentration using Qubit 
Amplicons from different patient samples needed to be pooled at the same mass 
concentration (or molar concentration if the amplicons varied >50bp in size), which required 
accurate determination of DNA concentration in each sample using the Invitrogen Qubit® 
dsDNA HS Assay Kit, and the Qubit® 2.0 Fluorometer. This was carried out as per 
manufacturer guidelines. Samples were then diluted to a concentration of 10ng/µl, and pooled 
into non-duplicate MID tag pools 
 
 
2.12 Margin of error calculations for minimum deep-sequencing subpopulation 
prevalence cut-off 
Carried out as per the following formula: E     
      
 
 
Where E is the margin of error, z is the confidence level (the value of 2.58 was used to obtain 
a 99% confidence level – meaning that if the sample was deep-sequenced 100 times, the 
number of reads obtained for the subpopulation in question should fall within the range 
calculated 99/100 times), ṕ is the proportion of reads in the sample corresponding to the 
subpopulation having its margin of error calculated, n is the sample size which corresponds to 
the total number of reads in the sample (Lohr 2009). The resulting number was then 
converted into the equivalent in percentage and subtracted from the percentage abundance of 
the subpopulation in question. If the new read percentage abundance then fell below 1%, the 
subpopulation was deemed unreliable and not taken forward for analysis. For example, if a 
putative subpopulation was present at 51 reads in 4581 total reads (i.e. 1.1%) the margin of 
error was calculated as 0.004, or 0.4%. Subtracting 0.4% from 1.1% would give a lower 
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boundary percentage of 0.7% (translating into 33 reads in 4581), which is below the 1% cut-
off, and hence the subpopulation would be discarded. 
 
2.13 Molecular epidemiological analysis 
2.13.1 Alignment and trimming 
Sequence alignments were generated using the MUSCLE (MUltiple Sequence Comparison 
by Log- Expectation) automated alignment program (Edgar 2004). Subsequent inspection of 
alignment results, manual editing and gap-stripping, was carried out using BioEdit version 
7.1.3.0. 
2.13.2 Counting nucleotide ambiguities in fasta sequences 
Microsoft Excel was used to calculate the number of ambiguous nucleotides in each fasta 
sequence within the UKHIVDRD. The overall aligned sequence file was transferred to 
Microsoft Excel in a manner that ensured one sequence per row. All sequences were adjusted 
so that only uppercase letters were included (i.e. any lowercase letters were converted into 
uppercase). All gap symbols “-” were removed prior to counting ambiguities, and DRAM 
codons removed with reference to the WHO 2009 Drug Resistance Mutation List (Bennett, 
Camacho et al. 2009). The following formula was used to enumerate each IUPAC ambiguity 
symbol, where “$D1” is the cell reference to the gap-stripped, uppercase fasta sequence, and 
where “R” is the IUPAC ambiguity symbol: 
=LEN($D1)-LEN(SUBSTITUTE($D1,"R","")) 
Other IUPAC symbols used were Y,S,W,K,M,B,D,H and V. Whilst B,D,H and V represent 
mixtures of three bases, the presence of these symbols were counted as one nucleotide 
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ambiguity only. The ambiguity score was calculated as the sum of all IUPAC symbol counts 
per sequence divided by the length of the sequence, i.e. =LEN($D1). 
2.13.3 Building trees (PhyML, BEAST, FastTree) 
UKHIVDRD FastTree clusters 
A UK HIV Drug Resistance Database sequence alignment was supplied by the Medical 
Research Clinical Trials Unit (MRC-CTU) which was generated using Local Alignment 
Program (LAP) to align sequences to a reference sequence (consensus B) (Huang and Zhang 
1996). Subtype specific sequence alignments were taken forward to generate phylogenies 
using FastTree version 2.1 (Price, Dehal et al. 2010). A tree was inferred using the General 
Time Reversible model of nucleotide evolution option, together with the Gamma option to 
approximate the different rates of evolution across different sites. For each phylogeny 
generated, support for branches was assessed using the bootstrapping method. Phylip’s 
SEQBOOT (http://evolution.genetics.washington.edu/phylip/doc/seqboot.html) was used to 
generate 1000 re-sampled alignments from the original alignment in question, and these 1000 
bootstrap alignments were analysed in FastTree2.1 using the -n option to generate 1000 
bootstrap trees. The Perl script CompareToBootstrap.pl (supplied on the FastTree website 
http://www.microbesonline.org/fasttree/) was used to compare the tree from the original 
alignment in question to the 1000 bootstrap trees. 
 
2.14 In-house Perl scripts 
2.14.1 Identifying transmission clusters 
Identification of transmission clusters was carried out using a custom written Perl script 
utilising BioPerl and the Analyses of Phylogenetics and Evolution (APE) package in R 
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respectively (Paradis, Claude et al. 2004): findclusterdistances.pl (available from the author 
upon request), together with the Awk programming language and Linux command line 
(Appendix 2). 
2.14.2 HIV-1 recent infection transmission models 
Two transmission models described in results chapter 4 were written as custom Perl scripts: 
recentestablishedsorter_adapted_for_infector_assignment.pl together with 
genetic_distance_model.pl (Appendix 2), both available from the author upon request. 
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Chapter Three 
 
Assessing the performance of a nucleotide ambiguity 
based measure of HIV-1 infection length 
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3 Assessing the performance of a nucleotide ambiguity based measure of 
HIV-1 infection length 
 
Abstract 
Individuals with recent HIV-1 infection are potentially major drivers of transmission cluster 
formation due to the high viral titres and ongoing risky sexual behaviour associated with this 
risk group. Methods exist to detect individuals in this category, in order to better understand 
the role they play in HIV-1 epidemics. Whilst the majority of these methods are laboratory 
based, this chapter develops and validates a method based upon detecting nucleotide 
ambiguities in pol consensus sequencing. 
Using a stringently categorised cohort from the Royal Free Hospital, all with avidity assay 
results, a pol consensus sequence nucleotide ambiguity cut-off of 0.17% was identified as 
offering the best discrimination between recent and established infection in the development 
cohort (sensitivity and specificity of 85% and 82% respectively). A more stringent cut-off of 
0.00% was also investigated. Validation on two additional cohorts showed a reduced ability 
to detect true recent infection using both cut-offs, though the 0.00% cut-off offered greater 
positive predictive power. 
Overall, despite certain limitations, the approach may offer a useful way to identify 
individuals likely to have recent infection when only viral consensus sequence is available, 
such as in national HIV drug resistance databases.  
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3.1 Introduction 
HIV epidemics in every setting, whether in a developing or developed country context, are 
driven by transmission from individuals at different stages of infection (Wawer, Gray et al. 
2005; Boily, Baggaley et al. 2009). A variety of clinical and behavioural factors affect the 
likelihood of transmission from any particular stage, such as viral load (Pilcher, Tien et al. 
2004), awareness of infection status (Marks, Crepaz et al. 2005) and antiretroviral treatment 
(ART) status (Donnell, Baeten et al. 2010). A number of studies support the hypothesis that 
the initial stage of HIV-1 infection plays a major role in onward transmission of the virus 
because of a combination of these factors. It is well established that acute infection is 
associated with high viral titres in plasma (Pilcher, Shugars et al. 2001; Fiebig, Wright et al. 
2003), and correspondingly high viral titres in genital compartments (Pilcher, Joaki et al. 
2007; Morrison, Demers et al. 2010). There is also evidence to support the idea that 
individuals recently infected with HIV-1 may be unaware of their infection status, and 
transmission rates from individuals unaware of their infection have been found to be higher 
than from diagnosed individuals (Marks, Crepaz et al. 2006). It is clearly important for 
policymakers determining national public health strategies to better understand their HIV 
epidemics. Defining the transmission dynamics of individuals in the initial stages of HIV 
infection, and the role that recent infection plays in onward transmissions is required to guide 
prevention measures designed to reduce onward spread of HIV. 
To date, monitoring of the numbers of individuals in the initial stage of HIV infection 
has most commonly used laboratory assays that measure the evolving strength of the anti-
HIV antibody response over time, such as guanidine-based avidity assays (Chawla, Murphy 
et al. 2007; Mastro, Kim et al. 2010) and branched peptide antigen (BED) based capture 
Enzyme-Immuno Assays (EIA) (Parekh, Kennedy et al. 2002). These are often then 
combined with other clinical biomarkers, CD4
+
 cell count for example, into algorithms such 
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as the Serologic Testing Algorithm for Recent HIV Seroconversion (STARHS), developed by 
the US Centers for Disease Control and Prevention (CDC) (Janssen, Satten et al. 1998), or the 
Recent Infection Testing Algorithm (RITA) used by Public Health England (Garrett, 
Lattimore et al. 2012). 
Recently (partly overlapping in time with the work carried out in this chapter), a 
number of studies have investigated using HIV-1 sequences obtained from patients as part of 
routine antiretroviral drug resistance surveillance to estimate infection length in individuals, 
without recourse to serological assays (Kouyos, von Wyl et al. 2011; Ragonnet-Cronin, Aris-
Brosou et al. 2012; Andersson, Shao et al. 2013). This approach is based upon the assumption 
that the majority of HIV-1 infections are founded by a single virus (Zhang, MacKenzie et al. 
1993; Zhu, Mo et al. 1993; Keele, Giorgi et al. 2008), which over time expands in a linear 
manner into a highly heterogeneous viral quasi-species that can be observed as mixed 
nucleotide peaks (“ambiguities”) in electropherograms of consensus Sanger sequences. 
Kouyos et al. (2011) used three different cohorts of individuals, with their stage of infection 
estimated by different means (Bayesian back calculation using clinical information together 
with last known negative/first known positive dates; seroconversion estimated from last 
known negative/first known positive dates <180 days apart; and diagnosis of primary 
infection respectively) to generate a nucleotide ambiguity cut-off of >0.50% to indicate 
likelihood of an individual having been infected for >1 year. Ragonnet-Cronin et al. (2012) 
generated a training data set using individuals with p24 Ag+/Ab- results or negative test date 
within the 155 days prior to diagnosis as recently infected individuals, and patients with 
samples collected >155 days after diagnosis as established infections. The study also looked 
at whether concentrating on particular sequence sites might provide more information than 
using the overall sequence (e.g. sites of greater entropy, sites associated with HLA epitopes).  
They found that a cut-off of <0.45% nucleotide ambiguities best identified individuals with 
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recent infection (<155 days old), and that concentrating on sites that increased in entropy 
over the course of infection did improve sensitivity and specificity. The aim of this study was 
to combine the application of HIV antibody avidity testing and Sanger sequencing in a cohort 
of newly HIV-1 diagnosed patients with detailed clinical histories, in order to develop a 
nucleotide sequence ambiguity classifier that enables identification of recent HIV-1 infection. 
We assessed the utility of the proposed classifier in different cohorts and used deep-
sequencing to explore the extent to which low level subpopulations may affect the utility of 
the approach. 
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3.2 Methods 
3.2.1 Study population 
Three anonymised cohorts of newly diagnosed HIV-1 infected patients were used to develop 
and validate the ambiguity classifier: 1) 517 patients that attended the Ian Charleson Day 
Centre of the Royal Free Hospital (RFH), London, between 2004 and 2010 ; 2) 670 patients 
that between 1997 and 2009 became part of the UK Register of HIV Seroconverters, a UK-
wide database of newly diagnosed patients whose time of seroconversion can be reliably 
estimated using laboratory evidence, and; 3) 169 patients that attended the HIV clinic of St 
Mary’s Hospital (SMH), London, between 2008 and 2010. Clinical data from all three 
cohorts was stripped of patient identifiable information prior to being made available to the 
study. 
 
3.2.2 Recent infection testing 
Guanidine-based avidity assay results were available for the Royal Free Hospital patient 
cohort through routine clinical care (assays were performed by diagnostic staff). The assay 
measures the strength of binding between immunoglobulin G antibodies and three HIV-1 
antigens (p24, env10 and env13) using the anti-HIV-1 and -2 VITROS ECiQ assay (Ortho-
Clinical Diagnostics, United Kingdom) (Chawla, Murphy et al. 2007). An avidity index of 
≤0.75 reproducibly identifies seroconversion within the previous 125 days (95% confidence 
interval [CI], 85 to 164 days). A subset of the SMH cohort had results from a ‘detuned’ 
enzyme immunoassay (EIA) which identifies recently infected individuals using a modified 
protocol of the standard EIA used to detect HIV infection, by increasing the specimen 
dilution and decreasing the sample volume and substrate incubation times to make the assay 
less sensitive. A standard optical density (SOD) cut-off of ≤1.0 is associated with a HIV 
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infection of approximately 170 days (CI 95%: 163 to 183 days) (Rawal, Degula et al. 2003). 
The remainder of the SMH cohort (post-2008) had avidity results obtained using the AxSYM 
HIV 1/2 gO immunoassay (Abbott Diagnostics, Maidenhead, UK) (Suligoi, Galli et al. 2002). 
 
3.2.3 Nucleotide sequence generation 
Nucleic acid was extracted from plasma samples obtained from the RFH cohort, PCR 
amplified and cycle-sequenced as previously described (sections 2.4, 2.5 and 2.8) by 
members of the diagnostic staff at the Royal Free Hospital as part of routine diagnostic care. 
Ambiguous nucleotide peaks (i.e. mixed peaks, Figure 3.1) were identified using the default 
SeqScape mixed base peak cut-off of 25% (i.e., if a secondary peak reaches ≥25% of the 
height of the major peak, it is called as a mixed base), together with manual inspection of 
sequence electropherograms by individual members of the diagnostic staff at the Royal Free. 
Pol sequences were also retrieved from the UK Register of HIV Seroconverters, which 
receives sequence data generated by contributing laboratories across the UK using the 
Viroseq assay (Abbott, Maidenhead, UK), the TRUGENE genotyping kit (Bayer HealthCare, 
Berkeley, CA) or in-house methods. Finally, pol sequences obtained from the SMH cohort 
were generated by the Retrovirology Laboratory of Imperial College, London, using an in-
house nested PCR approach employing primers located within conserved regions of the Gag 
and RT genes. 
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Figure 3.1. Screenshot of an electropherogram displayed in the SeqScape software, with 
arrows indicating mixed base peaks and with the IUPAC representative code above (Y 
for pYrimidine, i.e. C or T). 
 
3.2.4 Nucleotide ambiguity analysis 
All patient sequences were supplied as fasta files, and were stripped of codons associated 
with transmitted drug resistance mutations prior to subsequent nucleotide ambiguity analysis 
(Bennett, Camacho et al. 2009). International Union of Pure and Applied Chemistry (IUPAC) 
nucleotide ambiguity coded nucleotides were enumerated for each patient pol sequence, 
regardless of whether the code represented a bi-or tri- nucleotide mixture (e.g. ‘R’ and ‘V’ 
were both counted as single ambiguous nucleotides). ‘N’ IUPAC codes were not included in 
the ambiguous nucleotide count on the basis that they were likely to be indicative of poor 
quality sequence, rather than a tetra-nucleotide mixture. 
 
3.2.5 Establishment of a nucleotide ambiguity cut-off 
The 517 newly diagnosed RFH patients were initially assigned to one of two categories, 
suspected recent infection and established infection, based on a HIV antibody avidity index 
cut-off of 0.75. 
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Because late stage HIV can also result in a low avidity index (Chargelegue, Stanley et al. 
1995), patients with avidity ≤0.75 were only retained for further analysis if they fulfilled one 
or a combination of the following criteria: 
i. no evidence of AIDS defining illness at diagnosis, and 
ii. last negative test <12 months prior to diagnosis, and/or 
iii. documented seroconversion illness, and/or 
iv. evidence of high risk exposure event(s) in the previous 6 months, and/or 
v. confirmatory SOD result <1.0 obtained from ‘detuned’ assay 
 
A minimum viral load of 1000 copies/ml for the sample used for pol sequence generation was 
imposed to ensure a sufficient number of viral particles were input into the PCR to enable 
observation of a quasi-species in Sanger sequence electropherograms. Briefly, 1ml of plasma 
was input into the extraction, nucleic acid was eluted into 25ul of elution buffer and 10ul of 
this was input into the reverse transcription polymerase chain reaction (RT-PCR) step. 
Assuming an arbitrary worst case scenario extraction efficiency of 65% and reverse 
transcription step efficiency of 10%, then 1000 copies/ml would become 650 copies of virus 
extracted into 25ul of elution buffer, and therefore 260 copies of virus input into the RT-PCR 
step. At 10% efficiency this would generate 26 cDNA molecules for PCR. Even allowing for 
a PCR efficiency of 50%, 13 molecules of cDNA should enable a 20-30% quasi-species to be 
detected in an electropherogram. Using the percentage of ambiguous nucleotides across pol 
for both patient categories, 10-fold cross-validation was used to select the cut-off that 
maximised the Youden index (a statistic which finds the cut-off value where a gain (or a loss) 
in specificity results in a loss (or a gain) of the same amplitude in sensitivity) (Youden 1950). 
Receiver Operating Characteristics (ROC) curve analysis was used to assess cut-off 
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performance. The process of cut-off selection was repeated with all non-B subtypes removed 
from the analysis to investigate subtype specific influences on classifier cut-off selection. 
 
3.2.6 Validation of the nucleotide ambiguity cut-off in additional cohorts 
In order to validate the performance of the nucleotide ambiguity cut-off, the UK Register of 
HIV Seroconverters and SMH cohorts were filtered to remove patients with uncertain 
infection stage categorisation, to produce a more stringent cohort for validation. The 
following criteria were used: 
 
UK Register of HIV Seroconverters stringent cohort: 
 Patients were considered to have had a recent infection at diagnosis if they were found 
to have laboratory evidence of seroconversion (HIV antibody negative with positive 
RT-PCR; test “incident” at low level (standard optical density < 1.0) using detuned 
assay (must be subtype B); equivocal HIV antibody test supported by a repeat test 
within a 2-week period showing a rising optical density; clinical manifestations of 
symptomatic HIV seroconversion illness supported by antigen positivity and <4 bands 
positive on Western Blot), or with a HIV positive antibody test within 125 days of an 
HIV negative antibody test. 
 Patients were considered to have had an established infection at diagnosis if they had 
no contraindicative laboratory evidence and had a HIV positive antibody test greater 
than 125 days after a HIV negative antibody test. 
 
SMH stringent cohort: 
 Patients were considered to have had a recent infection at diagnosis if they had an 
avidity index of ≤0.75 or ‘detuned’ assay SOD result <1.0. 
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 Patients were considered to have had an established infection at diagnosis if they had 
an avidity index of >0.75 or indication of established infection through an alternative 
detuned assay. 
  
After categorising patients into those diagnosed with recent infection and those diagnosed 
with established infection, a further filter of a minimum of 800bp sequence length was 
imposed in order to avoid classification based upon low sequence ambiguity generated by 
virtue of short sequence length (1 IUPAC coded base in a 800bp amplicon translates to 
0.125% ambiguous nucleotides across the sequence, 2 translates to 0.25%). A count of 
nucleotide ambiguities was then made for each patient derived pol sequence, and the RFH 
cohort cut-off applied. A sensitivity and specificity analysis was then performed on each 
cohort to investigate cut-off performance. The sensitivity and specificity performance was 
repeated with all non-B subtype sequences removed. 
 
3.2.7 Clinical data analysis 
In order to further investigate the performance of the ambiguity cut-offs on the validation 
cohorts, for each nucleotide ambiguity cut-off and each cohort, a Student’s t-test (2-tailed, 
type 3) was used to compare the CD4
+
 cell counts and viral loads of the cohort patients 
categorised as recent infections using laboratory methodology (i.e. the original stringent 
classification outlined in the methods section) to the CD4
+
 cell count and viral loads of the 
same patient cohort categorised as recent infections on the basis of the nucleotide ambiguity 
cut-off alone. This was repeated for those cohort patients categorised as established 
infections. 
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3.2.8 Comparison of Sanger sequence ambiguous nucleotides to deep-sequencing 
A subset of the patients already identified as having been diagnosed with recent infection on 
the basis of avidity and clinical information had sections of their pol and env deep-sequenced 
using 454 pyrosequencing as previously described (section 2.10). Patients were selected on 
the basis of having plasma samples with ≥20000 HIV-1 RNA copies/ml available. Reads 
were quality filtered using the fastq filtering step within the UPARSE pipeline (Edgar 2013). 
A comparison was made between the consensus sequence ambiguous nucleotides and 
deep-sequencing results to gain a greater understanding of the viral dynamics that result in 
mixed nucleotides. Briefly, a per-nucleotide 'consensus' sequence was constructed from the 
deep-sequencing reads alignment by selecting the most abundant nucleotide at each position. 
This consensus sequence was then aligned and compared to the Sanger pol sequence from the 
same sample and scored for a) exact nucleotide matches, b) if there was an International 
Union of Pure and Applied Chemistry (IUPAC) ambiguity code in the Sanger sequence at the 
position in question then the nucleotide variants above a prevalence cut-off of 2% in the 
deep-sequencing alignment were used to construct an IUPAC ambiguity code, and this was 
compared to the Sanger IUPAC code for a match, c) if the Sanger pol sequence had an A, C, 
G or T at the position in question, but this did not match the most abundant nucleotide in the 
deep-sequencing, then the second most abundant nucleotide present in the deep-sequencing 
alignment was compared to see if it matched, d) all other mismatches were scored as non-
matches. 
In order to ascertain whether or not patients were likely to have been infected by or to 
have developed more than one viral subpopulation over time, which would impact upon the 
applicability of the classifier, the deep-sequencing reads for each sample were passed through 
the UPARSE read clustering pipeline. Initial ‘seed’ subpopulation sequences were identified 
as subpopulation centroids on the basis of read abundance and being >3% genetically distant 
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from other centroids. Remaining reads with ≥97% identity to any subpopulation centroid 
were then clustered with that subpopulation. Sensitivity analysis was carried out to observe 
whether or not altering the distance cut-off would change the number of subpopulations 
identified within each sample. Two further cut-offs of 1% and 2% were substituted into the 
original pipeline, with all other parameters remaining unaltered. Read counts for 
subpopulations identified using the 3% cut-off were subjected to a margin of error correction 
using a 99% confidence interval (section 2.12). The lower boundary margin of error corrected 
percentage was used to decide whether the subpopulation was present at abundance greater 
than the chosen read abundance cut-off of 1%. The Poisson-Fitter tool was used to give an 
estimate of infection date using 500 randomly selected reads from the most abundant 
subpopulation in patient first time point samples only, to avoid over-estimates of infection 
date cause by multiple subpopulations. Where samples met the assumption of a star-like 
phylogeny, the estimate of time since most common recent ancestor (MRCA) was taken to be 
equivalent to the date of infection. The median time to MRCA across samples meeting the 
assumption of star-like phylogeny was used for the remaining samples where the assumption 
was not met. 
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3.3 Results 
3.3.1 Classifier development 
Using a guanidine-based avidity assay index cut-off of ≤0.75, 131/517 (25.3%) RFH patients 
were classified as having undergone seroconversion within the previous 125 days (95% CI: 
85 to 164 days) and 386/517 (74.7%) patients were classified as having had an established 
infection at time of diagnosis. By case record review, 103/131 (78.6%) patients with avidity 
indices ≤0.75 had a history of seroconversion illness or high risk behaviour within the 
previous 6 months; 28/131 (21.4%) patients were excluded from the analysis because of a 
lack of such evidence, a CD4
+
 cell count below 150 copies/ml, or they presented with an 
AIDS defining illness, which is associated with a reduced antibody avidity index 
(Chargelegue, Stanley et al. 1995) (Table 3.2). An additional 5 individuals were excluded 
from this patient group on the basis of low viral load (<1000 copies/ml), leaving 98 patients 
with a median viral load of 64900 copies/ml (IQR: 17268-311454 copies/ml). In addition, 
17/386 patients with established infection at diagnosis were also excluded on the basis of low 
viral load, leaving 369 patients in this category. Patient pol sequences were stripped of 
codons associated with transmitted drug resistance mutations and the percentage of IUPAC 
nucleotide ambiguity coded nucleotides was correlated with avidity index using only the 98 
patients with verified recent infection and the 369 patients with avidity indices >0.75. 
 
RFH cohort, all subtypes: A cut-off of ≤0.17% ambiguous bases was found to 
maximise both sensitivity and specificity when used to identify sequences likely to 
have been generated from an individual who underwent seroconversion within the 
previous 125 days (95% CI: 85 to 164 days). The cut-off gave an area under the curve 
(AUC) of 0.83, and recent infection identification sensitivity 83/98 (85%) and 
specificity of 302/369 (82%). 83/150 individuals with a nucleotide ambiguity score 
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≤0.17% were clinically verified as recent infections. As the selection of patients was 
effectively cross-sectional, an estimate of prevalence of recent infection can be 
determined, allowing a positive predictive value of 0.85 to be calculated (Altman and 
Bland 1994). 
 
RFH cohort, subtype B only: A cut-off based solely on subtype B sequences was 
identified in the same way, using 83 patients diagnosed with recent infection by the 
specified criteria, and 176 diagnosed with established infection. A cut-off of 0.14% 
was identified as maximising both sensitivity and specificity (63/83, 76% and 
137/176, 78% respectively), with an AUC of 0.77, and positive predictive value of 
0.85. 
 
A more stringent cut-off of 0.00% nucleotide ambiguities was investigated to see if the 
performance of the classifier was significantly altered. 
 
RFH cohort, all subtypes, 0.00% cut-off: On the full cohort the cut-off gave a 
sensitivity and specificity of 62/98 (63%) and 350/369 (95%) respectively, with a 
positive predictive value of 0.98. 
 
RFH cohort, subtype B only, 0.00% cut-off: The subtype B only cohort gave a 
sensitivity and specificity of 48/83 (58%) and 161/176 (91%) respectively, with a 
positive predictive value of 0.96. 
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Table 3.2. Table shows numbers of RFH nucleotide ambiguity development cohort 
patients with avidity indices ≤0.75 excluded on the basis of a combination of clinical 
criteria. 
  
Exclusion criteria Number excluded
No last negative test <12 months prior to diagnosis
AND
no documented seroconversion illness
AND
no evidence of high risk exposure event(s) in the previous 6 months
AND
no confirmatory SOD result <1.0 obtained from ‘detuned’ assay 
13
No last negative test <12 months prior to diagnosis
AND
no documented seroconversion illness
AND
no confirmatory SOD result <1.0 obtained from ‘detuned’ assay 
5
No last negative test <12 months prior to diagnosis
AND
no evidence of high risk exposure event(s) in the previous 6 months
AND
no confirmatory SOD result <1.0 obtained from ‘detuned’ assay 
5
No last negative test <12 months prior to diagnosis
AND
no confirmatory SOD result <1.0 obtained from ‘detuned’ assay 
1
No documented seroconversion illness
AND
no evidence of high risk exposure event(s) in the previous 6 months
AND
no confirmatory SOD result <1.0 obtained from ‘detuned’ assay 
3
No evidence of high risk exposure event(s) in the previous 6 months
AND
no confirmatory SOD result <1.0 obtained from ‘detuned’ assay 
1
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3.3.2 Validation 
Validation of the cut-offs was carried out on two additional HIV-1 new diagnosis cohorts 
obtained from the UK Register of Seroconverters and St Mary’s Hospital. Of the original 670 
patients, 31 were removed from the UK Register of Seroconverters cohort due to sequence 
length falling below the 800bp length restriction, leaving 639 patients for the validation, 10 of 
the 169 original patients from the St Mary’s cohort were removed for the same reason, 
leaving 159 patients for the validation. 
 
UK Register of HIV Seroconverters and SMH cohorts, all subtypes, 0.17% cut-off: 
Applying the 0.17% cut-off to the UK Seroconverters Register cohort resulted in a 
sensitivity and specificity of 126/204 (62%), 258/435 (59%) respectively, and a 
positive predictive value of 0.52. For the SMH cohort the results for sensitivity and 
specificity were 17/27 (63%) and 85/132 (64%) respectively, with a positive 
predictive value of 0.39 (Table 3.3). 
 
UK Register of HIV Seroconverters and SMH cohorts, subtype B only, 0.14% cut-off: 
The results when using the 0.14% cut-off on subtype B only sequences for both 
cohorts were a sensitivity and specificity of 101/170 (59%) and 259/395 (66%) 
respectively and positive predictive value of 0.56 for the UK Seroconverters Register, 
and for the SMH cohort, a sensitivity and specificity of 15/24 (63%) and 50/89 (56%) 
respectively and positive predictive value of 0.35. 
 
UK Register of HIV Seroconverters and SMH full and subtype B only stringent 
cohort, 0.00% cut-off: After appropriate removal of all sequences below 800bp in 
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length, application of a 0.00% cut-off for the full UK Seroconverters Register cohort 
resulted in a sensitivity and specificity of 105/204 (51%) and 336/435 (77%) 
respectively and positive predictive value of 0.71, and for the subtype B only cohort 
86/170 (51%) and 307/395 (78%) respectively and positive predictive value of 0.69. 
For the SMH full cohort the sensitivity and specificity was 10/27 (37%) and 106/132 
(80%) respectively and positive predictive value of 0.42, and for the subtype B only 
cohort 9/24 (38%) and 69/89 (78%) respectively and positive predictive value of 0.43 
(Table 3.4). 
 
 
 
Table 3.3. Sensitivity and specificity results for the 0.17% nucleotide ambiguity cut-off 
when applied to the UK Register of HIV Seroconverters and SMH cohorts. Columns 
‘Recent’ and ‘Established’ correspond to categorisation using criteria outlined in 
methods section. Rows ‘≤0.17% ambiguities’ and ‘>0.17% ambiguities’ correspond to 
categorisation using the percentage of ambiguous nucleotides across the length of the 
pol sequence. 
 
UK Serocon stringent SMH stringent
0.17% 0.17%
Recent Established Recent Established
≤0.17% ambiguities 126 177 303 ≤0.17% ambiguities 17 47 64
>0.17% ambiguities 78 258 336 >0.17% ambiguities 10 85 95
204 435 27 132
0.62 0.59 0.63 0.64
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Table 3.4. Sensitivity and specificity results for the 0.00% nucleotide ambiguity cut-off 
when applied to the UK Register of HIV Seroconverters and SMH cohorts containing 
all subtypes (top panels), and containing patients with subtype B infections only (bottom 
panels). 
 
3.3.3 Clinical data analysis 
CD4
+
 cell counts and viral loads of the cohort patients categorised as recent infections using 
laboratory methodology were compared to the CD4
+
 cell count and viral loads of the same 
patient cohort categorised as recent infections on the basis of the nucleotide ambiguity cut-off 
alone. This was repeated for those cohort patients categorised as established infections. 
313/670 (47%) of UK Register of HIV Seroconverter patients had CD4
+
 cell count results 
obtained from blood samples taken > 1 month from the date of the blood sample the 
sequencing was carried out on, and these patients were excluded from the analysis. For all the 
RFH and SMH cohorts, CD4
+
 cell count medians for patients whose HIV-1 infection lengths 
were categorised on the basis of the nucleotide ambiguity classifier did not differ 
significantly from the CD4
+
 cell count medians of patients when categorisation of infection 
UK Serocon stringent SMH stringent
0.00% 0.00%
Recent Established Recent Established
≤0.00% ambiguities 105 99 204 ≤0.00% ambiguities 10 26 36
>0.00% ambiguities 99 336 435 >0.00% ambiguities 17 106 123
204 435 27 132
0.51 0.77 0.37 0.80
UK Serocon stringent B only SMH stringent B only
0.00% 0.00% cut-off
Recent Established Recent Established
0.00% ambiguities 86 88 174 0.00% ambiguities 9 20 29
>0.00% ambiguities 84 307 391 >0.00% ambiguities 15 69 84
170 395 24 89
0.51 0.78 0.38 0.78
83 
 
length was based on laboratory evidence. For the UK Register of HIV Seroconverter cohort, a 
significant difference was found between the median CD4
+
 count of those categorised as 
established infections on the basis of laboratory evidence and those categorised on the basis 
of the 0.17% cut-off. There was also a significant difference between the median viral loads 
of those categorised as recent infections on the basis of laboratory evidence and those 
categorised on the basis of the 0.17% cut-off. All other comparisons indicated no significant 
differences between median CD4
+
 counts and median viral loads in the UK Register of HIV 
Seroconverter cohort (Table 3.5). 
 
 
 
Table 3.5. Comparison of median CD4
+
 cell count and viral load between patients 
categorised as either recent infections or established infections by i) laboratory methods 
or ii) nucleotide ambiguity cut-off, using Wilcoxon rank sum test with continuity 
correction. 
Cohort
Nucleotide 
ambiguity cut-
off level
Laboratory 
classified 
Ambiguity 
classified 
p-value
Laboratory 
classified 
Ambiguity 
classified 
p-value
Royal Free Hospital stringent, viral load filtered 0.17 562 518 0.13 254 227 0.14
Royal Free Hospital stringent, viral load filtered 0.00 562 560 0.71 254 270 0.47
UK Seroconverter stringent 0.17 440 477 0.09 477 400 <0.05
UK Seroconverter stringent 0.00 440 473 0.15 477 443 0.24
St Mary's Hospital stringent 0.17 665 520 0.05 400 340 0.44
St Mary's Hospital stringent 0.00 665 495 0.11 400 395 0.71
Cohort
Nucleotide 
ambiguity cut-
off level
Laboratory 
classified 
Ambiguity 
classified 
p-value
Laboratory 
classified 
Ambiguity 
classified 
p-value
Royal Free Hospital stringent, viral load filtered 0.17 90157 43386 0.11 65612 80951 0.24
Royal Free Hospital stringent, viral load filtered 0.00 90157 55105 0.72 65612 70383 0.82
UK Seroconverter stringent 0.17 190839 100000 <0.01 56359 69219 0.09
UK Seroconverter stringent 0.00 190839 118000 0.08 56359 60650 0.40
St Mary's Hospital stringent 0.17 25069 18507 0.91 19027 19906 0.75
St Mary's Hospital stringent 0.00 25069 18507 1.00 19027 19891 0.95
Mean viral load (copies/ml) 
Recents Establisheds
Mean CD4 cell count (cells/mm3)
Recents Establisheds
84 
 
3.3.4 Comparison of Sanger sequence ambiguous nucleotides to deep-sequencing 
Deep-sequencing results for each patient time point were compared to the Sanger population 
pol sequence generated from the sample, where available. 34 patients had Sanger pol 
sequence available for one or more time points (62 samples overall). Sequences were 
manually edited using the SeqScape v2.6 software (Applied Biosystems, Warrington, United 
Kingdom) prior to reference to deep-sequencing results. When exact nucleotide matches 
between the deep-sequencing and Sanger sequences were compared, a median of 99.7% 
(IQR: 98.7,100%) of nucleotides matched across the deep-sequencing amplicon (~390bp). 
When IUPAC and second most abundant nucleotide matches were taken into account, 
agreement went up to a median of 100% of nucleotides (IQR:100,100%) across the 
amplicons. Of interest, 5 samples had nucleotides at an abundance of only 5-15% in the deep-
sequencing alignment were involved in an IUPAC ambiguity code match, a level much lower 
than classically accepted as likely to be revealed in Sanger sequence electropherograms. 
 The presence of minority subpopulations within patient samples was assessed using a 
read-clustering approach, with reads clustered into subpopulations with centroid sequences 
>3% genetically distant from one another. Subpopulations were verified by selecting only 
those present at a margin of error corrected cut-off of ≥1% total sample reads. Those meeting 
this criteria were then further scrutinised using BLAST and neighbor-joining trees, to assess 
the possibility that they were the result of contamination by multiplex identifier tag 
switching, or other sources of error (Carlsen, Aas et al. 2012). After margin of error 
correction, 45/65 (69.2%) and 43/65 (66.2%) samples had single pol and env subpopulations 
respectively, indicating 20/65 (30.8%) and 22/65 (33.8%) samples had >1 subpopulation in 
pol and env respectively. Where these minority subpopulations matched to within a <1% 
genetic distance of another subpopulation, unless the matching subpopulation was seen in 
additional time points from the same patient, it was excluded from the analysis on the basis 
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that it could be the result of MID tag switching. This filtering step reduced the number of 
samples likely to have >1 subpopulation to 13/65 (20.0%) and 18/65 (27.8%) for pol and env 
respectively. 
 Application of the Poisson-Fitter tool to 500 randomly selected reads from the 
dominant subpopulation of the first time point for each patient found that 22/36 patient first 
time points fitted the assumption of a star-like phylogeny. The median time since MRCA for 
these samples was 120 days (IQR: 106.5-137 days), and this value was used for the patients 
not fitting the assumptions of star-like phylogeny. Pertinent to the potential utility of the 
nucleotide ambiguity tool, 4/36 (11.1%) patients had good evidence for multiple 
subpopulations in pol at first time point, all were assigned a time since MRCA of 120 days 
(0/4 patients met the assumption of star-like phylogeny required by Poisson-Fitter). For env, 
8/36 (22.2%) patients had good evidence for multiple subpopulations, three of which matched 
samples with multiple subpopulations in pol (0/8 patients met the assumption of star-like 
phylogeny required by Poisson-Fitter). 
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3.4 Discussion 
This study aimed to investigate the use of a HIV-1 pol sequence nucleotide ambiguity 
classifier to determine the length of HIV-1 infection based solely on sequence information 
obtained as part of routine drug resistance surveillance. The classifier was developed on a 
cohort of patients who had guanidine-based avidity assay results and clinical information 
available, enabling stringent categorisation of patients into recent and established infection 
categories prior to sequence ambiguity analysis. The classifier cut-off selected was ≤0.17% 
nucleotide ambiguities across the pol region, which was taken to be indicative of recent 
infection, where recent infection was defined, through linkage with the avidity assay, as 
seroconversion within the previous 125 days (95% confidence interval 85 to 164 days). This 
cut-off was selected to maximise both sensitivity and specificity, which were calculated as 
85% and 82% respectively, with a positive predictive value of 0.85. 
When validated against two independent cohorts of newly diagnosed patients (from 
the UK Register of HIV Seroconverters and St Mary’s Hospital, London), the cut-off offered 
a reduced level of discrimination between recent and established infections, with sensitivity 
and specificity calculated as between 62-63% and 59-64% respectively, and a positive 
predictive value of 0.52 and 0.39 respectively. When the nucleotide ambiguity cut-off was 
reduced to 0.00% ambiguities across pol (with a minimum sequence length of 800bp), the 
positive predictive values were improved for both validation cohorts (0.71 and 0.42 
respectively), but were still low when compared to the development cohort positive 
predictive value of 0.98 at this cut-off level. 
Restricting the development cohort to the predominating subtype present, subtype B, 
and validating on only subtype B sequences from validation cohorts, did not alter the 
sensitivity and specificity to any great degree, regardless of whether the cut-off was 
developed to maximise sensitivity and specificity, or to maximise specificity only. This may 
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be a reflection of the predominance of subtype B in the development and validation cohorts, 
which varied from 71-88% subtype B. If this is the case, then it may be advisable to 
investigate potential subtype effects further in settings where subtype B is not the most 
common subtype present, as in these settings there may be a variety of factors that affect the 
immune response or the maturation curve dynamics of the underlying antigen avidity assay, 
such as HIV-1 subtype, genetic background and so forth (Sakarovitch, Rouet et al. 2007). 
It is important to note that sample size of a cohort will inevitably have an effect on the 
confidence that the selection is representative of the true underlying proportion of recent 
infections in the population as a whole. The smaller the sample size the greater the margin of 
error in the number of recent infections selected will be. This can have impressive effects 
upon the positive prediction value. For example, a margin of error at a 99% confidence level 
for the 159 patients in the St Mary’s cohort would mean that the underlying number of ‘true’ 
recent infections sampled could vary between 12 and 38 (the actual number sampled being 
27). This in turn can lead to variation in the positive predictive value of 0.24-0.69 when using 
the 0.17% nucleotide ambiguity cut-off. 
It is encouraging to observe that the clinical profile of RFH and SMH cohort patients 
identified as having recent infection using the nucleotide ambiguity classifier was not found 
to differ significantly from the patients with recent infection identified using laboratory 
methods, in terms of viral loads and CD4
+
 cell count. However, there were found to be 
differences between the median CD4
+
 count and median viral load for the UK Register of 
HIV Seroconverters cohort when using the 0.17% cut-off, which may indicate support for the 
use of the more stringent 0.00% cut-off. 
The analysis of deep-sequencing results enabled exploration of the underlying quasi-
species landscape that contributes to the consensus sequence seen when using traditional 
Sanger sequencing. It also enabled an assessment of the extent to which recent infections 
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consist of a single subpopulation that is generated by expansion of a single founder virion 
after infection – an assumption which, if violated in large numbers of patients, may impact 
upon the suitability of the nucleotide ambiguity methodology to determine length of 
infection. The high degree of concordance between deep-sequencing variants and Sanger 
sequencing nucleotide ambiguities suggests that Sanger sequencing is a good representation 
of the underlying quasi-species present within a patient, and that nucleotide ambiguities seen 
in electropherograms do represent the true underlying proportions of variants present when 
the minority species is at a certain minimum level of abundance. This validates the use of 
Sanger consensus sequences as a proxy for underlying genetic complexity in HIV-1 
infections, an assumption which the use of nucleotide ambiguity implicitly makes. 
It is important to note that the route of HIV-1 infection can confound nucleotide 
ambiguity based classifier accuracy due to the fact that infection routes associated with risk 
groups such as men who have sex with men (MSMs) and people who inject drugs (PWIDs) 
may enable a greater number of viral particles to found an infection, generating an immediate 
quasi-species (Bar, Li et al. 2010; Li, Bar et al. 2010). Co-infection, where an individual is 
infected by two or more individuals before the initial infection has had a chance to establish 
itself, may also lead to confounding nucleotide ambiguities in the viral sequence, but is 
thought to be comparatively rare in the overall HIV-1 infected population (Cornelissen, 
Jurriaans et al. 2007). The results of the read clustering approach taken in this study strongly 
indicate that the majority of infections in this cohort were founded by a single virion, or 
several highly genetically similar virions, as has been observed in studies in other populations 
(Zhang, MacKenzie et al. 1993; Zhu, Mo et al. 1993; Keele, Giorgi et al. 2008). Of the 9 
individuals with >1 subpopulation in pol or env in their first time point, 3 individuals had 
support for 2 subpopulations in both pol and env, 5 had evidence of 2 subpopulations in env 
but not in pol, and 1 had support for 2 subpopulations in pol but only 1 in env. This perhaps 
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suggests that env may be under greater pressure to diversify under host immune pressure, 
such that even if one virion founded the infection, immune pressure is rapidly brought to 
bear, and evolution to evade this pressure occurs in env first. Overall, the low number of 
patients in this cohort with evidence for >1 subpopulation in the time point closest to 
infection lends legitimacy to the application of the nucleotide ambiguity classifier to patients 
newly diagnosed with HIV-1. However, it may well be worth more thoroughly investigating 
patients likely to have been infected by different transmission routes (e.g. MSMs and 
PWIDs), and who may therefore be subject to differing infecting inoculums, as it may not be 
appropriate to apply the ambiguity classifier to their viral sequences. 
The three other similar studies on this topic produced nucleotide ambiguity cut-offs of 
>0.50% for infections >1 year (Kouyos, von Wyl et al. 2011), <0.45% for infections <155 
days (Ragonnet-Cronin, Aris-Brosou et al. 2012), and <0.47% for infections <1 year 
(Andersson, Shao et al. 2013).  It is worth noting that across 1300bp (the typical length of pol 
sequenced for drug resistance surveillance), the overall range, including the results of this 
chapter, of  0.17% to 0.50%  translates to between 2 and 7 ambiguous nucleotides. Whilst the 
variability of the cut-offs and the definitions of the recent infection period do differ, the 
combined message from these previous studies and the results of this chapter seems to be that 
nucleotide ambiguity does increase over the initial period of infection, and as such it can be 
used to identify individuals with recent infection with a sensitivity and specificity 
approaching that of laboratory tests.  
In terms of issues and limitations of the study, it is important to acknowledge that 
differences in sequencing and sequence analysis performance across different clinical 
laboratories have the potential to impact upon the applicability of the classifier across 
sequences generated by different laboratories. The potential impact of this issue could be 
further investigated by performing repeats of  sequencing runs to check for the consistency of 
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ambiguous peaks between experiments. The extent to which the same individual calls 
ambiguous nucleotides at different time points, and how different individuals call the same 
ambiguous nucleotides could also be ascertained experimentally. Reassurance that the 
potential significance of this factor may not have an overly negative impact upon the 
suitability of the nucleotide ambiguity approach comes from an investigation into variation in 
DNA sequencing performance across laboratories carried out by Patton, Wallace et al. 
(Patton, Wallace et al. 2006). The study used a set of reference DNA samples (fragments of 
exon 10 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene) to 
investigate laboratory differences in the quality of sequence data, ability to detect variant 
genotypes, and mutation nomenclature. They found a 5% genotyping error rate, split roughly 
equal between false negative and false positive errors. In their judgement, the majority of the 
sixty-one laboratories included in the analysis “produced results of acceptable diagnostic 
quality as judged by these indicators” and suggested that where errors did occur, it was 
primarily down to “human error, failure of mutation scanning software, or a combination of 
both”. 
With this last comment in mind, and with the caveat that Patton, Wallace et al. (2006) 
did not aim to compare performance in identification of ambiguous nucleotides in 
sequencing, it is arguable that a nucleotide ambiguity cut-off of 0.00% may reduce the 
significance of sequence quality issues in this context (in combination with a minimum 
sequence length requirement). Sequence quality issues, though having the potential to 
increase false positive ambiguous peaks (whether human or software read), should have less 
of an effect on specificity: intuitively, it seems unlikely that poor quality sequence above a 
certain length would have no ambiguous nucleotides, and hence unlikely that a sequence with 
more than 0.00% ambiguous nucleotides – poor quality or not – would be classified recent by 
mistake. The minimum sequence length of 800bp imposed in this study means that, on 
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average, the presence of zero ambiguous nucleotides should imply an ambiguous nucleotide 
rate of no more than 0.0625% (because 0.5 ambiguous nucleotides across 800bp is 0.0625%, 
and, probabilistically, at this rate one in every two sequences should harbour an ambiguous 
nucleotide). Substantially shorter sequences with zero ambiguous nucleotides could lead to an 
incorrect estimation of nucleotide ambiguity – e.g. if there are zero ambiguous nucleotides in 
400bp of truncated pol sequence, it is impossible to know if the full 800bp pol sequence 
would have had zero or ≥1 nucleotide ambiguities. The 800bp minimum sequence length also 
allows laboratories utilising the TRUGENE HIV-1 Genotyping Assay to apply the nucleotide 
ambiguity classifier to their archived sequences, as the assay generates sequence for codons 
1-99 of protease and codons 41-237 of reverse transcriptase (i.e. 885bp of pol) (Grant, 
Kuritzkes et al. 2003). Further work on the impact laboratory and protocol variation may 
have upon sequence quality may be warranted. 
A final point must be made in relation to the use of the guanidine-based avidity assay 
as the reference standard, whilst the assay itself is not a gold-standard. This is, of course, not 
without precedent in the development of clinical markers, where there may often not be a 
single gold-standard reference test available, and a variety of methods have been proposed to 
address this (Spiegelman, Schneeweiss et al. 1997; Hawkins, Garrett et al. 2001; Rutjes, 
Reitsma et al. 2007). It may be worth investigating patients where the guanidine-based 
avidity assay and nucleotide ambiguity results are discordant, and employ some other 
indicators of infection length such as CD4
+
 cell count, in order to ascertain the likely cause of 
the discrepancy. In terms of an accurate assessment of overall sensitivity, specificity and 
positive predictive value that take the sensitivity and specificity of the guanidine-based assay 
into account, various methods for carrying this out in a statistically robust manner remain 
under development, and so it is beyond the scope of this study to fully resolve this limitation. 
Whilst this may impact upon the use of the nucleotide ambiguity classifier in isolation in a 
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clinical setting, the classifier arguably remains useful in the context of additional clinical data 
in individual patient scenarios, and is likely to be a useful research tool when applied to 
large-scale patient cohorts, with limited clinical data available to complement their viral 
sequence data. 
In conclusion, we have investigated population sequence nucleotide ambiguity as a 
measure of the length of HIV-1 infection by linking virus sequence with results from a 
guanidine-based avidity assay able to identify individuals who have seroconverted within the 
previous 125 days. As noted by previous investigators in this area, the classifier has the 
potential to be useful in a clinical setting as part of an overall recent infection testing 
algorithm, when applied in conjunction with additional data, such as CD4
+
 cell count. The 
classifier may also be useful on its own when utilising sequence data obtained from national 
drug resistance surveillance databases, where additional clinical data may not be available for 
the majority of patients. In this context, the classifier has the potential to be combined with 
phylogenetic approaches to investigate the role of the initial stage of HIV-1 infection in 
larger-scale epidemic transmission dynamics. 
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4 An investigation into the extent to which individuals with recent 
infection drive the formation of HIV-1 transmission clusters in the UK 
 
Abstract 
A significant proportion of HIV-1 transmission within the UK epidemic may come from 
individuals in the recent phase of infection due to particular risk factors associated with this 
risk group. Phylogenetic approaches can shed light on the extent to which this is true, and this 
chapter represents a large scale phylogenetic analysis of infected individuals in the UK, in 
combination with application of a nucleotide ambiguity based marker of infection length 
developed in chapter three. 
Within the UK HIV Drug Resistance Database, 5250 transmission clusters were identified 
using a bootstrap support cut-off of ≥0.95 and a maximum intra-cluster pairwise genetic 
distance ≤0.045 substitutions per nucleotide (Hamming distance). A disproportionate number 
of individuals classified as having recent infection at blood sample collection date were found 
to be linked to transmission clusters. Using two proof-of-principle modelling approaches, 
there was evidence that larger clusters had a greater proportion of transmissions from the 
recent phase of infection. 
The approach taken within the chapter lends further support to the hypothesis that individuals 
with recent infection play a disproportionate role in the UK HIV-1 epidemic. The work also 
demonstrated the utility of a consensus sequence based marker of infection length for the 
investigation of epidemic dynamics. 
 
95 
 
4.1 Introduction 
The initial stages of HIV-1 infection, around the period of seroconversion, are associated 
with extremely high levels of viral replication (Pilcher, Shugars et al. 2001; Fiebig, Wright et 
al. 2003), with individuals in this period frequently having plasma HIV-1 RNA levels in 
excess of 10
6
 copies/ml. High virus levels in blood are mirrored in the elevated levels found 
in genital secretions (Pilcher, Joaki et al. 2007; Morrison, Demers et al. 2010), with a number 
of studies indicating that higher viral levels in the genital compartment increase the 
probability of transmission to sexual partners per coital act (Leynaert, Downs et al. 1998; 
Hollingsworth, Anderson et al. 2008). 
 Mathematical models incorporating this higher level of infectivity with particular 
patterns of sexual behaviour during the early stage of infection, when individuals may not be 
aware of their infection status, suggest that individuals with recent infection play a 
disproportionate role in the spread of national HIV-1 epidemics (Jacquez, Koopman et al. 
1994; Koopman, Jacquez et al. 1997). These studies, however, have lacked important data on 
contact networks, such as the rate at which individuals form sexual relationships with others. 
 More recently, there have been attempts to use a phylogenetic approach to gain a 
greater understanding of transmission events and contact networks. These are captured as 
statistically robust clusters of individuals with highly related viral strains, representing chains 
of infections more closely linked to each other than the average level of linkage across the 
epidemic as a whole. Once identified, factors leading to the formation of these more highly 
related clusters, such as the stage of HIV-1 infection, can be assessed (Lewis, Hughes et al. 
2008; Fisher, Pao et al. 2010). To date, these studies have supported the idea of a 
disproportionate role in transmission for individuals with recent infection. The studies have 
addressed particular HIV epidemics of limited size, where transmission intervals were 
assessed using either serological data available in individual clinics, or methodologies that 
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would be computationally unfeasible with the large numbers of sequences involved on the 
scale of whole epidemics (Lewis, Hughes et al. 2008; Fisher, Pao et al. 2010). 
 This study represents an extension of the phylogenetic approach, by investigating a 
large-scale national HIV-1 phylogeny using viral samples obtained from HIV-1 infected 
individuals from across the UK between 1997 and 2009. The analysis incorporates a 
previously developed classifier for use with nucleotide sequence data which categorises 
individuals into two categories: individuals with recent infection at blood sample collection 
date and individuals with established infection at blood sample collection date. The 
classification is based upon the proportion of ambiguous nucleotides present in the viral 
sequence of the individual, and the period considered to be recent is 125 days post-
seroconversion (95% CI: 85 to 164 days). Transmission clusters were identified using 
standard phylogenetic methodology, and individuals within those clusters categorised into 
those having had a recent infection at time of blood sample collection, and those not, and 
their contribution to transmission within the cluster assessed. The analysis was then extended 
to include transmitted drug resistance circulating within this group, as this may also have 
important consequences for healthcare intervention strategies. 
 Two proof-of-concept methods were investigated to demonstrate the potential utility 
of applying the nucleotide ambiguity classifier to sequences within a phylogeny in order to 
shed light on the transmission dynamics of individuals with recent infection within clusters. 
Both methods utilised a combination of information captured by phylogenetic analysis and 
results of the application of the nucleotide ambiguity classifier to examine the extent to which 
individuals in the initial stages of HIV infection may disproportionately contribute to onward 
transmission of HIV in the UK epidemic.  
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4.2 Materials and Methods 
4.2.1 Identifying transmission clusters within UK HIV Drug Resistance Database 
The UK HIV Drug Resistance Database (UKHIVDRD), established in 2001, is a central 
repository for drug resistance tests performed as part of routine HIV clinical care throughout 
the UK. The UKHIVDRD release used in this study contained 55556 pol gene sequences 
collected from 43002 anonymised individuals. 
 Sequences were supplied individually pre-aligned to a reference sequence (consensus 
B) using the LAP alignment program (Huang and Zhang 1996). Where duplicate sequences 
from the same patient existed, the chronologically earliest sequence was used. For practicality 
of analysis, sequences were divided into subtype subsets based on the REGA subtyping 
algorithm (De Oliveira, Deforche et al. 2005). To avoid possible convergent evolution due to 
transmitted drug resistance associated mutations (DRAMs) at particular codons, phylogenies 
were constructed using FastTree2.1 (Price, Dehal et al. 2010) with i) alignments with DRAM 
associated codons removed, and ii) alignments with only the 1
st
 and 2
nd
 nucleotide positions 
from each codon removed. Bootstrapping was carried out using 1000 replicates with 
FastTree2.1. 
 Clustering of particular sequences was deemed to be robust if there was bootstrap 
support of ≥0.95 in both DRAM codon stripped and 3rd codon position only trees, and a 
maximum intra-cluster pairwise genetic distance ≤0.045 substitutions per nucleotide 
(Hamming distance). Nested clusters were removed, so that all sequences linked to clusters 
were linked to one cluster only. As transmission clusters comprising individuals from the UK 
were the primary focus of the study, clusters from each subtype subset were aligned with 
relevant subtype sequences from the Los Alamos database (with UK sampled sequences 
removed) and trees re-drawn in order to identify and remove or split clusters that were linked 
to non-UK sequences with Shimodaira-Hasegawa-like local support values of ≥0.99 
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(Shimodaira and Hasegawa 1999). All sequences were assessed for treatment status using 
information submitted to the UKHIVDRD from clinics, and for evidence of drug resistance 
using the Sierra web tool (http://hivdb.stanford.edu/pages/webservices/). 
 
4.2.2 Assessing contribution of individuals with recent infection and established 
infection to transmission clusters 
In order to assess the role of individuals categorised as having been recently infected at time 
of blood sample collection in the formation of transmission clusters, two levels of focus were 
taken; one with a reduced set of individuals that had greater laboratory and clinical 
characterisation, allowing a more stringent categorization of either recent or established 
infection (New diagnosis cohort); the second with a UK-wide population that had more 
limited laboratory and clinical data available (Overall UK HIV Drug Resistance Database). 
 For the New diagnosis cohort, laboratory and clinical data and viral sequences 
stripped of personal identifiable information were obtained from 1570 individuals newly 
diagnosed with HIV-1, whose data were held either at The Royal Free and St Mary’s 
Hospitals in London, or the UK Register of HIV Seroconverters: a UK-wide database of 
individuals with documented evidence of seroconversion. Individuals were categorized as 
having a recent or established infection at the time of HIV diagnosis on the basis of either 
i. laboratory based serology, 
ii. a combination of last negative/first positive HIV test date together with application of 
a nucleotide ambiguity classifier based upon viral sequence nucleotide ambiguity, or 
iii. application of the nucleotide ambiguity classifier alone, where no other data was 
available 
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New diagnosis cohort viral sequences already submitted to the UKHIVDRD as part of 
routine national HIV anti-retroviral drug resistance surveillance procedures were identified to 
avoid duplication. 
 Secondly, a nucleotide ambiguity classifier based upon viral sequence nucleotide 
ambiguity alone was applied to all treatment naive individuals in the UKHIVDRD, in an 
attempt to gain a larger picture of the contribution to onward transmission from each 
infection category across different subtypes and cluster sizes. 
 Previous work developing the nucleotide ambiguity classifier investigated two cut-
offs for categorisation of infection length, a 0.17% nucleotide ambiguity cut-off that aimed to 
maximise both the sensitivity and specificity of categorisation of individuals with recent 
infection at blood sample collection date, and a second, more stringent cut-off of 0.00% 
nucleotide ambiguities across ≥800bp sequence, which was previously found to increase the 
positive predictive value of the classifier – both cut-offs were applied within this study 
(chapter three). 
 
4.2.3 Modelling recent infection dynamics within clusters 
A model of infection transmission within clusters was developed in an attempt to describe the 
extent to which individuals categorised as having had recent infection at blood sample 
collection date contribute to onward transmission close to their infection. The model was set-
up as follows: firstly, it was necessary to discard individuals categorised as having had 
established infections at time of blood sample collection, where according to the assumptions 
of the nucleotide ambiguity classifier, it is not possible to put a minimum-bound on the date 
of infection (i.e. established infections are only known to have not seroconverted in the 
previous 125 days). Next, a date of seroconversion was inferred for each individual with 
recent infection by subtracting 125 days from their blood sample collection date, thereby 
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allowing the recent infection to be ordered with respect to calendar date of infection. This in 
turn enabled analysis of the extent to which those still close to their date of infection (which 
is likely to have occurred 2-3 weeks prior to seroconversion) may drive transmission within 
an epidemic: briefly, a count of the number of infections coming from within the 125 day 
recent infection window was carried out by assuming each infection was generated by the 
infection immediately upstream of it, i.e. a consecutive date ordered approach (Fig 4.1.). This 
simplification assumes each individual may transmit to no more than one individual in the 
cluster (apart from the chronologically last individual, who is the last in the chain), and likely 
serves to minimise the time between transmissions, potentially leading to an over-estimation 
of the number of transmissions from the recent phase of infection. To address this issue, the 
model compares this count of the number of infections coming from within the 125 day 
recent infection window for any particular cluster to an equivalent count based on a cluster 
reconstructed to match the original in terms of size and proportion of recent infections, but 
with randomly assigned seroconversion dates. It is postulated that if such a comparison 
reveals that UK phylogeny based transmission clusters display a greater degree of overlap of 
recent phase infections compared to equivalent clusters with randomly assigned dates of 
seroconversion (i.e. not based on actual blood sample dates), it may imply that transmission 
clusters across the UK have a higher rate of individuals in the recent phase of their HIV-1 
infections linked to others also in the recent phase of their infection than may be expected by 
chance. This in turn would support the paradigm that transmission from the recent phase of 
infection is the primary driver in the formation of such clusters. 
 In more detail, for each cluster identified within the UK phylogeny, an equivalent 
cluster was reconstructed, whereby the infections within the original cluster were randomly 
re-assigned a seroconversion date somewhere between the oldest and youngest original 
cluster blood sample collection dates. A subset of these infections were then randomly 
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categorised as recent infections in a proportion matching the original cluster, and the degree 
of overlap between recent phase infections compared to that of the original cluster; in effect 
the model attempts to detect greater temporal grouping of recent infections (i.e. overlap of 
recent infection windows) than expected if having a recent HIV-1 infection makes an 
individual no more likely to transmit to another individual than having an established 
infection. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Schematic showing infection modelling approach. Top and second row: 
original cluster infections are mapped onto a timeline using sample dates from 
UKHIVDRD, or at random for the ‘stochastic’ scenario. Third row: seroconversion 
date is inferred from sample date for all recent infections; established infections are 
ignored because no infection date can be inferred. Bottom row: the consecutive infection 
scenario assumes each individual infects the individual immediately downstream. 
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4.2.4 Counting recent phase transmissions using nucleotide ambiguity and pairwise 
genetic distance 
An additional attempt to investigate the extent to which transmission clusters are driven by 
recent infection was made by combining the nucleotide ambiguity cut-off with pairwise 
nucleotide distance measures. A reasonable estimate of the rate of nucleotide evolution for 
HIV-1 was obtained from previous work (Leitner and Albert 1999), as 2.7 ± 0.5 x 10
-3
 in p17 
and 6.7 ± 2.1 x 10
-3
 substitutions/site per year in the V3 loop. Although the V3 region is 
likely to be under greater selective pressure than pol in the initial stages of infection, the latter 
rate of evolution was taken to be a useful upper limit of genetic distance for the model. This 
rate translates into ~3.0 substitutions per 125 days across the 1300bp region of pol typically 
submitted to the UKHIVDRD and if the pair of sequences were also categorised as recent 
infections, on the basis of the nucleotide ambiguity classifier, and their 125 day recent 
infection windows overlapped, the putative transmission was counted as being from the 
recent phase of infection. Where multiple individuals overlapped in a single group in this 
manner, counts of recent phase infections were adjusted appropriately (i.e. a putative recent 
phase transmission event between patient A and patient B, and between B and patient C 
means that there cannot have been a putative recent phase transmission event between patient 
A and patient C). 
 It should be stressed that, as with the cluster reconstruction approach outlined above, 
this method does not attempt to identify actual transmission events between individuals with 
highly related sequences. In such pairings there remains the possibility that a third person, not 
captured within the UKHIVDRD, may have transmitted HIV to both individuals in question, 
and that these two individuals were diagnosed before the virus had significantly diverged 
from the original infecting virus. A further caveat is that the model cannot capture individuals 
who may have been part of a recent phase transmission event at some point in the past, but 
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were categorised as having been in the established phase of infection when sampled, or where 
the blood from two individuals involved in a recent phase transmission event was sampled at 
sufficiently distant time points that the virus had time to diverge beyond the pairwise distance 
threshold. 
 In light of these caveats, the method primarily attempts to enable comparisons 
between subtypes and between cluster sizes, in terms of the difference in the number of 
transmissions from individuals with recent infection. A greater or lesser proportion of 
transmission events identified as coming from the recent infection phases when comparing, 
for example, different categories of cluster size, may indicate the extent to which recent 
infection is playing a role within different parts of the UK HIV-1 epidemic. 
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4.3 Results 
4.3.1 Study population characteristics 
The initial sequence dataset was comprised of 55556 anonymised HIV pol sequences 
obtained from 43002 individuals in the United Kingdom between 1997 and 2010 Where 
multiple sequences existed for the same patient, the chronologically earliest sample was used 
for analysis, resulting in the removal of 12554 sequences. A subset 16362 of individuals 
within the UKHIVDRD had demographic data available as part of the UK Collaborative HIV 
Cohort (UK CHIC, www.ukchic.org.uk) (Table 4.1.). 
 The pol sequences covered the protease gene (297bp) and part of the reverse 
transcriptase gene (1023bp), and were subtyped using the REGA subtyping algorithm (De 
Oliveira, Deforche et al. 2005). A wide variety of subtypes and circulating recombinant forms 
were represented, with the main subtypes being present in the following proportions: A 
(5.8%), B (54.0%), C (23.4%), CRF01_AE (1.5%), CRF02_AG (3.9%), D (1.3%), G (1.9%), 
unassigned (6.9%) and the remaining 1.3% being made up of less common subtypes and 
recombinants forms. 
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Table 4.1. Demographic breakdown of 16362 UK Collaborative HIV Cohort patients 
linked to the UK HIV Drug Resistance Database. 
 
 
4.3.2 Identification of putative transmission clusters 
All 55556 pol gene sequences collected from across the UK as part of routine transmitted 
drug resistance surveillance were aligned individually to a reference sequence (consensus B) 
using the LAP alignment program (Huang and Zhang 1996). 12554 sequences were removed 
from the alignment, and the remaining sequences were then divided into subtype subsets 
based on the REGA subtyping algorithm for computational practicality (with 2 individuals 
being excluded from the subsets on the basis of one patient having group O HIV-1 and one 
patient having HIV-2 according to REGA subtyping). Phylogenetic trees were constructed 
All UK CHIC patients
Female 3509 (21.5%)
Male 12848 (78.5%)
Blood products 70 (0.4%)
Heterosexual 4416 (27.7%)
Homo/bisexual 9179 (57.7%)
IDU 444 (2.8%)
Not known 1226 (7.7%)
Other 584 (3.7%)
Black-African 3173 (20.5%)
Black-Caribbean 443 (2.9%)
Black-other/unspecified 287 (1.9%)
Indian/Pakistani/Bangladeshi 155 (1%)
Not known 679 (4.4%)
Other 383 (2.5%)
Other Asian/Oriental 231 (1.5%)
Other/Mixed 571 (3.7%)
White 9541 (61.7%)
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using the FastTree2.1 phylogenetic algorithm utilising i) alignments stripped of codons linked 
to drug resistance associated mutations (DRAMs), and ii) alignments with the 1
st
 and 2
nd
 
nucleotide positions of each codon removed. Bootstrapping was carried out in FastTree2.1 
with 1000 replicates. Clusters of sequences with bootstrap support ≥95% and a maximum 
intra-cluster genetic distance ≤0.045 substitutions per nucleotide were deemed likely to 
represent groups of individuals with viruses significantly more closely related to each other 
than on average within the overall UKHIVDRD, in turn potentially identifying individuals 
involved in onward transmission of HIV due to particular underlying epidemiological or 
biological factors. In terms of the effect of nucleotide ambiguities on the identification of 
transmission clusters, FastTree2.1 treats ambiguous nucleotides as missing data and hence 
will ignore such sites. The Analyses of Phylogenetics and Evolution (APE ) module in R 
(Paradis, Claude et al. 2004) was used to calculate the pairwise Hamming distances between 
sequences in clusters. The Hamming distance is simply the number of differences between 
two strings, and hence an ambiguous nucleotide at a particular site in one sequence compared 
to a pure nucleotide in the other sequence will be counted as a difference between the two 
sequences even if the ambiguous nucleotide incorporates the pure nucleotide (e.g. R vs. A). 
This was deemed to be unlikely to present a major issue for the methodology when the 
overall distribution of nucleotide ambiguities in the UKHIVDRD was considered: across the 
43002 unique patient sequences, the median percentage ambiguity was 0.69% (90 CI: 0.00% 
to 2.06%), whereas a cluster would have to contain a sequence with a percentage ambiguity 
of at least 4.5% to exclude it from being identified as a potential transmission chain. Overall, 
the cluster definition criteria resulted in identification of 5250 potential transmission clusters, 
involving 16923/43002 (39.4%) individuals from the UKHIVDRD (Table 4.2.). Of these 
clusters, 1887 (36.0%) were made up of greater than two individuals (i.e. excluding 
transmission pairs). 
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Table 4.2. Numbers of transmission clusters identified using ≥95% bootstrap and 
maximum intra-cluster pairwise genetic distance ≤0.045 substitutions per nucleotide, 
broken down by subtype and cluster size. 
 
 
4.3.3 Analysis of transmission cluster proportions and clinical data 
1. New diagnosis cohort 
687/1570 (43.8%) individuals had the stage of their infection at diagnosis categorized on the 
basis of serology, 604/1570 (38.5%) by a combination of known last negative HIV test date 
first positive HIV test date and application of the nucleotide ambiguity classifier, and 
279/1570 (17.8%) by application of the nucleotide ambiguity classifier alone. 1231/1570 
(78.4%) of sequences from the new diagnosis cohort were part of the UKHIVDRD. Of these 
1231 sequences, 519 (42.2%) belonged to a putative transmission cluster. 
 
0.17% nucleotide ambiguity cut-off: 
Overall, 381/1570 (24.3%) individuals were categorized as having had recent infection at 
diagnosis. 1291 individuals were classified on the basis of laboratory evidence of 
Subtype No. clusters No. cluster > 2 No. clusters ≥ 10
A 305 78 2
B 2466 1066 130
C 1488 429 8
CRF01_AE 82 21 0
CRF02_AG 247 74 0
D 57 17 1
G 112 33 1
Non-major 86 28 2
U 407 141 9
Total 5250 1887 153
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seroconversion, or a combination of known last negative HIV test date first positive HIV test 
date and application of the 0.17% nucleotide ambiguity classifier, 285/1291 (22.1%) 
individuals were categorised as recent infections. 
 
0.00% nucleotide ambiguity cut-off: 
When using the 0.00% nucleotide ambiguity cut-off, 309/1539 (20.1%) individuals were 
categorized as having had recent infection at diagnosis. 1254 individuals were classified on 
the basis of laboratory evidence of seroconversion, or a combination of known last negative 
HIV test date first positive HIV test date and application of the 0.00% nucleotide ambiguity 
classifier, 253/1254 (20.2%) individuals were categorised as recent infections. 
2. Overall UK HIV Drug Resistance Database 
UKHIVDRD individuals classified as treatment experienced at their earliest sample date 
were deemed likely to be present in the database because they were experiencing virological 
failure, and it was assumed to be improbable that they had a recent infection at that time 
point. Accordingly, the nucleotide ambiguity classifier was only applied to UKHIVDRD 
individuals classified as treatment naive. Of the 43002 individuals within the UKHIVDRD, 
23320 (54.2%) were classified as treatment naive at blood sample collection date (excluding 
one patient infection subtyped by REGA as HIV-2). Application of the 0.17% nucleotide 
ambiguity cut-off to the 23320 treatment naive individuals categorised 5975/23320 (25.6%) 
individuals as having had a recent infection at blood sample collection date. 
 
0.17% nucleotide ambiguity cut-off: 
For all subtype categories combined, treatment naive individuals classified as having had 
recent infection at blood sample collection date using the 0.17% cut-off were more likely to:  
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i) have higher median first and last (before treatment) CD4+ cell counts (469 cells/mm3 
vs. 350 cells/mm
3
, Mann-Whitney p-value < 0.0001 and 357 cells/mm
3
 vs. 254 
cells/mm
3
, Mann-Whitney p-value < 0.0001 respectively), 
ii) have lower median last viral load (before treatment) (27762 copies/ml vs. 41864, 
Mann-Whitney p-value < 0.0001), 
iii) be male (Fisher’s exact test p < 0.0001, OR 2.58 [CI 95: 2.27, 2.94]), 
iv) be identified with the men who have sex with men (MSM) risk group (Fisher’s exact 
test p < 0.0001, OR 1.82 [CI 95: 1.67, 2.00]), and 
v) iv) have white ethnicity (Fisher’s exact test p < 0.0001, OR 1.99 [CI 95: 1.81, 2.19]) 
compared to individuals classified as having had established infection at blood sample 
collection date. 
 
0.00% nucleotide ambiguity cut-off: 
When applying the 0.00% nucleotide ambiguity cut-off, together with a minimum sequence 
length requirement of 800bp, 21686/43002 (50.4%) UKHIVDRD individuals were classified 
as treatment naive at blood sample collection date. 3040/21686 (14.0%) of these individuals 
were categorised as having had a recent infection at blood sample collection date. 
 Re-examination of the clinical data in combination with the 0.00% nucleotide 
ambiguity cut-off found a largely similar pattern to that seen with the 0.17% cut-off, with 
treatment naive individuals categorised as having had recent infection at blood sample 
collection date being more likely to: 
i) have higher median first and last (before treatment) CD4+ cell counts (480 
cells/mm
3
 vs. 373 cells/mm
3
, Mann-Whitney p-value < 0.0001 and 362 cells/mm
3
 
vs. 268 cells/mm
3
, Mann-Whitney p-value < 0.0001 respectively), 
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ii) have a lower last viral load (before treatment) (25900 copies/ml vs. 39000 
copies/ml, Mann-Whitney p-value < 0.0001), 
iii) be male (Fisher’s exact test p < 0.0001, OR 2.75 [CI 95: 2.28, 3.33]), 
iv) be identified with the men who have sex with men (MSM) risk group (Fisher’s 
exact test p < 0.0001, OR 1.93 [CI 95: 1.71, 2.19]), and  
v) have white ethnicity (Fisher’s exact test p < 0.0001, OR 2.19 [CI 95: 1.93, 2.50]) 
compared to individuals classified as having had established infection at blood 
sample collection date. 
 
4.3.4 Relative proportions of recent and established infections linked to clusters 
1. New diagnosis cohort 
For the 0.17% nucleotide ambiguity cut-off, a greater absolute number of established 
infections were found to map to clusters than recent infections (366/519, 70.5% vs. 153/519, 
29.5% respectively). However, individuals categorised as having had recent infection at 
blood sample collection date were more likely than not to be linked to a transmission cluster 
compared to individuals categorised as having had an established infection (p < 0.0001, OR 
1.72 [CI 95: 1.31, 2.26]). Broken down by subtype this association was found to be 
statistically significant for subtypes B and C only (Table 4.3.). 
 
 
Subtype
Linked to 
clusters
Not linked to 
clusters
Linked to 
clusters
Not linked to 
clusters
p-value
odds ratio          
[CI 95%]
A 2 4 12 25 1.00 1.04 [0.08,8.50]
B 128 98 282 386 <0.05 1.79 [1.30,2.45]
C 17 4 48 83 <0.05 7.25 [2.20,31.36]
CRF01_AE 4 5 3 7 0.65 1.81 [0.20,18.60]
CRF02_AG 0 1 5 9 1.00 0.00 [0.00,77.91]
D 0 0 1 7 1.00 0.00 [0.00,Inf]
G 1 1 3 12 0.43 3.61 [0.04,338.34]
non_major 3 0 10 0 1.00 0.00 [0.00,Inf]
U 0 25 0 45 1.00 0.00 [0.00,Inf]
Total 155 138 364 574 <0.0001 1.77 [1.35,2.33]
Patients with recent infection Patients with established infection
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Table 4.3. Proportions of new diagnosis cohort individuals with recent or established 
infection linked to clusters, using the 0.17% nucleotide ambiguity cut-off. 
 
 Application of the 0.00% nucleotide ambiguity cut-off found that 395/519 (76.1%) of 
infections mapped to clusters were established and 124/519 (23.9%) were recent infections. 
The relative proportions of individuals linked to clusters within each group showed a similar 
pattern to that seen for the 0.17% cut-off: individuals categorised as having had recent 
infection at blood sample collection date were more likely than not to be linked to 
transmission clusters compared to individuals categorised as having had an established 
infection (p < 0.002, OR 1.56 [CI 95: 1.17, 2.09]). 
2. Overall UK HIV Drug Resistance Database 
The relative proportions of recent and established infections linked to clusters were assessed 
for all 23320 treatment naive individuals in the UKHIVDRD. 9488/23320 (40.7%) treatment 
naive individuals were linked to clusters compared to 13832/23320 (59.3%) not linked to 
clusters. 3081/5975 (51.6%) recent infections were linked to clusters compared to 
6407/17345 (36.9%) established infections (Fisher’s exact test p-value < 0.0001, OR 1.82 (95 
CI: 1.71, 1.93), indicating individuals with recent infection were more likely than not to be 
linked to a cluster compared to individuals with established infection for subtypes B, C, 
CRF02_AG, the non-major subtype subset and the unassigned subtype subset (Table 4.4a.). 
The remaining subtype subsets did not show any significant difference between recent 
infections and established infections in terms of the odds of belonging to a cluster. 
 A similar pattern was found when using the 0.00% nucleotide ambiguity definition of 
recent infection, with recent infections in subtypes B, C, CRF02_AG and the non-major 
subtypes being more likely than not to be linked to clusters compared to established 
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infections. The unassigned subtype group no longer showed a significant difference between 
the two categories (Table 4.4b.). 
 
 
 
Table 4.4a. Is the proportion of recent infections linked to clusters significantly different 
to the proportion of established infections linked to clusters? Table shows counts of 
overall numbers of treatment naive individuals in each subtype, the number of 
treatment naives further subdivided into infections that were recent or established at 
blood sample collection date (based on 0.17% nucleotide ambiguity cut-off), and then 
the numbers of recent and established infections further subdivided into individuals 
linked or not linked to clusters. Fisher’s exact test p-value was derived from comparing 
the proportion of clustering/non-clustering individuals in the recent infection category 
versus those in the established infection category. 
 
 
 
 
Subtype Total treatment naive
Total recent 
treatment naive
Linked to 
clusters
Not linked to 
clusters
Total established 
treatment naive
Linked to 
clusters
Not linked to 
clusters
p-value
odds ratio                                   
[CI 95%]
A 982 184 59 125 798 225 573 0.32 1.20 [0.83,1.72]
B 12491 3921 2193 1728 8570 3685 4885 <0.0001 1.68 [1.56,1.82]
C 5822 879 394 485 4943 1452 3491 <0.0001 1.95 [1.68,2.27]
CRF01_AE 481 140 39 101 341 69 272 0.07 1.52 [0.94,2.45]
CRF02_AG 971 210 92 118 761 240 521 <0.05 1.69 [1.22,2.34]
D 181 18 6 12 163 40 123 0.40 1.53 [0.44,4.77]
G 472 104 34 70 368 116 252 0.81 1.06 [0.64,1.72]
Non-major 308 80 59 21 228 119 109 <0.05 2.57 [1.43,4.75]
U 1612 439 205 234 1173 461 712 <0.05 1.35 [1.08,1.70]
Total 23320 5975 3081 2894 17345 6407 10938 <0.0001 1.82 [1.71,1.93]
Treatment naive patients with recent infection Treatment naive patients with established infection
Subtype Total treatment naive
Total recent 
treatment naive
Linked to 
clusters
Not linked to 
clusters
Total established 
treatment naive
Linked to 
clusters
Not linked to 
clusters
p-value
odds ratio         
[CI 95%]
A 900 103 37 66 797 226 571 0.13 1.42 [0.89,2.22]
B 11708 1969 1121 848 9739 4398 5341 <0.0001 1.61 [1.45,1.77]
C 5467 476 210 266 4991 1549 3442 <0.0001 1.75 [1.44,2.13]
CRF01_AE 456 81 20 61 375 83 292 0.66 1.15 [0.62,2.07]
CRF02_AG 854 93 41 52 761 266 495 0.09 1.47 [0.92,2.32]
D 175 6 3 3 169 43 126 0.19 2.91 [0.38,22.55]
G 395 41 17 24 354 118 236 0.30 1.42 [0.68,2.87]
Non-major 284 39 30 9 245 138 107 0.02 2.58 [1.13,6.44]
U 1447 232 109 123 1215 507 708 0.15 1.24 [0.92,1.66]
Total 21686 3040 1588 1452 18646 7328 11318 <0.0001 1.69 [1.56,1.83]
Treatment naive patients with recent infection Treatment naive patients with established infection
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Table 4.4b. Shows the same information as Table 4.4a. using a nucleotide ambiguity cut-
off of 0.00% and minimum pol sequence length of 800bp, and shows that the significant 
relationships broadly hold. 
 
 The greater number of large clusters identified for subtypes B and C warranted further 
investigation of the effect of the size of the cluster on the proportions of recent and 
established infections linked to transmission clusters. Despite a greater absolute number of 
individuals with established infection at blood sample collection date being linked to clusters 
containing 10 or more individuals, individuals categorised as having had recent infection at 
date of blood sampling (here defined by the 0.17% nucleotide ambiguity cut-off only) were 
still found to be more likely to belong to a cluster than not (Table 4.5.). A similar trend 
existed for individuals linked to transmission pairs. 
 
 
 
 
Table 4.5. The proportion of recent infections (here defined by the 0.17% nucleotide 
ambiguity cut-off) linked to clusters by cluster size: clusters involving 10 or more 
individuals showed a significant difference in the proportion of recent infections linked 
to them compared to equivalent proportion in established infections, a similar pattern 
existed for transmission pairs. 
Subtype
Linked to clusters 
≥ 10
Not linked to 
clusters ≥ 10
Linked to clusters 
≥ 10
Not linked to 
clusters ≥ 10
p-value odds ratio [CI 95%]
B 808 3113 1111 7459 <0.0001 1.74 [1.57,1.93]
C 38 841 73 4870 <0.0001 3.01 [1.97,4.55]
Subtype
Linked to 
transmission pair
Not linked to 
transmission pair
Linked to 
transmission pair
Not linked to 
transmission pair
p-value odds ratio [CI 95%]
B 496 3425 974 7596 <0.05 1.13 [1.00,1.27]
C 183 696 842 4101 <0.05 1.28 [1.06,1.54]
Recent infections Established infections
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In order to investigate potential ascertainment bias inherent in the transmission cluster 
identification stage, due to incorporation of a genetic distance measurement, a less stringent 
bootstrapping value of ≥85% and a range of maximum intra-cluster pairwise genetic 
distances were used to identify transmission clusters (0.015 to 0.065), and an analysis of the 
proportion of recent infections versus the proportion of established infections linked to 
clusters was carried out. To a large extent, all statistically significant associations were found 
to hold across each criteria combination (Table 4.6.). 
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Table 4.6. Table showing how changes in bootstrap cut-off support values and 
maximum pairwise genetic distance cut-offs (substitutions per nucleotide) in cluster 
identification affects the proportion of recent (as defined by 0.17% ambiguity cut-off) 
and established infections found to be linked to clusters (N.B. absolute counts in the 
table are prior to splitting or removal of non-UK clusters). The majority of significant 
differences remained, with changes in bootstrap and distance cut-off making a 
Subtype
Genetic 
distance
Linked Not linked Linked Not linked p-value Linked Not linked Linked Not linked p-value
1.5 118 332 569 1341 0.15 99 351 482 1428 0.16
2.5 156 294 690 1220 0.59 123 327 570 1340 0.30
3.5 179 271 742 1168 0.75 138 312 599 1311 0.82
4.5 190 260 754 1156 0.29 146 304 610 1300 0.87
5.5 205 245 808 1102 0.22 146 304 610 1300 0.87
6.5 208 242 829 1081 0.29 146 304 610 1300 0.87
1.5 2419 3809 5239 10857 <0.0001 1866 4362 3992 12104 <0.0001
2.5 3130 3098 6701 9395 <0.0001 2402 3826 5052 11044 <0.0001
3.5 3642 2586 7897 8199 <0.0001 2796 3432 5943 10153 <0.0001
4.5 3971 2257 8646 7450 <0.0001 3087 3141 6514 9582 <0.0001
5.5 4099 2129 8902 7194 <0.0001 3180 3048 6742 9354 <0.0001
6.5 4126 2102 8987 7109 <0.0001 3189 3039 6756 9340 <0.0001
1.5 654 1208 2951 6128 0.03 570 1292 2518 6561 0.01
2.5 795 1067 3436 5643 <0.0001 684 1178 2877 6202 <0.0001
3.5 857 1005 3624 5455 <0.0001 730 1132 3005 6074 <0.0001
4.5 879 983 3672 5407 <0.0001 758 1104 3048 6031 <0.0001
5.5 891 971 3706 5373 <0.0001 765 1097 3066 6013 <0.0001
6.5 892 970 3707 5372 <0.0001 765 1097 3066 6013 <0.0001
1.5 66 150 153 369 0.79 58 158 123 399 0.35
2.5 79 137 179 343 0.55 63 153 130 392 0.23
3.5 80 136 181 341 0.55 63 153 130 392 0.23
4.5 80 136 181 341 0.55 63 153 130 392 0.23
5.5 80 136 181 341 0.55 63 153 130 392 0.23
6.5 80 136 181 341 0.55 63 153 130 392 0.23
1.5 120 220 452 936 0.34 113 227 391 997 0.07
2.5 151 189 547 841 0.10 137 203 461 927 0.02
3.5 158 182 578 810 0.11 144 196 485 903 0.01
4.5 166 174 595 793 0.05 146 194 488 900 0.01
5.5 167 173 596 792 0.04 146 194 488 900 0.01
6.5 167 173 596 792 0.04 146 194 488 900 0.01
1.5 19 66 107 320 0.68 19 66 101 326 0.89
2.5 21 64 129 298 0.36 21 64 119 308 0.60
3.5 23 62 138 289 0.37 22 63 120 307 0.79
4.5 27 58 145 282 0.80 23 62 126 301 0.70
5.5 27 58 145 282 0.80 23 62 126 301 0.70
6.5 27 58 145 282 0.80 23 62 126 301 0.70
1.5 47 135 195 486 0.52 38 144 171 510 0.28
2.5 63 119 241 440 0.86 51 131 209 472 0.52
3.5 72 110 266 415 0.93 56 126 223 458 0.66
4.5 74 108 276 405 1.00 57 125 228 453 0.60
5.5 74 108 276 405 1.00 57 125 228 453 0.60
6.5 74 108 277 404 1.00 57 125 228 453 0.60
1.5 49 93 136 297 0.53 46 96 128 305 0.53
2.5 59 83 161 272 0.37 55 87 152 281 0.48
3.5 68 74 198 235 0.70 61 81 183 250 0.92
4.5 92 50 231 202 0.02 88 54 218 215 0.02
5.5 95 47 236 197 0.01 89 53 223 210 0.03
6.5 95 47 236 197 0.01 89 53 223 210 0.03
Recent Established
85% 95%
G
A
B
C
CRF01_AE
Recent
Non-major
CRF02_AG
D
Established
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difference for subtype A, CRF02_AG, the non-major subtypes and the unassigned 
subtypes – though plateauing of the numbers of clusters found at increasing genetic 
distance cut-off was seen. 
 
4.3.5 Drug resistance in the UK HIV Drug Resistance Database  
All 43002 non-duplicate patient sequences were analysed for major drug resistance mutations 
using Sierra, the Stanford HIV Web Service submission tool 
(http://hivdb.stanford.edu/DR/webservices/index.html), ignoring all drug resistance mutations 
not listed in the WHO 2009 Drug Resistance Mutation List (Bennett, Camacho et al. 2009). 
1924/23320 (8.3%) treatment naive individuals showed evidence of one or more transmitted 
drug resistance mutations acquired from individuals harbouring drug resistant virus (Table 
4.7.). Both the 0.17% and 0.00% nucleotide ambiguity cut-offs for identifying recent 
infection were imposed to investigate the proportion of transmitted drug resistance (TDR) in 
recent infections compared to established infections. It was found that there was 
proportionally greater TDR in recent infections when using both cut-offs (Table 4.8.). 
 
 
No. of patients across 
all subtypes (n=23320)
No. of subtype B 
patients (n=12491)
Overall DR (in any class) 1924 (8.3%) 1360 (10.9%)
NNRTI resistance 1924 (8.3%) 1360 (10.9%)
NRTI resistance 788 (3.4%) 467 (3.7%)
PI resistance 404 (1.7%) 258 (2.1%)
IN resistance 0 (0.0%) 0 (0.0%)
Resistance to ≥2 classes 1121 (4.8%) 670 (5.4%)
Overall DR in recent infections 573 (2.5%) 464 (3.7%)
Overall DR in established infections 1351 (5.8%) 896 (7.2%)
Overall DR in patients linked to clusters 897 (3.8%) 706 (5.7%)
Overall DR in patients not linked to clusters 1027 (4.4%) 654 (5.2%)
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Table 4.7. Table showing numbers of treatment naive individuals with drug resistance 
mutations for all subtypes and for subtype B (the subtype expected to contain the 
greatest number of individuals with drug resistance), categorised by drug class, 
infection status, and whether or not they are linked to clusters (DR = drug resistance, NNRTI 
= non-nucleoside reverse transcriptase inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, PI = 
protease inhibitor, IN = integrase inhibitor). 
 
 
 
 
Table 4.8. Is the proportion of recent infections harbouring transmitted drug resistance 
(TDR) greater than the proportion of established infections harbouring TDR? Upper 
table shows counts for 0.17% nucleotide ambiguity cut-off, bottom table shows counts 
for 0.00% nucleotide ambiguity cut-off. In both instances there is a significant 
difference in proportions (Pearson’s Chi-squared test with Yates’ continuity 
correction).  
 
0.17%
TDR no TDR Total
Recent 566 5409 5975
Established 1358 15987 17345
Total 1924 21396 23320
Χ2 = 15.64 p-value < 0.0001
0.00%
TDR no TDR Total
Recent 290 2750 3040
Established 1510 17136 18646
Total 1800 19886 21686
Χ2 = 6.95 p-value = 0.0084
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4.3.6 Co-clustering of treatment naive drug susceptible and treatment experienced 
drug resistant individuals 
To assess the potential for treatment naive individuals categorised as having had a recent 
infection at blood sample collection date to be infected with a drug resistant virus from anti-
retroviral treatment (ART) experienced individuals failing treatment, an assortativity 
coefficient was calculated to gauge the extent of co-clustering between these patient 
categories. For each subtype subset, a matrix of pairwise connections within and between 
treatment naive individuals with recent infection (using both the 0.17% and 0.00% ambiguity 
cut-offs) but no evidence of drug resistant virus, and treatment experienced individuals with 
drug resistant virus (regardless of infection stage) was set up, and an assortativity coefficient 
calculated as described elsewhere (Newman 2003) and previously used in a similar context 
(Volz, Koopman et al. 2012) (Table 4.9a.). An assortativity coefficient of 0 indicates no 
assortative mixing (i.e. there are as many connections between individuals from different 
categories as there are between individuals from the same category); whereas a coefficient of 
1 indicates perfect assortative mixing (i.e. connections are only between individuals of the 
same category). 
 When the 0.17% ambiguity cut-off was used to identify individuals with recent 
infections, the overall assortative coefficient for the clusters was 0.45. By subtype subset, all 
subtypes except D had a positive coefficient value – though caution should be employed 
when dealing with small numbers of infections. These results, together with the initial 
analysis above, indicate a strong likelihood of drug susceptible treatment naive individuals 
with recent infection to co-cluster with each other, and likewise drug resistant treatment 
experienced individuals to co-cluster with each other. However, there is clearly opportunity 
for transmission of drug resistant virus between the categories - particularly for subtype B, 
where most drug resistance was found, which had more connections between the two groups 
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than within the treatment experienced individuals with drug resistant virus (485 vs. 401 
respectively). 
 When the 0.00% ambiguity cut-off was applied the assortativity coefficient remained 
positive for all subtypes (with the exception of subtype D again), but was smaller in value for 
all subtype except B, CRF02_AG and the non-major subtype subset, where the value 
increased (Table 4.9b.). 
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Table 4.9a. Counts of pairwise connections between treatment naive drug susceptible 
individuals with recent infection and treatment experienced drug resistant individuals 
as categorised using the 0.17% ambiguity cut-off, where counts are of pairwise 
connection within the same cluster. Assortativity coefficients are calculated from the 
matrices of these pairwise counts, with values from > 0 to 1 indicating more connections 
between individuals of the same category than between different patient categories. 
 
 
Table 4.9b. Counts of pairwise connections between treatment naive drug susceptible 
individuals with recent infection and treatment experienced drug resistant individuals 
as categorised using the 0.00% ambiguity cut-off, where counts are of pairwise 
connection within the same cluster.  
Subtype
Recent, no DR ↔ 
Recent, no DR
Recent, no DR ↔ 
Experienced, DR
Experienced, DR ↔ 
Experienced, DR
Assortativity 
coefficient
A 12 3 24 0.69
B 5982 485 401 0.38
C 173 51 125 0.48
CRF01_AE 7 3 7 0.40
CRF02_AG 36 2 6 0.70
D 0 1 5 -0.17
G 15 0 3 1.00
Non-major 419 4 3 0.42
U 138 18 49 0.62
Total 6782 567 623 0.45
Subtype
Recent, no DR ↔ 
Recent, no DR
Recent, no DR ↔ 
Experienced, DR
Experienced, DR ↔ 
Experienced, DR
Assortativity 
coefficient
A 2 3 24 0.29
B 1961 252 401 0.50
C 42 31 125 0.38
CRF01_AE 2 3 7 0.10
CRF02_AG 12 0 6 1.00
D 0 0 5 -
G 1 0 3 1.00
Non-major 69 0 3 1.00
U 49 13 49 0.58
Total 2138 302 623 0.55
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4.3.7 Modelling recent infection dynamics within clusters 
A model of intra-cluster transmission dynamics was developed to gauge the extent to which 
the initial stages of HIV infection contribute to onward transmission in the context of 
transmission clusters.  
 In an attempt to test the sensitivity of the model results to the length of the recent 
infection phase, the definition of the recent phase of infection was altered in steps of 20 days, 
from 20 to 400 days in length. This was carried out on three different cluster size categories: 
clusters containing a minimum of either 2, 3 or 10 recent infections, in order to investigate 
dynamics in clusters of different sizes (N.B. although cluster size does not correspond 
directly with the number of recent infections in a cluster, there is a strong linear correlation, 
with an R
2
 value of 0.84 (data not shown)). For all analyses, a count of the number of 
possible transmission events that could have taken place within the cluster was made (only 
counting individuals categorised as recent infections), together with a measure of the 
proportion of these potential transmissions that would have occurred whilst the individual in 
question was still in the recent phase stage of infection. Results for the UK phylogeny based 
clusters and the reconstructed clusters with randomised dates of seroconversion were then 
compared for each cluster size and recent phase window size, using Fisher’s exact test to 
determine if the counts deviated significantly between the two cluster types. 
 Results of the model run with the minimum number of recent infections required per 
cluster set to 2 revealed that for subtype B, significantly more potential recent phase 
transmissions took place in the reconstructed clusters with randomised infection dates 
compared to UK phylogeny based clusters the longer the recent infection phase windows (i.e. 
for the 240, and 280-400 day windows) (Table 4.10a). In contrast, when the minimum 
number of recent infections per cluster was set to 3, recent infection window lengths of 20 
and 40 days were found to result in a significantly higher number of potential recent phase 
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transmissions in the UK phylogeny based clusters compared to the reconstructed, randomised 
date clusters. When the minimum number of recent infections per cluster was set to 10, a 
recent infection window length of 20 days was found to result in a significantly higher 
number of potential recent phase transmissions in the actual clusters compared to the 
reconstructed, random date clusters. Subtype C did not reveal any significant differences 
across cluster size or window length (Table 4.10a.), but the number of eligible clusters 
available when the minimum number of recent infections per cluster was set to 10 was just 1. 
 When the model was re-run using the 0.00% ambiguity cut-off to categorise recent 
infections, the overall number of eligible clusters was reduced across all size categories for 
subtype B and Subtype C. Only subtype B revealed a significant difference in numbers of 
recent phase infections between the actual UK phylogeny clusters and the reconstructed, 
random date clusters. This was for clusters with a minimum of 3 recent infections, with a 
recent phase window length of 20 days (Table 4.10b.). 
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Table 4.10a. Transmission model results for subtypes B and C for three categories of 
minimum number of infections required per cluster. Black blocks indicate significantly 
higher numbers of potential recent phase transmissions in the constructed clusters 
compared to the UK phylogeny based clusters; grey blocks indicate significantly higher 
numbers of potential recent phase transmissions in the UK phylogeny based clusters 
compared to the constructed clusters; clear blocks indicate no significant difference. For 
subtype B, greater numbers of recent phase infections at short window lengths in 
comparison to the randomised infection date scenario implies a higher degree of 
infections overlap at this window size compared to the randomised date scenario, in 
turn suggesting recent infections (20 to 40 days post-seroconversion) may tend to infect 
other recent infections whilst still in the very early stages of infection.  
Minimum number of recent 
infections in cluster 2 3 10 2 3 10
Number of potential recent 
infection events in cluster 1142 891 352 89 45 9
Number of clusters eligible for 
analysis 435 184 20 56 12 1
Mean potential recent infection 
events per cluster 2.6 4.8 17.6 1.6 3.8 9.0
Recent infection phase window 
(days)
20
40
60
80
100
120
140
160
180
200
220
240
260
280
300
320
340
360
380
400
Ordered vs. RandomisedOrdered vs. Randomised
Subtype B Subtype C
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Table 4.10b. The model was re-run using a 0.00% ambiguity cut-off to categorise recent 
infection. Grey blocks indicate significantly higher numbers of potential recent phase 
transmissions in the UK phylogeny based clusters compared to the constructed clusters; 
clear blocks indicate no significant difference. For subtype B, greater numbers of recent 
phase infections at a 20 day recent phase window length in comparison to the 
randomised infection date scenario implies a higher degree of infections overlap at this 
window size compared to the randomised date scenario, in turn suggesting recent 
infections may tend to infect other recent infections whilst still in the very early stages of 
infection. 
  
Minimum number of recent 
infections in cluster 2 3 10 2 3 10
Number of potential recent 
infection events in cluster 443 324 109 31 14 10
Number of clusters eligible for 
analysis 191 72 6 22 5 0
Mean potential recent infection 
events per cluster 2.3 4.5 18.2 1.4 2.8 -
Recent infection phase window 
(days)
20
40
60
80
100
120
140
160
180
200
220
240
260
280
300
320
340
360
380
400
Ordered vs. Randomised Ordered vs. Randomised
Subtype B Subtype C
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4.3.8 Counting recent phase transmissions using nucleotide ambiguity and pairwise 
genetic distance 
An investigation into combining the nucleotide ambiguity classifier with a minimum pairwise 
genetic distance cut-off to identify putative recent phase infections was carried out across 
subtypes, on three different cluster size categories: pairs, clusters containing 3 to 9 
individuals, and clusters containing 10 or more individuals. Briefly, for each cluster analysed, 
all pairwise relationships falling below a cut-off of 0.03 nucleotide substitutions were then 
checked to see if they involved individuals categorised as recent infections on the basis of 
nucleotide ambiguity, and if so, whether or not their 125 day recent phase infection windows 
overlapped. If these three conditions were met, the pair was deemed to be a potential recent 
phase transmission event (though it is important to note that the possibility that a third person, 
not captured by the UKHIVDRD, infected both individuals at a similar time point cannot be 
ruled out by this method). 
 Using the 0.17% ambiguity cut-off produced a greater overall number of putative 
recent phase infections for all subtypes and all cluster size categories, compared to using the 
more stringent 0.00% ambiguity cut-off (Table 4.11.). Subtype B showed a significant 
increase in the proportion of total potential cluster transmissions (determined by subtracting 1 
from the overall cluster size, this time including both recent and established infections) 
coming from the recent phase of infection when increasing the cluster size category (i.e. 
transmission pairs vs. clusters containing 3 to 9 individuals, and clusters containing 3 to 9 
individuals vs. clusters containing 10 individuals or more) (Fisher’s exact test, p-value < 
0.05). For subtype C, there was a significant increase in the proportion of total potential 
cluster transmissions coming from the recent phase of infection when moving from clusters 
containing 3 to 9 individuals to clusters containing 10 individuals or more, for both 0.00% 
and 0.17% ambiguity cut-offs. The non-major subtype subset had significant increases in the 
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proportion of total potential cluster transmissions coming from the recent phase of infection 
moving from pairs to clusters containing 3 to 9 individuals, and from clusters containing 3 to 
9 individuals to clusters containing 10 individuals or more, but this was for the 0.17% 
ambiguity cut-off only. Finally, the unassigned subtype subset showed a significant increase 
in the proportion of total potential cluster transmissions coming from the recent phase of 
infection when moving from pairs to clusters containing 3 to 9 individuals for the 0.17% 
ambiguity cut-off only. The remaining subtypes did not reveal any significant differences in 
the proportion of total potential cluster transmissions coming from the recent phase of 
infection across cluster size categories. 
 
 
Table 4.11. Comparing the proportion of putative recent phase infections between 
cluster size categories and the two ambiguity cut-off levels for each subtype. Only 
subtypes revealing a significant difference between proportions (Fisher’s exact test, p < 
0.05) are shown (in bold). * indicates significant difference when comparing 
transmission pairs to clusters containing 3 to 9 individuals, and † indicates significant 
difference when comparing clusters containing 3 to 9 individuals to clusters containing 
10 individuals or more. 
Cluster size
potential transmissions 
(cluster size -1)
potential transmissions 
(cluster size -1)
0.00% 0.17% 0.00% 0.17%
pairs 1400 8 (0.6)* 21 (1.5)* 1059 4 (0.4) 12 (1.1)
3 to 9 3130 39 (1.2)*† 126 (4.0)*† 1118 6 (0.5)† 21 (1.9)†
10 up 2589 214 (8.3)† 468 (18.1)† 141 8 (5.7)† 18 (12.8)†
Cluster size
potential transmissions 
(cluster size -1)
potential transmissions 
(cluster size -1)
0.00% 0.17% 0.00% 0.17%
pairs 58 0 (0.0) 0 (0.0)* 266 2 (0.8) 5 (1.9)*
3 to 9 78 3 (3.8) 10 (12.8)*† 423 12 (2.8) 24 (5.7)*
10 up 83 9 (10.8) 24 (28.9)† 115 2 (1.7) 7 (6.1)
recent phase transmissions 
(% total)
recent phase transmissions 
(% total)
U
B C
Non_major
recent phase transmissions 
(% total)
recent phase transmissions 
(% total)
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4.4 Discussion 
We investigated the role of recent infection in transmission clusters within the UK HIV-1 
epidemic at two depths of focus: the first, based on a cohort of individuals newly diagnosed 
with HIV-1, with well-defined laboratory-based evidence of seroconversion, offered a greater 
degree of confidence in terms of the categorisation of individuals into those who had a recent 
infection at diagnosis and those who had an established infection, but with a concomitant 
limitation on the number of individuals available. The second level of focus was wider in 
scope, but necessarily less in-depth; representing a trade-off in terms of the stringency of 
recent/established infection categorization and a more comprehensive coverage of the overall 
UK HIV-1 epidemic. 
 The new diagnosis cohort and the UKHIVDRD were found to have similar 
proportions of individuals categorised as recent infections at blood sample collection date 
when the 0.17% nucleotide ambiguity cut-off was applied, 381/1570 (24.3%) and 
5975/23320 (25.6%) respectively. Although the ambiguity classifier was incorporated into 
the new diagnosis cohort categorisation of recent and established infection, only in 279/1570 
(17.8%) cases was it used in isolation, where there was no other evidence to aid 
classification, and when these patients were excluded, the proportion of recents was only 
slightly lower (285/1291 (22.1%)). The similarity of the proportions for the new diagnosis 
cohort and the UKHIVDRD lends support to the validity of the nucleotide ambiguity analysis 
methodology. When the 0.00% nucleotide ambiguity cut-off was applied, the proportion of 
recent infections in the two cohorts diverged somewhat, with 20.2% and 14.0% of infections 
being categorised as recent in the new diagnosis cohort and UKHIVDRD respectively. It is 
difficult to compare these figures with results from other studies, as location, demographics 
in terms of ethnicity and risk group, recent infection ascertainment and definition and other 
factors differ widely between studies – however both the upper range of 25.6% and the lower 
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range of 14.0% have support in the literature. Using various combinations of serological 
evidence to identify recent infection, 24.9% of 7902 French patients diagnosed in 2003-2005 
were classified as having recent infection at sample collection date (Semaille, Barin et al. 
2007); Fisher et al. found that 19% of 859 MSM attending a UK clinic between 2000 and 
2006 had recent infections (Fisher, Pao et al. 2010); a similar percentage of 20% was found 
by Yerly et al. in a Swiss cohort of 637 individuals diagnosed between 2000 and 2008 (Yerly, 
Junier et al. 2009). Whilst the proportion of infections categorised as recent in the 
UKHIVDRD when applying the 0.00% nucleotide seems substantially different to these 
previous studies, it matches well with the proportion of recent infections estimated from 
Recent Infection Testing Algorithm (RITA) results obtained for 3070/5970 (51%) people 
newly diagnosed in England, Wales and Northern Ireland in 2011 (Health Protection Agency 
2012). The results of that study suggested that 16% of newly diagnosed subjects had been 
infected in the previous 4 to 6 months. 
 It is also reassuring to observe that UKHIVDRD individuals identified as recent 
infections using the nucleotide ambiguity classifier displayed statistically significant 
differences in their demographic and clinical profile compared to those categorised as having 
had an established infection at blood sample collection, and that these differences make sense 
in the context of other studies looking at clinical and epidemiological differences between 
individuals with recent versus established HIV-1 infections, e.g. higher baseline CD4
+
 cell 
count, white ethnicity and MSM risk group (Manavi, McMillan et al. 2004; Girardi, Sabin et 
al. 2007). 
 This study found that a disproportionate number of individuals with recent infections 
were linked to clusters compared to individuals with established infections, for both the new 
diagnosis cohort and the overall UKHIVDRD. This was predominantly driven by subtypes B 
and C for the new diagnosis cohort, but expanded to include subtypes B, C, CRF02_AG and 
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the non-major subtype subset for the overall UKHIVDRD. The extent to which transmission 
clusters may have enabled transmission of drug resistant virus from treatment experienced 
individuals, failing therapy, to uninfected individuals was investigated using an assortativity 
coefficient to measure the degree of mixing between treatment naive individuals with recent 
infection but without drug resistant virus, and treatment experienced individuals (regardless 
of infection stage) with drug resistant virus. A relatively low level of mixing seemed to occur 
between these two categories, but there is clear scope for transmission of drug resistant virus 
from treatment experienced individuals to treatment naive individuals within transmission 
clusters, particularly in subtype B. 
 As highlighted in the introduction, other studies have attempted to use phylogenetic 
approaches to assess the extent to which individuals in the initial stages of HIV infection 
might go on to infect others, and have found broadly similar patterns of disproportionate 
linkage of individuals with recent infection to clusters (Brenner, Roger et al. 2007; Fisher, 
Pao et al. 2010). However, without knowing when transmissions took place within a cluster, 
it is likely to be misleading to assume that linkage of a recent infection to a cluster means that 
there was a transmission from the recent infection phase. Recent infection is by definition 
transient, and an individual may have their virus sampled soon after infection, but may not 
transmit their infection until it is more established (or not at all) (Brown, Gifford et al. 2009). 
The two methods developed in this study were attempts to address this issue by aiming to 
construct proxy measurements of the actual number of transmissions from the recent 
infection phase, which may enable informative comparisons between different demographic 
sub-structures of the epidemic (e.g. MSM vs. heterosexual risk group, transmission pairs vs. 
larger clusters). 
 The first method used UK-based phylogenies to identify transmission clusters to 
enable a count of the number of recent infections overlapping with each other within each 
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cluster to be made, and then compared this to clusters of equivalent size, containing an 
identical proportion of recent infections, but with randomised seroconversion dates. Results 
showed that for subtype B, when the period of recent infection was defined as 20 or 40 days, 
there was a significantly greater degree of overlap of recent infections in UK phylogeny 
clusters compared to equivalent clusters with randomised seroconversion dates than might be 
expected by chance within the ≥3 recent infections or ≥10 recent infections categories. This 
suggests that in larger clusters there is a greater degree of temporal overlap of infections in 
the periods shortly after seroconversion, compared to transmission pairs. This finding lends 
support to the hypothesis that clusters of infections are driven by individuals still in the initial 
stages of infection, who are likely to have higher viral titres in their blood and genital 
compartments, and may be unaware of their infection status. The fact that a similar result is 
not observed in subtype C may reflect different dynamics at play in a sub-epidemic made up 
predominantly of heterosexual transmission (Tatt, Barlow et al. 2004), and could mean that 
individuals in this sub-epidemic are less likely to transmit whilst in the recent stage of their 
infection, or simply that large clusters are less likely to form. One possible strategy to address 
the latter hypothesis may be to perform a randomised sub-sampling of subtype B clusters, and 
within those clusters a randomised sub-sampling of infections, to more closely match the 
numbers and size of the subtype C clusters, and to repeat the phylogenetic analysis and 
application of the model. If the pattern for subtype B clusters is still found at this reduced 
sampling density, then it may suggest that the differences between the subtypes is more to do 
with real differences in transmission dynamics, if the result is lost at this reduced sampling 
density, it points to the lower number of clusters and individuals with subtype C being the 
primary cause of the difference in results. 
 For subtype B clusters containing at least 2 recent infections, it was found that higher 
numbers of recent phase infections occurred in the UK phylogeny base clusters compared to 
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the randomised infection date clusters when the period of recent infection was defined as 240 
days or greater. This at first unintuitive finding may still fit with the concept of temporal 
grouping of infections. Infections in the randomised infection date clusters should have, by 
definition, a random distribution across the time span of the cluster, and therefore an increase 
in the recent infection period should increase the chances that adjacent recent infections will 
overlap with each other, particularly if the recent infection period becomes large relative to 
the overall time span of the cluster. However, if there is already a higher degree of temporal 
grouping of recent infections in the UK phylogeny based clusters, then there may not be the 
same kind of overall uniform spread of infections across the cluster time span, but instead a 
number of islands of infections, which may not overlap as quickly with other islands as the 
infection window length is increased (Fig 4.2.). 
 
 
Figure 4.2. A schematic outlining why subtype B clusters with randomised 
seroconversion (and hence infection) dates might exhibit greater numbers of recent 
phase transmission events at larger recent infection phase window settings compared to 
UK phylogeny based clusters, * indicates a recent phase transmission event. 
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Overall, this model is a preliminary proof-of-concept approach, and an investigation into 
possible ways in which application of the nucleotide ambiguity classifier may allow a greater 
insight into the role of recent infection in the formation of transmission chains within the UK 
HIV-1 epidemic. Further work is required to investigate the sensitivity of the model, and the 
ability of the model to detect true temporal clustering of infections, possibly by constructing 
clusters with pre-determined degrees of recent infection overlap, and testing how the model 
behaves. 
 The second method employed to gauge the number of recent phase infections in 
clusters used a combination of recent infection overlap and a pairwise genetic distance cut-
off. Because the method cannot exclude the possibility of third-party individuals not captured 
by the UKHIVDRD playing a role in transmission events in clusters, the method produces a 
proxy for the actual number of recent infection phase transmission events that have taken 
place in each cluster. The method found that for subtypes B, C, the non-major subtype subset, 
and the unassigned subtype subset, there were increases in the proportion of putative recent 
phase transmissions between the cluster size categories. For subtype B this was true across all 
three cluster size categories and at both the 0.17% and 0.00% nucleotide ambiguity cut-off, 
and suggests that for the subtype B epidemic in particular, there is robust support for the 
hypothesis that clusters of HIV-1 infections may be driven by a high proportion of 
transmissions from individuals in the recent phase of their infection. 
 It is important to acknowledge potential limitations to the methodology employed in 
this study. The first limitation is that the UKHIVDRD may not be representative of the 
overall HIV-1 epidemic in the UK. If individuals from particular risk groups, ethnicities, and 
socio-economic conditions are more or less likely to receive late HIV diagnoses (Manavi, 
McMillan et al. 2004; Boyd, Murad et al. 2005; Girardi, Sabin et al. 2007), then this may lead 
to the UKHIVDRD being skewed by a particular dominating risk group and/or ethnicity (in 
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this case white MSMs). There may also be ascertainment bias inherent in the transmission 
cluster identification stage, which by its very process usually incorporates a genetic distance 
measurement that may tend to favour identification of clusters containing individuals whose 
viruses have had less time to genetically diverge from each other, thereby potentially inflating 
the numbers of recent infections linked to transmission clusters (Volz, Koopman et al. 2012). 
To investigate this second possibility, less stringent combinations of bootstrap value and 
maximum intra-cluster pairwise genetic distances were used to identify transmission clusters. 
Analysis of the proportion of recent infections versus the proportion of established infections 
linked to clusters found that to a large extent, all statistically significant associations were 
found to hold across each criteria combination, indicating that the results of the analysis, 
particularly for subtypes B and C, are relatively robust to ascertainment bias introduced by 
the cluster identification methodology. Focussing on the methodologies used to assess the 
degree of onward transmission from the recent infection stage within clusters, it is clear that 
the models used necessarily represent an oversimplification of the true dynamics at play 
within actual transmission chains, and several caveats must be acknowledged: firstly, a caveat 
which applies not just to this study, but to all approaches based upon phylogenies sampled 
from a population, is that not all members of a transmission chain are likely to have been 
captured by the UKHIVDRD: some clusters may represent everyone from the actual local 
chain of infection, but many will not. If this difference in coverage is strongly linked to risk 
group, ethnic or socio-economic factors then this may lead to ascertainment biases that need 
to be addressed by the analysis. A closely related issue is the influence of contact tracing on 
the identification of transmission clusters. In the context of HIV, contact tracing primarily 
involves the identification of current and previous sexual partners of the infected individual 
who may have been unaware of exposure to the virus, and may wish to be screened for 
infection. Intuitively, it seems possible that for patients diagnosed with recent infection this 
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may lead to successful identification and subsequent testing of a greater proportion of current 
and previous partners compared to those diagnosed with established infections, due to the 
more limited timeframe within which to recall and identify these individuals. If infected by 
the initial HIV-1 positive individual with recent infection, these current and previous partners 
will necessarily have recent infections. These partners may then identify current and previous 
partners in turn, leading to a limited positive feedback phenomenon which may inflate the 
numbers of recent infections linked to clusters relative to established infections. Whilst the 
impact of clustering on the effectiveness of contact tracing has been investigated to some 
extent (Eames and Keeling 2003; House and Keeling 2010), there is a paucity of research into 
potential recent infection clustering bias introduced through contact tracing. The 
effectiveness of contact tracing in identifying infected individuals in various settings has been 
examined, and a systematic review of some of these studies suggest that perhaps 1-8% of 
individuals identified as potentially exposed to infection and not identified by other means 
were diagnosed with HIV through partner notification (Hogben, McNally et al. 2007). Whilst 
these studies did not focus on the proportion of recent infections identified through contact 
tracing, it may be possible to model this aspect using estimates of the incidence of recent 
infection taken from random testing studies in order to assess the extent to which the 
proportion of recent infections linked to transmission clusters may be over-inflated relative to 
established infections through differences in contact tracing efficiency. 
 In conclusion, the results of this study suggest that individuals categorised as having 
had a recent infection at sample date are disproportionately linked to transmission clusters in 
the UK epidemic, and that this effect may be compartmentalised into specific subtypes. 
Furthermore, there is evidence supporting a disproportionate role for onward infection from 
the recent stage of infection within individuals harbouring subtype B virus. There is scope for 
transmission of drug resistance from treatment experienced individuals to treatment naive 
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individuals within clusters due to individuals from both categories mixing within 
transmission networks, and this will require ongoing monitoring. Finally, incorporating 
consensus sequence based nucleotide ambiguity classifiers of HIV infection age into 
methodologies attempting to assess transmission dynamics of HIV epidemics – particularly 
when combined with pairwise genetic distance measurements – may present an effective way 
of investigating the extent to which individuals in different stages of infection contribute to 
HIV-1 epidemics, and could therefore open up investigations of this type in other national 
epidemics, where such sequence repository resources are available. 
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5 HIV-1 deep-sequencing subpopulation dynamics in recent infection and 
over time 
 
Abstract 
There is support for the concept of a genetic bottleneck operating on HIV-1 transmission 
during sexual contact. Such a bottleneck may serve to reduce the complexity of the virus that 
is transferred to the uninfected individual, possibly to the extent that a single or few viruses 
establish infection in the recipient. This initially homogeneous viral population then increases 
in diversity due to error prone replication and host immune pressure. This chapter 
investigates a cohort of individuals with recent infection using a deep-sequencing approach in 
order to ascertain the viral dynamics at play at this stage. 
36 individuals, 9 of whom had multiple pre-treatment time points available for study, had 
their virus deep-sequenced. A read clustering approach was used to assess the extent to which 
the viruses developed subpopulation structure within the host due to immune pressure. At the 
earliest sampled time point, 30.6% patients had evidence of >1 subpopulation in pol and 
47.2% patients had evidence of >1 subpopulation in env. Individuals with multiple time 
points displayed increases in pol and or env subpopulations over time in the majority of cases, 
with a few individuals retaining a single subpopulation over all time points. 
The study revealed a complex mixture of HIV-1 dynamics in early infection in a relatively 
small cohort. The read clustering approach offered a useful perspective on how HIV-1 
explores evolutionary pathways within its host; exploration that has important implications 
for vaccine design and antiretroviral drug treatment. 
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5.1 Introduction 
Evidence for a genetic bottleneck operating on HIV-1 during sexual transmission was 
published over 20 years ago (Zhang, MacKenzie et al. 1993; Zhu, Mo et al. 1993), and has 
more recently gained further support (Keele, Giorgi et al. 2008; Salazar-Gonzalez, Salazar et 
al. 2009; Fischer, Ganusov et al. 2010). If such a bottleneck exists, it has implications for 
vaccine and microbicide design (McMichael, Borrow et al. 2009; Haase 2010), and may open 
up the possibility of using limited viral quasi-species diversity to identify recent infections 
(Kouyos, von Wyl et al. 2011; Poon, McGovern et al. 2011; Ragonnet-Cronin, Aris-Brosou et 
al. 2012). Such a bottleneck may operate through a combination of i) high levels of virion 
blockage at the mucosal barrier (Keele and Estes 2011), ii) stochastic attenuation of viruses 
due to errors introduced during replication either by the virus reverse transcriptase (RT) or 
innate antiretroviral factors such as the APOBEC3G cytidine deaminase (Finzi, Plaeger et al. 
2006; McMichael, Borrow et al. 2009), iii) selection of particular V3 loop configurations of 
the envelope glycoprotein during the very early stages of infection prior to seroconversion 
(Zhang, MacKenzie et al. 1993) or iv) selection through differences in cell tropism between 
virions (Gray, Sterjovski et al. 2005). Host immune pressure begins to act upon the founding 
virus early after transmission, primarily through CD8
+
 T cells, and leads to genetic 
diversification across the genome (Zhang, MacKenzie et al. 1993; Fischer, Ganusov et al. 
2010; Henn, Boutwell et al. 2012). Some mutations may enable escape from host immune 
pressure whilst reducing the replicative capacity or some other aspect of viral fitness (e.g. 
transmissibility), and thus additional compensatory mutations may emerge and become 
linked. These selective mechanisms generate viral subpopulations that exist at various and 
fluctuating levels within an individual depending on subsequent immune and drug pressure 
(Huang, Gamarnik et al. 2003; Bordería, Lorenzo-Redondo et al. 2010). Some subpopulations 
may become the dominant quasi-species within the patient over time or become fixed at a 
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non-dominant minority level (Wilke 2005); some subpopulations may also become dominant 
in one compartment (e.g. genital) but not another (e.g. blood) if immune pressure and target 
cell populations differ (Haggerty and Stevenson 1991; Rozera, Abbate et al. 2009). An 
understanding of intra-patient quasi-species dynamics may lead to further insights into the 
role of host immune pressure on viral evolution, providing further clues to vaccine and 
microbicide development; whereas an understanding of how these subpopulations are 
transmitted between individuals may enable a greater understanding of the properties of HIV-
1 epidemics. The phylogenetic approaches used to investigate transmission dynamics of 
epidemics may be confounded by lack of sufficient refinement to take into account 
preferential transmission of minority subpopulations or preferential outgrowth of minority 
subpopulations transmitted alongside major subpopulations. Directly pertinent to this latter 
point is evidence indicating that caution may be required when applying the assumption of 
single virion founded infections linearly increasing in genetic diversity over time (Li, Bar et 
al. 2010; Redd, Mullis et al. 2012; Wagner, Pacold et al. 2013). A donor who has had a dual 
infection may transmit virions containing highly diverse viruses to the recipient, or an 
individual may be superinfected with a HIV-1 strain very different to the initial infecting 
strain, situations which may lead to complex intra-patient subpopulation dynamics. These 
dynamics may be partially obscured by observing genetic variants on an individual nucleotide 
level, in contrast to a more sophisticated treatment of viral variants as being linked with each 
other, i.e. subpopulations of linked variants (Baccam, Thompson et al. 2001; Domingo, 
Sheldon et al. 2012). These subpopulations may represent species that have evolved away 
from the founding virus through a fitness landscape requiring multiple compensatory 
mutations, or may allow identification of species of different subtype to the major species, 
indicating a history of co- or superinfection in the current host or somewhere in the preceding 
transmission chain. 
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 This study aimed to tackle some of the above issues by carrying out deep-sequencing 
of 36 patients with early HIV-1 infection in both pol and env. The study assessed the 
complexity of the viral quasi-species within patient plasma samples, with a view to detecting 
the extent to which the infections are likely to have been founded by single virions. Nine 
patients had multiple time points available, allowing insight into how the quasi-species 
changes over time. A putative transmission cluster detected using traditional Sanger pol 
sequence was also investigated using deep-sequencing, in an attempt to uncover complexities 
of quasi-species transmission dynamics not revealed through consensus sequencing.  
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5.2 Methods 
5.2.1 Patient samples 
Samples were obtained from 36 anonymised patients newly diagnosed with HIV-1 infection 
between 2004 and 2009 at the HIV service of the Royal Free London NHS Foundation Trust. 
Plasma samples were obtained as part of routine procedures and clinical data such as viral 
load and CD4
+
 cell count were collected. A guanidine based HIV antibody avidity assay was 
also performed at diagnosis to assess likely length of HIV infection (Chawla, Murphy et al. 
2007). 
 
5.2.2 Sample preparation 
Multiple samples subsequent to diagnosis were available for 9/36 patients, with the remaining 
27 patients having one time point only. All samples were subjected to 454 pyrosequencing as 
previously described (section 2.10). 
 
5.2.3 Subpopulation identification 
Fastq reads were quality filtered using a maximum expected error cut-off of 0.5, as 
implemented in the UPARSE pipeline (Edgar 2013). A minimum length open-reading frame 
filter of 390bp for the pol amplicon and 380bp for the env amplicon was imposed to retain 
only reads likely to encode functional gene products (i.e. avoiding reads with artificial 
homopolymer insertions). Forward and reverse reads were combined and aligned using 
Muscle (Edgar 2004). Any columns in the alignment containing gaps were then removed, and 
reads clustered into operational taxonomic units (henceforth referred to as subpopulations) as 
per the UPARSE pipeline, using a 1% genetic distance cut-off. Reads were then mapped to 
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subpopulations using a ≥99% identity cut-off (Fig 5.1). Sensitivity analysis was carried out to 
observe whether or not altering the distance cut-off would change the number of 
subpopulations identified within each sample: a more generous cut-off of 3% was substituted 
into the original pipeline, with all other parameters remaining unaltered. Read counts for 
subpopulations identified using the 1% cut-off were subjected to a margin of error correction 
using a 99% confidence interval (Lohr 2009). A cut-off based upon the lower boundary 
margin of error corrected percentage was used to decide whether the subpopulation was 
present at abundance greater than the chosen read abundance cut-off of 1% (section 2.12). 
Once putative subpopulations had been identified in this manner they were subjected to a 
further filtering step using BLAST and genetic distance to identify minority subpopulations 
that matched to within a <1% genetic distance of another subpopulation. If the matching 
subpopulation was not seen in additional time points from the same patient, it was excluded 
from the analysis on the basis that it could be the result of MID tag switching (Carlsen, Aas et 
al. 2012). Subtyping of each subpopulation within each sample was carried out using 
COMET (Pineda-Peña, Faria et al. 2013), and confirmed by the Los Alamos Recombinant 
Identification Program web tool (Siepel, Halpern et al. 1995). 
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Figure 5.1. Schematic illustrating the principle of subpopulation identification using the 
UPARSE pipeline. 
 
5.2.4 Estimation of patient infection date 
A total of 500 randomly selected reads from the most abundant subpopulation in patient first 
time point samples only were submitted to the Poisson-Fitter tool in order to avoid over-
estimating infection length because of multiple subpopulations (Giorgi, Funkhouser et al. 
2010). If samples were deemed to have met the assumption of having a star-like phylogeny 
then the number of days to the most common recent ancestor (MRCA) was used as the date 
of infection. The median time to MRCA for those patients fitting a star-like phylogeny was 
used for samples where the assumption was not met. 
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5.2.5 Tropism 
For each subpopulation identified in a sample, all original, ungapped unique reads within 
each subpopulation was submitted to the geno2pheno web tool designed for 454 reads 
(http://454.geno2pheno.org/index.php/) for tropism determination. 
 
5.2.6 Transmitted drug resistance 
For each sample subpopulation above the lower margin of error limit of 1%, the drug 
resistance profile of each unique read within that subpopulation was ascertained using the 
Stanford HIVdb tool (http://sierra2.stanford.edu/sierra/servlet/JSierra), with reference to the 
World Health Organization 2009 List of Mutations for Surveillance of Transmitted Drug 
Resistant HIV Strains (Bennett, Camacho et al. 2009). Due to the length of the pol amplicon, 
only resistance to NRTIs and NNRTIs was assessed.  
 
5.2.7 Transmission chain samples 
Pol Sanger consensus sequences for all 36 patients, together with 531 sequences obtained 
from the same London based cohort were subjected to phylogenetic analysis after stripping 
drug resistance associated codons based upon the Bennett 2009 list (Bennett, Camacho et al. 
2009). Potential clusters were identified by constructing trees using PhyML3.0 (Guindon, 
Dufayard et al. 2010) with a General Time Reversible (GTR) model of substitution with 
proportion of invariable sites and gamma shape parameter estimated from the data, and then 
identifying clusters on the basis of having ≥95% bootstrap support from 1000 bootstrap 
replicate approximate likelihood trees constructed in FastTree2.1, and a mean pairwise 
Hamming distance ≤0.045. The same process was carried out on the pol and env deep-
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sequencing amplicon subpopulations in order to identify clusters of non-primary 
subpopulations that may have been obscured in the Sanger pol sequence trees. 
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5.3 Results 
5.3.1 Sample preparation and read generation 
A total of 65 plasma samples were available for analysis (median viral load 5.2 log10 
copies/ml, IQR: 4.8-5.7). A median of 5964 (IQR: 5402-6593) pol and 4650 (IQR: 4066-
5135) env reads were available for each sample pre-quality filtering. After quality filtering 
using a maximum expected error threshold as implemented in UPARSE, a median of 3012 
(IQR: 2527-3540) pol and 2888 (IQR: 2201-3411) env reads were available for analysis per 
sample. 
 
5.3.2 Subpopulation identification 
For the 36 patients with deep-sequencing results available there was a median of 1 
subpopulation for pol (IQR: 1-2) and 2 subpopulation for env (IQR: 1-2) across all time 
points. The clone control had 1 subpopulation in pol and 1 subpopulation in env at the 1% 
read prevalence cut-off. The clone control had 3 subpopulations identified for pol at lower 
prevalence (0.5%, 0.4% and 0.2%) and 1 subpopulation identified for env at lower prevalence 
(0.9%), but these percentage abundances dropped further when using the lower bound of the 
margin of error (Lohr 2009). BLAST was used to identify potential sources of clone control 
contamination within the overall patient samples, and identical matches were found to other 
subpopulations within the same pool, suggesting that these reads were the result of crossover 
between samples, possibly due to MID tag errors (Carlsen, Aas et al. 2012). It should be 
emphasized that this was not the result of PCR contamination between samples, as the clone 
control was amplified in a separate reaction at a different time to the patient samples. 
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Putative subpopulations were subjected to the margin of error minimum bound filter and 
BLAST analysis to remove subpopulations present at low abundance or potentially present as 
a result of low-level MID tag contamination. This process removed 326/456 (71.5%) pol 
subpopulations across all samples (318 due to margin of error correction filtering, 8 due to 
BLAST filtering) present at a median abundance of 0.37% (IQR: 0.17-0.67%), and 385/624 
(61.7%) env subpopulations across all samples (381 due to margin of error correction 
filtering, 4 due to BLAST filtering) present at a median abundance of 0.37% (IQR 0.16-
0.76%). At the earliest sampled time point, median 139 days (IQR: 125.5-156 days) after 
estimated infection date as estimated using the Poisson-Fitter tool, 11/36 (30.6%) patients had 
evidence of >1 subpopulation in pol and 17/36 (47.2%) patients had evidence of >1 
subpopulation in env (Table 1). For the 30/65 (53.8%) patient time points with >1 pol 
subpopulation, the average pairwise genetic distance between subpopulations was a median 
Hamming distance of 1.3% (IQR: 1.1-2.1%), and for the 41/65 (63.1%) patient time points 
with >1 env subpopulation, these subpopulations were a median Hamming distance of 1.4% 
(IQR: 1.2-2.3%) away from each other (measured using the ‘centroid’ seed sequence for each 
subpopulation) (N.B. by definition, the median distance between subpopulation must be >1%, 
since this is the distance specified in the UPARSE pipeline). For context, comparing patient 1 
primary subpopulation in the first time point with the primary subpopulation in the fifth time 
point, over 57 weeks later, revealed a Hamming distance of 0.3% in pol and 1.3% in env 
respectively (N.B. the UPARSE parameters used to identify subpopulations specified that 
centroids must be >1% genetic distance from each other, but this does not apply to 
subpopulations from different time points). 
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Table 5.1. Clinical data from diagnosis for 36 patients eligible for deep-sequencing. 
Avidity index is the guanidine based avidity assay result used to estimate length of HIV-
1 infection. T0 sample is the first time point sample that deep-sequencing was carried 
out on, which was not always the same as the diagnosis sample. Subpopulations at T0 is 
Patient Diagnosis date
CD4 
count
Avidity 
index
Time 
point
Sample 
identifier
Sample date Viral load
Pre-qc 
reads
Post-qc 
reads
Pre-qc 
reads
Post-qc 
reads
Pol Env
Patient 1 10/06/2004 560 0.163 t0 Pool4_TC1 15/09/2004 36672 4722 2052 (43) 3781 2198 (58) 1 4
t1 Pool4_TC2 17/12/2004 24844 4876 2124 (44) 3980 1992 (50) 2 9
t2 Pool3_TC3 11/03/2005 39971 5808 2726 (47) 5759 3136 (54) 1 10
t3 Pool3_TC6 15/06/2005 49809 5398 2387 (44) 5135 2759 (54) 2 7
t4 Pool4_TC5 21/10/2005 35732 4954 2103 (42) 4425 2160 (49) 2 8
Patient 2 06/10/2004 302 0.234 t0 Pool3_TC1 30/11/2004 74842 6218 3068 (49) 5075 3042 (60) 1 1
t1 Pool2_TC2 18/02/2005 51151 5074 2307 (45) 3389 1659 (49) 1 1
t2 Pool3_TC4 04/05/2005 78929 6031 2800 (46) 5308 2710 (51) 2 2
t3 Pool3_TC5 23/05/2005 90618 6190 2922 (47) 4837 2448 (51) 1 2
Patient 3 19/10/2004 359 0.161 t0 Pool2_TC1 19/10/2004 297620 6553 2999 (46) 3594 926 (26) 2 4
Patient 4 08/02/2005 663 0.144 t0 Pool4_TC3 01/03/2005 455309 4849 2838 (59) 4810 2476 (51) 2 2
t1 Pool1_TC3 06/04/2005 506240 6798 4002 (59) 4503 1909 (42) 3 3
t2 Pool1_TC4 27/04/2005 243047 5962 3584 (60) 4412 2056 (47) 4 3
t3 Pool1_TC5 23/06/2005 380285 5694 3474 (61) 4019 1906 (47) 4 4
t4 Pool3_TC7 22/08/2005 88451 6853 3982 (58) 4590 1850 (40) 4 6
t5 Pool4_TC4 30/09/2005 21545 5438 3182 (59) 4654 2102 (45) 3 8
Patient 5 10/02/2005 348 0.328 t0 Pool1_TC1 10/02/2005 146868 6742 2860 (42) 4010 2763 (69) 1 1
Patient 6 16/02/2005 628 0.583 t0 Pool1_TC2 16/02/2005 281955 4747 2659 (56) 4227 2816 (67) 1 1
Patient 7 10/03/2005 355 0.238 t0 Pool5_TC1 16/03/2005 >1,000,000 7634 2613 (34) 3704 1665 (45) 2 2
Patient 8 17/05/2005 278 0.35 t0 Pool5_TC2 10/10/2005 150875 7643 3710 (49) 3646 2494 (68) 2 2
t1 Pool4_TC6 14/11/2005 187633 5390 2569 (48) 5405 3382 (63) 2 3
t2 Pool5_TC3 12/12/2005 626596 8414 4264 (51) 4293 2911 (68) 1 2
Patient 9 15/06/2005 634 0.17 t0 Pool3_TC8 19/10/2005 58433 5704 1912 (34) 5514 3214 (58) 2 13
t1 Pool3_TC10 20/12/2005 37387 6081 1997 (33) 5962 3291 (55) 1 13
t2 Pool4_TC7 22/03/2006 52619 5891 1241 (21) 5133 2949 (57) 2 12
t3 Pool4_TC10 22/08/2006 49123 5047 1193 (24) 4751 2776 (58) 1 7
Patient 10 26/07/2005 283 0.52 t0 Pool2_TC3 18/08/2005 80164 6028 2364 (39) 4492 2432 (54) 1 1
Patient 11 28/12/2005 412 0.33 t0 Pool2_TC4 28/12/2005 1391869 5835 2803 (48) 4904 2919 (60) 1 1
Patient 12 06/01/2006 587 0.24 t0 Pool5_TC4 06/01/2006 >10,000,000 8801 4783 (54) 4727 1894 (40) 1 1
Patient 13 17/01/2006 1066 0.47 t0 Pool1_TC6 17/01/2006 4452318 5717 2525 (44) 4893 3212 (66) 1 4
t1 Pool1_TC7 27/01/2006 1878960 6679 2816 (42) 5539 3480 (63) 4 5
t2 Pool1_TC8 10/02/2006 1390722 5413 2282 (42) 4660 2966 (64) 4 5
t3 Pool3_TC11 30/03/2006 155060 6593 2757 (42) 5842 3370 (58) 4 6
t4 Pool3_TC13 25/04/2006 130031 6487 2798 (43) 5699 3165 (56) 4 13
t5 Pool1_TC10 10/05/2006 519051 6412 2732 (43) 5807 3525 (61) 4 12
Patient 14 04/04/2006 295 0.7 t0 Pool2_TC5 03/04/2006 261986 4783 1682 (35) 3973 1739 (44) 1 1
Patient 15 22/08/2006 1057 0.4 t0 Pool2_TC6 21/08/2006 50850 5422 1942 (36) 4013 2167 (54) 1 1
Patient 16 29/09/2006 378 0.6 t0 Pool4_TC11 28/09/2006 327130 6038 3807 (63) 5066 2165 (43) 8 1
Patient 17 09/11/2006 502 0.6 t0 Pool4_TC13 09/11/2006 696163 5804 2085 (36) 4650 2724 (59) 1 1
Patient 18 20/03/2007 1036 0.5 t1 Pool1_TC11 15/03/2007 1652460 6518 3630 (56) 5617 3800 (68) 1 1
Patient 19 10/04/2007 787 0.4 t0 Pool5_TC5 13/04/2007 107360 8509 3087 (36) 4224 1985 (47) 1 1
Patient 20 11/05/2007 1001 0.6 t0 Pool2_TC7 11/05/2007 268640 5903 2727 (46) 4779 2763 (58) 1 1
Patient 21 25/05/2007 764 0.6 t0 Pool2_TC8 25/05/2007 141578 4684 2469 (53) 3357 1620 (48) 1 4
Patient 22 31/05/2007 608 0.3 t0 Pool5_TC6 31/05/2007 >10,000,000 7858 4581 (58) 4243 2780 (66) 1 2
Patient 23 12/06/2007 399 0.4 t0 Pool4_TC14 12/06/2007 33082 5169 2253 (44) 3875 2173 (56) 1 2
Patient 23 t1 Pool3_TC14 15/06/2007 52299 4863 2485 (51) 5170 3197 (62) 1 1
Patient 23 t2 Pool3_TC15 21/08/2007 90528 5964 2828 (47) 5347 3508 (66) 1 1
Patient 24 28/06/2007 462 0.5 t0 Pool2_TC11 29/06/2007 130267 4236 1547 (37) 3734 640 (17) 4 3
Patient 25 01/11/2007 951 0.7 t0 Pool2_TC14 01/11/2007 299850 5923 2816 (48) 4495 1842 (41) 1 11
Patient 26 07/11/2007 272 0.7 t0 Pool5_TC10 12/11/2007 604026 8506 4696 (55) 5195 3232 (62) 2 5
Patient 27 23/04/2008 516 0.5 t0 Pool2_TC15 23/04/2008 94013 5246 2534 (48) 3651 2109 (58) 1 1
Patient 28 13/06/2008 339 0.5 t0 Pool5_TC13 13/06/2008 108093 8324 3641 (44) 3286 1078 (33) 1 2
Patient 29 30/07/2008 919 0.1 t0 Pool4_TC16 29/07/2008 40064 5862 3371 (58) 5202 3202 (62) 1 2
Patient 30 18/08/2008 494 0.3 t0 Pool5_TC14 18/08/2008 354973 8111 3659 (45) 3687 1951 (53) 1 1
Patient 31 17/09/2008 326 0.4 t0 Pool2_TC16 17/09/2008 8232216 5131 1685 (33) 4526 1563 (35) 2 1
Patient 32 17/10/2008 349 0.5 t0 Pool2_TC18 17/10/2008 4304339 6035 1385 (23) 4015 1027 (26) 3 2
Patient 33 21/01/2009 744 0.3 t0 Pool5_TC15 16/01/2009 40100735 6155 2647 (43) 4206 2774 (66) 1 1
Patient 34 28/01/2009 221 0.2 t0 Pool5_TC16 30/01/2009 >10,000,000 7726 4595 (59) 4207 2077 (49) 3 2
Patient 35 21/05/2009 806 0.3 t0 Pool4_TC17 21/05/2009 140230 5185 2704 (52) 5002 2227 (45) 1 1
Patient 35 t1 Pool3_TC16 29/05/2009 96840 6097 3062 (50) 4644 2228 (48) 1 1
Patient 35 t2 Pool4_TC18 12/06/2009 40174 5835 3032 (52) 5111 2379 (47) 1 1
Patient 36 19/06/2009 760 0.1 t0 Pool1_TC17 26/06/2009 872971 6911 2902 (42) 5177 3287 (63) 1 1
Patient 36 t1 Pool3_TC17 10/08/2009 61034 6756 2637 (39) 5233 3355 (64) 2 2
Patient 36 t2 Pool5_TC18 11/12/2009 87052 6124 2464 (40) 4224 2743 (65) 5 4
Patient 36 t3 Pool1_TC18 04/03/2010 182705 6093 2275 (37) 4867 3185 (65) 5 2
Pol Env Subpopulations
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the number of subpopulations > 1% abundance in the first time point sample. Pre-qc 
read number refers to number of reads after mapping reads to pol or env regions based 
upon primer sequence. Post-qc reads refers to read number after imposing a read 
quality filtering step through the UPARSE pipeline, together with an open-reading 
frame minimum length filter to remove spurious reads generated through indels. 
 
5.3.3 Patients with multiple time points 
Pol: 6/9 patients with multiple time points available had single pol subpopulations at first 
time point, 3/9 had evidence of >1 pol subpopulation. Of those patients with single pol 
subpopulations at first time point, 4/6 went on to increase in subpopulation number in later 
time points, the remaining two maintained a single subpopulation across all time points, for 
follow-up periods of 10 and 3 weeks respectively. 
Overall pairwise genetic diversity (i.e. combined across subpopulations) in pol increased 
from first to last time point for 7/9 (77.8%) patients, but the increase was not consistent 
between each time point for all patients (Fig 5.2). 
Env: 3/9 patients with multiple time points had single env subpopulations at first time point, 
6/9 had evidence of >1 env subpopulation. Of those patients with single env subpopulations at 
first time point, 2/3 went on to increase in subpopulation number in later time points, the 
infection of the remaining patient maintained a single subpopulation across all time points, 
for 3 weeks. 
Overall pairwise genetic diversity (i.e. combined across subpopulations) in env increased 
from first to last time point for 6/9 (66.7%) patients, but the increase was not consistent 
between each time point for all patients (Fig 5.2). 
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Figure 5.2. Plots showing overall changes in pairwise Hamming distance between reads 
across all subpopulations combined for the 9 patients with multiple time points 
available (blue solid lines for pol, and red dashed lines for env). 
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For each of the 9 patients with multiple time points, the inverse Simpson index of diversity 
was calculated for the primary subpopulation in the first time point and the most abundant 
closest matching subpopulation in subsequent time points using the Vegan package in R 
(Oksanen, Blanchet et al. 2013), where an increase in the index indicates an increase in 
subpopulation diversity (i.e. a greater number of unique reads, and fewer identical reads) (Fig 
2.). Where the percentage read abundance of the primary subpopulation remained close to 
100%, the diversity index and overall subpopulation number remained relatively stable. It is 
in patients 1, 4, 13 and 36 that display the most radical disruption in primary subpopulation 
read abundance and diversity within that read. In these four patients, primary subpopulation 
read abundance seems to inversely correlate with overall subpopulation number. 
 
 
 
 
 
Figure 5.3. Plots showing changes in the total subpop(ulation) number in each patient 
time point, together with the inverse Simpson index for the primary subpopulation in t0 
tracked through all time points (with higher values indicating greater diversity), and the 
% abundance of that primary subpopulation in each time point. For each patient, left 
panel shows results for pol, and right panel results for env. Axis colours are matched to 
plot colours for clarity.   
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Rate of evolution of subpopulations: the rate of evolution seen in the primary pol and env 
subpopulations between first and last time point in the 9 patients with multiple samples, was a 
median 2.4 x 10
-3
 nucleotide substitutions per site per year (IQR: 0 to 7.6 x 10
-3
) and 2.9 x 10
-
2
 nucleotide substitutions per site per year (IQR: 1.3 x 10
-2
 to 4.6 x 10
-2
) in pol and env 
respectively, based upon Hamming distance. 
Subpopulation subtypes: The HIV-1 subtype did not agree between the predominant pol and 
env amplicons in 3/36 patient first time points. In 4/21 patients with >1 pol or env 
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subpopulation at their first or subsequent time points, the additional subpopulations were of 
different subtype to the primary subpopulation (either in pol or env). 
Two of these patients displayed outgrowth of secondary/tertiary subpopulations of different 
subtype to the primary subpopulation over multiple time points: 
 Patient 8 had a primary subtype B subpopulation in env in the first time point, with a 
secondary subtype A1 subpopulation present at 2.5% abundance. In the second time 
point, this A1 subpopulation had diversified into two subpopulations present at 6.9% 
and 3.9%, and by the third time point had merged into one subpopulation present at 
30.8% abundance. The primary pol subpopulation remained subtype B across all three 
time points (Table S1.). 
 Patient 36 had a primary subtype B subpopulation in both pol and env in the first time 
point (with a suggestion by the COMET subtyping algorithm to check for presence of 
CRF29_BF in the pol amplicon), with no evidence of secondary subpopulations above 
1% abundance. By the second time point, pol had developed a secondary subtype B 
subpopulation at 11.1% (with a suggestion by the COMET subtyping algorithm to 
check for presence of CRF12_BF), and env had developed a secondary subpopulation 
at 44.2% abundance with an A1 subtype. By the third time point, pol had developed 5 
subtype B subpopulations (at 57.3%, 15.6%, 3.4% and 3.2% abundance respectively), 
and a subtype D subpopulation at 3.2% (though subtype B and D are genetically 
highly similar, and so this subpopulation may also be subtype B, but with insufficient 
sequence to allow correct allocation of subtype (Robertson, Anderson et al. 1999)), 
and the env A1 subpopulation had grown to an abundance of 75.3%, with 3 secondary 
subpopulations: 2 subtype F1 subpopulations, present at 16.0% and 5.1% abundance, 
and another subtype A1 subpopulation present at 2.5%. In time point 4, pol was found 
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to have 5 subtype subpopulations in pol at 60.1%, 19.5%, 3.0%, 2.1% and 2.0%, 
whereas the subtype A1 subpopulation in env was found to be present at 94.1% 
abundance and just one secondary subpopulation, subtype B, at 5.0% (Appendix 3). 
 
5.3.4 Genetic distance sensitivity analysis 
The genetic distance used to separate initial subpopulation ‘seeds’ (centroids) and 
subsequently cluster highly related reads within a sample was altered to assess the effect on 
the overall subpopulation number identified within each sample. An original >1% genetic 
distance between putative subpopulations, and a corresponding clustering of all sequences 
with ≥99% genetic identity to the initial subpopulation ‘seed’ sequence, was replaced by a 
>3% genetic distance cut-off for initial subpopulation ‘seeds’, combined with a 
corresponding ≥97% genetic identity cut-off. Results indicated a reduced number of 
subpopulations for both pol and env identified at the more generous cut-off (Table 5.4). 
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Patient 
Time 
point
Sample 
identifier
Pol Env Pol Env
Patient 1 t0 Pool4_TC1 1 4 1 1
t1 Pool4_TC2 2 9 1 1
t2 Pool3_TC3 1 10 1 1
t3 Pool3_TC6 2 7 1 1
t4 Pool4_TC5 2 8 1 1
Patient 2 t0 Pool3_TC1 1 1 1 1
t1 Pool2_TC2 1 1 1 1
t2 Pool3_TC4 2 2 1 1
t3 Pool3_TC5 1 2 1 1
Patient 3 t0 Pool2_TC1 2 4 1 2
Patient 4 t0 Pool4_TC3 2 2 1 1
t1 Pool1_TC3 3 3 1 1
t2 Pool1_TC4 4 3 1 1
t3 Pool1_TC5 4 4 1 1
t4 Pool3_TC7 4 6 1 1
t5 Pool4_TC4 3 8 1 1
Patient 5 t0 Pool1_TC1 1 1 1 1
Patient 6 t0 Pool1_TC2 1 1 1 1
Patient 7 t0 Pool5_TC1 2 2 2 1
Patient 8 t0 Pool5_TC2 2 2 2 2
t1 Pool4_TC6 2 3 2 2
t2 Pool5_TC3 1 2 1 2
Patient 9 t0 Pool3_TC8 2 13 1 2
t1 Pool3_TC10 1 13 1 1
t2 Pool4_TC7 2 12 1 1
t3 Pool4_TC10 1 7 1 3
Patient 10 t0 Pool2_TC3 1 1 1 1
Patient 11 t0 Pool2_TC4 1 1 1 1
Patient 12 t0 Pool5_TC4 1 1 1 1
Patient 13 t0 Pool1_TC6 1 4 1 2
t1 Pool1_TC7 4 5 2 2
t2 Pool1_TC8 4 5 2 2
t3 Pool3_TC11 4 6 2 2
t4 Pool3_TC13 4 13 2 2
t5 Pool1_TC10 4 12 2 1
Patient 14 t0 Pool2_TC5 1 1 1 1
Patient 15 t0 Pool2_TC6 1 1 1 1
Patient 16 t0 Pool4_TC11 8 1 1 1
Patient 17 t0 Pool4_TC13 1 1 1 1
Patient 18 t1 Pool1_TC11 1 1 1 1
Patient 19 t0 Pool5_TC5 1 1 1 1
Patient 20 t0 Pool2_TC7 1 1 1 1
Patient 21 t0 Pool2_TC8 1 4 1 1
Patient 22 t0 Pool5_TC6 1 2 1 1
Patient 23 t0 Pool4_TC14 1 2 1 1
Patient 23 t1 Pool3_TC14 1 1 1 1
Patient 23 t2 Pool3_TC15 1 1 1 1
Patient 24 t0 Pool2_TC11 4 3 1 1
Patient 25 t0 Pool2_TC14 1 11 1 1
Patient 26 t0 Pool5_TC10 2 5 2 2
Patient 27 t0 Pool2_TC15 1 1 1 1
Patient 28 t0 Pool5_TC13 1 2 1 2
Patient 29 t0 Pool4_TC16 1 2 1 1
Patient 30 t0 Pool5_TC14 1 1 1 1
Patient 31 t0 Pool2_TC16 2 1 1 1
Patient 32 t0 Pool2_TC18 3 2 2 2
Patient 33 t0 Pool5_TC15 1 1 1 1
Patient 34 t0 Pool5_TC16 3 2 1 2
Patient 35 t0 Pool4_TC17 1 1 1 1
Patient 35 t1 Pool3_TC16 1 1 1 1
Patient 35 t2 Pool4_TC18 1 1 1 1
Patient 36 t0 Pool1_TC17 1 1 1 1
Patient 36 t1 Pool3_TC17 2 2 2 2
Patient 36 t2 Pool5_TC18 5 4 3 2
Patient 36 t3 Pool1_TC18 5 2 3 2
3% subpopulations1% subpopulations
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Table 5.4. Comparing subpopulation numbers for pol and env using a 1% and 3% 
genetic distance cut-off in the UPARSE pipeline. 
 
 
5.3.5 Tropism 
Overall 19/238 (8.0%) of the stringently filtered env subpopulations submitted to the 
geno2pheno 454 web tool was found to have >0% of predicted percentage of X4-tropic virus 
at an FPR of 5%, ranging from 1.4% to 8.2%, with one subpopulation having a percentage of 
61.9%. This subpopulation belonged to the first time point of patient 35 (single env 
subpopulations across all three time points), highly likely to have been sampled from Fiebig 
stage II (patient diagnosed with p24 Ag
+
/Ab
-
 results) (Cohen, Gay et al. 2010). By the second 
time point 8 days later, a single nucleotide mutation in the subpopulation representative 
sequence resulted in an amino acid change from glutamic acid to glycine at position 24 of the 
V3 loop (20-WYTPEQITGDI-30 to 20-WYTPGQITGDI-30), changing the of predicted 
percentage of X4-tropic virus at an FPR of 5% from 61.9% to 0.3%. 
 
5.3.6 Transmitted drug resistance 
Resistance to NRTIs and NNRTIs was assessed for all 129 pol subpopulations containing 
>1% of reads in each sample (margin of error corrected), using the Sierra web service 
available on the Stanford HIV Drug Resistance Database website. Overall, 101/129 
subpopulations had drug resistance, with a median of 3 drug resistance mutations (IQR: 1-5). 
Of these 101 drug resistance subpopulations, there was a median of 2.8 reads per drug 
resistance mutation (IQR: 1-5.6). Due to the error prone process of deep-sequencing, it is 
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possible that some of these mutations were introduced as part of the experimental procedure, 
and indeed, the average reads per drug resistance mutation appeared to reveal a division 
between those subpopulations with <10 reads per drug resistance mutation (116 
subpopulations, median 2.0 reads per mutation, IQR: 0.8 to 4.6 reads per mutation) and those 
with >150 reads per mutation (13 subpopulations, median 931.5 reads per mutation, IQR: 
258.2 to 1419.5 reads per mutation), possibly suggesting the former represent mutations that 
are either present at extremely low levels in the majority of treatment naive individuals in the 
cohort, or that the mutations are spurious artefacts of the 454 sequencing process.  
NRTI resistance: Taking forward only the 13 subpopulations with >150 average number of 
reads per mutation, 7/13 subpopulations had a T215S mutation, 5 from one patient with 4 
time points available across 25 weeks of follow-up (with the third time point have two 
subpopulations, both carrying the T215S mutation), and the remaining two from patients with 
only one time point available. 1/13 subpopulations had K219E, 3/13 had K219N 
(subpopulations from the same patient time point), and 1/13 subpopulations had a K219Q 
mutation. 
NNRTI resistance: 1/13 subpopulations had a Y188C mutation. 
 
5.3.7 Transmission chain samples 
A phylogenetic tree was constructed with PhyML3.0 (Guindon, Dufayard et al. 2010) using 
the 36 patient pol Sanger sequences, together with 531 sequences obtained from the same 
London based cohort. All sequences had drug resistance associated codons removed prior to 
analysis (Bennett, Camacho et al. 2009). Clusters were identified on the basis of having 
≥95% bootstrap support from 1000 bootstrap replicate approximate likelihood trees 
constructed in FastTree2.1, and a mean pairwise Hamming distance ≤0.045. Two potential 
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clusters involving patients from the deep-sequencing cohort were identified, one involving 3 
patients located within a subtype B cluster of 12 sequences with 100% bootstrap support and 
mean pairwise Hamming distance of 0.009, and one in a CRF02_AG cluster of 2 sequences 
with 100% bootstrap support and mean pairwise Hamming distance of 0.017. Further 
phylogenetic trees were constructed using the pol or env subpopulations from the 36 deep-
sequencing patients only. 
Subtype B cluster: 3 patients involved in a subtype B cluster of 12 individuals in the Sanger 
pol sequence tree had deep-sequencing results available: patient 8, patient 21 and patient 22. 
Patient 8 showed 2 pol subpopulations at t0 (80.5% and 16.7% abundance respectively, both 
subtype B) and t1 (90.8% and 2.4% abundance respectively, both subtype B), but only one 
pol subpopulation in t2. 
Patient 21 showed a single pol subpopulation at t0 (subtype B). 
Patient 22 showed a single pol subpopulation at t0 (subtype B). 
In the phylogenetic tree based upon deep-sequencing subpopulations, the secondary pol 
subpopulations detected in patient 8 at t0 and t1 were found to cluster with the pol 
subpopulation of patients 21 and 22 (bootstrap support score 97%, mean pairwise Hamming 
distance 0.004, Fig 4). 
Of note, the first time point sampled for deep-sequencing for patient 8 was obtained 21 weeks 
after diagnosis - comparison of the first time point with the Sanger pol sequence generated at 
diagnosis indicates the primary subpopulation sampled at diagnosis had become the 
secondary subpopulation by the first time point submitted to deep-sequencing (21 weeks 
later). 
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In the env phylogenetic tree constructed from deep-sequencing subpopulations, the secondary 
env subpopulations detected in patient 8 at t0, t1 and t2 clustered with the env subpopulations 
detected in patients 21 and 22 (bootstrap support score 95% and the mean pairwise Hamming 
distance 0.034). In patient 8, in contrast to the pol secondary subpopulation, the env 
secondary subpopulation showed a steady increase over subsequent time points, suggesting it 
may have eventually emerged as the primary env subpopulation (Fig 5.) 
A slightly larger cluster included four env subpopulations from patient 36: the subtype A1 
secondary subpopulation detected at t1 (which became the primary subpopulation in t2 and 
t3), and the subtype A1 primary subpopulations from t2 and t3 (Fig 5). The cluster showed 
100% bootstrap support with a mean pairwise Hamming distance of 0.053. 
CRF02_AG cluster: 2 patients involved in a CRF02_AG transmission pair in the Sanger pol 
sequence tree had deep-sequencing results available: patient 26 and patient 29. 
Patient 26: showed 2 pol subpopulations at t0 (both CRF02_AG). 
Patient 29: showed one pol subpopulation at t0 (CRF02_AG). 
Subpopulations were found to cluster in both the pol and env trees, this was with a bootstrap 
support score of 81% and 100% and a mean pairwise Hamming distance of 0.027 and 0.021 
in pol and env respectively (Figs 5.5a and 5.5b). 
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Fig 5.4a.PhyML tree for pol subpopulations across all time points for all 36 patients. 
Clusters identified in Sanger sequence pol trees are highlighted. 
 
Fig 5.5b. PhyML tree for env subpopulations across all time points for all 36 patients. 
Clusters identified in Sanger sequence pol trees are highlighted. 
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5.4 Discussion 
This study set out to examine the intra-host viral complexity in patients with early HIV-1 
infection, using a deep-sequencing approach to delve into the quasi-species dynamics taking 
place at a level beyond the reach of traditional Sanger sequencing. Analysis of the first time 
point results across the 36 patients indicated that 11/36 (30.6%) and 17/36 (47.2%) 
individuals had >1 subpopulation in pol and env respectively. Given that the time of infection 
is unknown for these patients, but is estimated to be 139 days on average using the Poisson-
Fitter tool, and it is clear that subpopulation numbers (as defined as >1% genetically distant 
from one another) change between time points that are substantially less than 139 days, it is 
difficult to assess the extent to which these subpopulations are evolving from one founding 
virus, or >1 founding virus. The 1/4 and 2/8 instances of secondary subpopulations of 
different subtype to the primary subpopulation in the first time point for pol and env 
respectively, seem to strongly indicate that the secondary subpopulations did not evolve from 
the primary subpopulations in each case, but was more likely the result of 
dual/superinfection. 
 In terms of subpopulation dynamics over time, this study identified a mixture of 
individuals exhibiting uniform subpopulation number over time, and individuals where 
substantial growth of initially minor subpopulations occurred over the time points. Perhaps 
most interesting were the two subjects (patients 8 and 36) that displayed substantial growth of 
a subpopulation that was in the minority, or not even present at ≥1% abundance, in the first 
time point, but then subsequently showed a large increase in abundance. Furthermore, these 
subpopulation outgrowths occurred in env but not to the same extent in pol, suggestive of 
recombination occurring over time somewhere between the two amplicon regions. This 
recombination and potential change in fitness could potentially be further investigated using 
transmissibility and replicative fitness assays (Njai, Gali et al. 2006), together with whole 
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genome sequencing of virus sampled from patients 8 and 36 to determine the existence of 
breakpoint locations. The link between changes in subpopulation number and changes in 
diversity over time points was not uniform cut across the 9 patients. In some instances 
(patients 1, 4 , 13 and 36) increases in diversity within the primary env subpopulation seemed 
to occur in tandem with increases in subpopulation number, possibly reflecting host pressure 
on the primary subpopulation, forcing it to explore multiple evolutionary pathways, with 
successful ‘child’ subpopulations developing into subpopulations >1% genetically distant 
from the ‘parent’ subpopulation; corresponding drops in the time point percentage abundance 
for the t0 primary subpopulations fit with this interpretation. Other patients appear to have 
little evolution in either pol or env, and it is interesting to speculate on the differences 
between these patient subsets, i.e. potential effects of Human Leukocyte Antigen (HLA) 
types of the patients. 
 It is also intriguing that the subtype A1 env subpopulations that seemed to be 
responsible for the substantial growths in patients 8 and 36 were highly related, and related to 
viruses in two other individuals that displayed strong indications of being epidemiologically 
linked to patient 8 on the basis of pol Sanger consensus sequencing (patients 21 and 22). One 
possible scenario could be that patient 8 was infected by an individual with a dual subtype B 
and subtype A1 infection, but that the A1 subtype virus was initially restricted or out-
competed by the subtype B virus. Then, over time, possibly through recombination, the viral 
quasi-species developed into a primary subpopulation with a subtype B pol region and 
subtype A1 env region (the subtype of other regions remain to be elucidated). This virus was 
then transmitted to patients 21 and 22 (whether directly or not is impossible to determine, as 
there were 12 individuals in the pol Sanger consensus sequence cluster, and there may have 
been further individuals involved in the cluster who have not been diagnosed by the clinic in 
question). The virus was transmitted to patient 36 at a later time point, but as with patient 8, it 
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may have been initially restricted or outcompeted in some way by a co-founder virus but 
went on to outgrow that initial virus rapidly to become the primary subpopulation 24 weeks 
later, possibly with partial recombination once again, as the initial primary subtype B 
subpopulation in pol remains the primary subpopulation through all four time points (the 
likelihood of there being a super-infection event between t0 and t1 for patient 36 seems to be 
slim given the 6 week gap between samples, but cannot be ruled out). 
 In terms of one potential explanation of why particular viruses may play a more 
prominent role at the transmission founder stage and then go on to be outcompeted or evolve 
away from their initial form is the tropism of the virion, i.e. which co-receptor is preferred for 
host cell entry. Viruses that preferentially bind the CCR5 receptor appear to dominate early in 
HIV infection (Van't Wout, Kootstra et al. 1994; Salazar-Gonzalez, Salazar et al. 2009), with 
CXCR4 viruses becoming more prevalent later in infection (Schuitemaker, Koot et al. 1992; 
Connor, Sheridan et al. 1997), though it is still unclear if this is a cause of or correlation with 
disease progression. In previous studies, CXCR4 tropic viruses have been found at low levels 
in individuals prior to treatment with the co-receptor antagonist maraviroc (Archer, Rambaut 
et al. 2010; Bunnik, Swenson et al. 2011). It is debated to what extent these low-frequency 
CXCR4 tropic variants are the result of evolution from CCR5 viruses after transmission, or 
whether they are transmitted alongside CCR5 tropic variants (Archer, Rambaut et al. 2010; 
Bunnik, Swenson et al. 2011; Chalmet, Dauwe et al. 2012). This study found only one 
CXCR4 tropic subpopulation out of 238 subpopulations from the 36 individuals at an FPR of 
5.0%. The subpopulation was the major subpopulation from the first time point (date of 
diagnosis) of a patient that was diagnosed very early after infection, prior to HIV antibody 
seroconversion. By the second time point, 8 days later, a single nucleotide mutation had 
resulted in the switch of an amino acid in the V3 loop, changing the prediction of tropism. 
For the remaining patients with clear growth of minor subpopulations over time points, there 
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was no evidence that the tropism of the virus as determined by the V3 loop region was 
instrumental in the process – though other aspects of the envelope gene itself both within and 
outside of the 400bp env amplicon may have influenced viral fitness (Lynch, Shen et al. 
2009). 
 Another potential factor involved in evolution and competition between viruses that 
can be inferred directly from the deep-sequencing data is antiretroviral drug resistance. 
Though all individuals in the study were treatment naive, it is possible that some were 
infected by individuals failing therapy, and who had developed drug resistant viral strains as 
a consequence. Alternatively, a treatment-naive source may have carried transmitted drug 
resistance. It has been shown that the fitness costs imposed by drug resistant mutations in the 
absence of drug pressure leads to the loss of the drug resistant viral strain and reversion to 
wildtype virus archived prior to therapy initiation (Hedskog, Mild et al. 2010). However, 
there was insufficient evidence of drug resistant virus playing a role in the dynamics of the 
patients in this study, as only one of the 6 patients with a drug resistance mutation had 
multiple time points available. For this patient, patient 2, the revertant mutation T215S 
(García-Lerma, Nidtha et al. 2001) was present in all four major time points as the top 
subpopulations (>94% abundance) over a 25 week period. 
 There are a number of limitations to the study that need to be acknowledged. 
Although a useful window has been opened onto the complexities of subpopulation dynamics 
within single patients, and transmission of these subpopulations between patients, by the use 
of two different regions of the HIV genome, the limited nature of the genome coverage 
means that all regions of interest could not be investigated for possible roles in quasi-species 
evolution and interchange of primary subpopulations. Other studies that have carried out full 
genome deep-sequencing (some using ‘deep-cloning’) analysis have focused primarily on 
detecting epitopes important for targeting by the host immune pressure, with a view to 
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applying the findings to vaccine development (Keele, Giorgi et al. 2008; Henn, Boutwell et 
al. 2012), and have not attempted to detect large scale genomic rearrangements that might be 
driven by other factors affecting virus replication, such as cell entry mechanisms or virion 
release. This study focused on a subset of patients with recent infection, verified by 
laboratory and clinical information. The actual date of infection was estimated using a tool 
based upon Hamming distance frequency distributions (Giorgi, Funkhouser et al. 2010). 
Comparison of the results obtained for individuals with >1 pol subpopulation when mixed 
subpopulation reads (from subpopulations of different subtype) and primary subpopulation 
reads were submitted revealed that large differences can be observed in the estimated time to 
MRCA if the input is not corrected for infection by multiple founder virions that are 
genetically divergent (data not shown). Ideally, it would have been useful to have had more 
accurate information on time of infection for all patients, and to have caught them in the very 
early stages, such as for patient 8, sampled in Fiebig stage II. However, the average time to 
MRCA predicted by the Poisson-Fitter tool using only reads from the primary subpopulation 
was a median of 139 days (IQR: 125.5-156 days), and this matches well with the dates 
estimated by the guanidine based avidity assay initially employed to select for patients highly 
likely to have recently seroconverted (the avidity assay cut-off used in this study (≤0.75) 
identifies patients likely to have seroconverted within the previous 125 days (95 CI: 85- 164 
days)). Finally, although the number of patients involved in this study is high in comparison 
to many previous HIV deep-sequencing studies (Hedskog, Mild et al. 2010; Bunnik, Swenson 
et al. 2011; Gianella, Delport et al. 2011), it is still smaller than ideal in terms of applicability 
of the findings to the general infected population. Selecting patients with sufficiently high 
viral loads to enable confident sampling of low level quasi-species prevalence imposes a 
major restriction on patient samples available for analysis, and means that the study, together 
with those previously highlighted, provides more of an illustration of the possible avenues of 
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evolution explored by HIV within and between patients, and how these can be radically 
different between individuals, suggesting possible areas for more in depth focus in future 
work. 
 In conclusion, this study has emphasised the dynamic nature of early phase HIV 
infection in a large cross-sectional sample of newly diagnosed patients, 9 with multiple time 
points allowing for analysis of quasi-species evolution. The study took a subpopulation 
reconstruction approach in order to treat mutations in different parts of the sequenced 
amplicons as linked, not as isolated variants that would have overlooked the interdependence 
of different regions of the HIV genome. In terms of evidence for infections being founded by 
single virions, the results of the clustering approach is in broad agreement with previous work 
(Keele, Giorgi et al. 2008; Fischer, Ganusov et al. 2010), with 30.6% of the 36 patients 
having evidence of >1 subpopulation in pol. The percentage is higher in env, at 47.2%, but 
this region of the viral genome is under greater host immune system pressure, and hence may 
evolve at a faster rate over the initial infection. The study also illustrates the utility and 
limitations involved in using single regions of the HIV genome for molecular 
epidemiological inference: a phylogenetically plausible transmission cluster detected using 
standard pol Sanger consensus sequence taken for routine drug resistance surveillance was 
also detected with molecular epidemiology of deep-sequencing data, but it was only in the 
deep-sequencing data from pol and env, and over multiple time points, that a more detailed, 
complex picture of the inter- and intra-patient evolutionary dynamics was revealed. 
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Chapter Six 
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Kumasi, Ghana: a resource limited, generalised 
HIV-1 epidemic setting 
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6 Molecular epidemiology of new HIV-1 diagnoses in Kumasi, Ghana: a 
resource limited, generalised HIV-1 epidemic setting 
 
Abstract 
This chapter investigates a HIV-1 epidemic in the context of a resource-limited setting using 
a molecular epidemiological approach to investigate the extent to which the epidemic is 
structured into transmission clusters. The chapter also investigates the use of a nucleotide 
consensus sequence classifier of infection length developed in chapter three in assessing the 
extent to which individuals diagnosed with recent infection play a role within the cohort in 
question. 
Newly HIV diagnosed individuals attending the Komfo Anokye HIV clinic in Kumasi, 
Ghana, had their blood sampled and shipped to the UK. The pol and env regions of the virus 
were sequenced, and an antibody avidity assay performed on patient samples to assess stage 
of infection. Phylogenetic analysis did not reveal extensive clustering of transmissions (4 
transmission pairs out of 288 individuals with pol sequence available for analysis). Results 
from the avidity assay results and nucleotide ambiguity classifier did not correlate, but did 
co-segregate (high avidity/high nucleotide ambiguity, low avidity/low nucleotide ambiguity). 
There does not appear to be a major clustering of transmissions within this setting, suggesting 
risk groups associated with clustering in resource-rich settings are not a major factor in 
Kumasi. Results from the application of the avidity assay and nucleotide ambiguity classifier 
suggest that both approaches may need to be further optimised for non-UK settings, but may 
prove useful in the future. 
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6.1 Introduction 
In Ghana, a country with a population of 25.0 million (http://data.un.org), there were an 
estimated 240000 individuals living with HIV (type 1 and 2) in 2012, and the estimated HIV 
prevalence was 1.4% among those aged 15-49 years (UNAIDS 2013). Ghana is defined as a 
lower middle income country by the World Bank (http://data.worldbank.org/country/ghana), 
with a life expectancy at birth of 61 years (2011) and gross national income per capita of 
$1,550 (current US$, 2012) (c.f. United Kingdom: 81 years and $38,670 respectively). 
Antiretroviral therapy (ART) was first introduced in 2003 (Ohene and Forson 2009), and 
there are now 66366 (60.3%) HIV positive individuals receiving therapy, of an estimated 
110000 individuals eligible for treatment (UNAIDS 2013). According to national guidelines, 
ART is initiated when patients have a CD4
+
 cell count <350 cells/mm
3
 and/or symptoms 
corresponding to WHO clinical stages 3 and 4 (National HIV/AIDS/STI Control Programme 
2010). Monitoring of ART efficacy is carried out by assessing body weight, clinical events 
(e.g., opportunistic infections), CD4
+
 cell counts, haemoglobin and serum biochemistry for 
hepatic transaminases and creatinine levels. HIV-1 RNA load monitoring is not routine, but is 
recommended to take place 6 months after commencement of therapy and subsequently every 
12 months. Additionally, viral load monitoring may be requested in order to confirm 
treatment failure if the patient CD4
+
 cell count is found to be declining, or clinical disease is 
progressing. The lack of viral load monitoring means that individuals failing ART are not 
identified early enough to limit emergence of drug resistance (Hamers, Wallis et al. 2011). In 
addition, limited second and third-line regimen options often result in clinicians being forced 
to allow patients to persist on failing therapy or recycle previously used agents (Bennett, 
Myatt et al. 2008). These considerations point to the development of a reservoir of resistant 
strains in treated people, posing a risk of onward transmission of resistant variants; indeed, 
173 
 
there is evidence of an increase in transmitted drug resistance since the roll-out of ART in 
west Africa (Gupta, Jordan et al. 2012; Stadeli and Richman 2013). 
Hitherto, most molecular investigations of the HIV epidemic in Ghana have been 
based upon limited numbers of samples (Ishikawa, Janssens et al. 1996; Brandful, Ampofo et 
al. 1998; Sagoe, Dwidar et al. 2007), or have used samples obtained primarily prior to the roll 
out of ART (Fischetti, Opare‐Sem et al. 2004). These studies have demonstrated a 
preponderance of CRF02_AG strains in the national epidemic. More recently, a larger 
molecular epidemiological study of 207 Ghanaian HIV-1-seropositive persons accessing the 
national ART program between 2002 and 2004 (Delgado, Ampofo et al. 2008) detected 
unique pol recombinant forms in 25% of the subjects, mostly derived from CRF02_AG. This 
suggests that multiple HIV-1 infections – occurring as either dual- or super-infections – were 
common. While two ART-naïve patients were found to harbour transmitted drug resistance 
(TDR) mutations in reverse transcriptase, the study was performed early after the start of the 
national ART programme in Ghana, and before TDR would have been expected to start to 
emerge (Frentz, Boucher et al. 2012; Stadeli and Richman 2013). 
This study has focussed on one catchment area, namely patients newly diagnosed with 
HIV in 2008-2012 who attended a large teaching hospital in Kumasi, the second largest city 
of Ghana. The clinic catchment area is peri-urban, and over 5000 patients are in follow-up 
(every 3-4 months), with ~2500 having started ART. A 2007 study established that the 
majority of patients on ART in this cohort were female (79.7%), and that over a third of 
patients (34.8%) self-identified as unemployed (Ohene and Forson 2009). Our aim was to 
characterise the molecular epidemiology of HIV-1 infection in this regional cohort, and test 
the performance of the tools developed within a UK cohort for investigating time of infection 
and transmission patterns. Linked to this, one important aim of the study was to determine the 
prevalence of transmitted drug resistance within the now mature ART programme.  
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6.2 Methods 
6.2.1 Study population 
Serum and plasma samples were collected from randomly selected newly diagnosed patients 
attending the HIV clinic at Komfo Anokye Teaching Hospital in Kumasi, Ghana, between 
2008 and 2012, stored locally at -80
o
C, and shipped on dry ice to the UK for testing. 
Associated clinical and laboratory data were collected from the case records and anonymised. 
The study was approved by the Committee on Human Research Publications and Ethics at 
Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana. 
6.2.2 Guanidine-based avidity assay 
Patient plasma or serum were defrosted and vortexed, prior to undergoing guanidine-based 
avidity testing on the Vitros ECiQ Immunodiagnostic System as previously described 
(section 2.3). An avidity index of ≤0.75 was regarded to be indicative of seroconversion 
within the previous 125 days (95 CI: 85 to 164 days) (Chawla, Murphy et al. 2007). Result 
interpretation also took into account the CD4
+
 cell count at the time of presentation to reduce 
the risk of falsely assigning the infection to the recent category in patients with advanced 
immune compromise (Chargelegue, Stanley et al. 1995). Previous work associated with the 
UK cohort used to develop the nucleotide ambiguity cut-off (chapter 3) found that median 
CD4
+
 cell counts for 103 individuals carefully defined as recent infections (within 125 days 
of seroconversion) was 565 cells/mm
3
 (IQR: 415-760 cells/mm
3
). For 101 patients from the 
same cohort with avidity indices ≤0.80 but with good evidence of an established infection, 
the median CD4
+
 cell count was 121 cells/mm
3
 (IQR: 25-357 cells/mm
3
). Finally, the median 
CD4
+
 cell count for 32 patients diagnosed with strong evidence of advanced disease/AIDS 
(e.g. PCP) was 42.5 cells/mm
3
 (17-89 cells/mm
3
). With these CD4
+
 cell count medians and 
inter-quartile ranges in mind, cut-offs of 150 and 100 cells/mm
3
 were selected as filters for 
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individuals with avidity indices ≤0.75, to gauge the effect of removing such individuals from 
the Kumasi new diagnosis cohort had on the overall proportion of patients classified as 
recently infected using both the avidity indices or nucleotide ambiguity cut-off.  
6.2.3 Sequencing 
Pol consensus sequencing was carried out as per a previously described in-house assay 
(section 2.5). A protocol was also developed to enable sequencing of a large region of the 
HIV-1 genome, including Rev, Vpu, gp120 and over half of gp41, in order to improve the 
molecular epidemiological analysis, as previously described (sections 2.6 and 2.7). The 
protocol followed a nested PCR strategy, with both sets of primers designed within genomic 
regions conserved across multiple subtypes of HIV-1 (A1, B, C, D, F, G, J, CRF01_AE, 
CRF02_AG and CRF06_cpx) in order to maximise the chances of successful amplification of 
novel subtypes and recombinant structures. Subtyping was carried out using the COntext-
based Modelling for Expeditious Typing (COMET) web tool (http://comet.retrovirology.lu/). 
6.2.4 Transmitted drug resistance 
Pol consensus sequence electropherograms were manually inspected for quality prior to 
being submitted to the Calibrated Population Resistance tool (Gifford, Liu et al. 2009) for 
analysis using the World Health Organization 2009 Mutation List (Bennett, Camacho et al. 
2009). 
6.2.5 Transmission cluster identification 
In order to identify any putative transmission clusters, pol sequence electropherograms were 
inspected for quality, aligned and stripped of drug resistance associated codons (Bennett, 
Camacho et al. 2009). Phylogenetic analysis was carried out using PhyML3.0 (GTR model of 
nucleotide evolution), with 1000 bootstrap trees generated using the FastTree2.1 program. 
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Potential transmission clusters were identified using criteria of ≥95% bootstrap support and 
maximum intra-cluster Hamming distance of ≤0.045.  
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6.3 Results 
6.3.1 Study population and guanidine-based avidity assay results 
A total of 456 subjects entered the study between 2008 and 2012 with median age 37yrs 
(IQR: 30-44yrs); 333 (73.0%) were female. Avidity testing was performed on samples taken 
within median 4 days (IQR: 1-68 days) of first HIV positive test. Overall 155/456 (34.0%) 
patients had an avidity index ≤0.75, and 301 (66.0%) had an index >0.75. CD4+ cell counts of 
<150 and <100 cells/mm
3 
at diagnosis were investigated as proxies for advanced disease 
stage, which increases the risk of falsely categorising an infection as recent. Among the 155 
patients with avidity index ≤0.75, 13 had CD4+ cell counts <150 and 4 <100 cells/mm3 (with 
8 individuals without baseline CD4
+
 cell count results). Based on these criteria 143/452 
(31.6%) and 134/443 (30.2%) patients showed evidence of a recent infection at diagnosis. 
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Table 6.1. Demographic and clinical breakdown of the 260 patients for whom both 
clinical and sequence data were available. 
 
6.3.2 HIV-1 subtypes 
Overall, 288/456 (63.2%) plasma samples yielded a pol sequence. A total of 260 new 
diagnosis patients recruited from the HIV clinic had clinical and sequence data available. 
They were predominantly female (69.6%), with a median age of 37 (IQR: 30,45) and median 
CD4
+
 cell count of 369 cells/ml (IQR: 225,530) (Table 6.1.). Based on pol sequences, 
CRF02_AG was the most common genetic type (225/288, 78.1%); the second most prevalent 
genetic type was CRF06_cpx (14, 4.9%). A total of 31 (10.8%) sequences could not be 
assigned to a recognised genetic type by the COMET algorithm, possibly representing unique 
Median age in years (IQR)   37 (30, 45)
Median CD4 cell count, cells/ml (IQR)   369 (225, 530)
Female (%)  181 (69.6)
Male (%)  79 (30.4)
Subtype (%)  
A1 6 (2.3)
B 1 (0.4)
C 1 (0.4)
D 1 (0.4)
G 7 (2.7)
CRF02_AG 204 (78.5)
CRF06_cpx 14 (5.4)
Other 26 (10.0)
Resistance (%)  
Any major mutation  7 (2.7)
Major NRTI mutations  3 (1.2)
Major NNRTI mutations  4 (1.5)
PIs (major mutations)  1 (0.4)
≥ 2 classes 1 (0.4)
KATH HIV clinic new diagnosis cohort (n=260)
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recombinant forms (URFs) (Table 6.2.). Of these, 12/31 pol sequences contained a 
combination of CRF02_AG and CRF06_cpx: the env regions were pure CRF02_AG in 2/12, 
pure CRF06_cpx in 4/12, and a mosaic of CRF02_AG and CRF06_cpx in 3/12 (Table 6.3.). 
To briefly investigate the extent to which subtyping results were affected by methodology 
and subtype reference sequences, all 288 pol sequences were run through the REGA 
subtyping algorithm for comparison with COMET and 34/288 (11.8%) sequences were found 
to have discordant results (23 were assigned CRF02_AG in COMET, but could not be 
assigned by REGA). 
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Table 6.2. A total of 31 pol sequences were unable to be unambiguously assigned to a 
subtype or CRF by the COMET subtyping tool. The COMET suggested structure is 
indicated after the semi-colon. The right hand column lists the number of sequences 
belonging to each structure. 
 
 
Table 6.3. Table showing the pol and env region subtype/CRF assignment by COMET 
for the 12 viruses that appeared to be potential CRF02_AG/CRF06_cpx recombinants; 
02_AG = CRF02_AG, 06_cpx = CRF06_cpx, 09_cpx = CRF09_cpx. 
Pol subtype Frequency
unassigned_1;02_AG, A1 2
unassigned_1;02_AG, D 1
unassigned_1;09_cpx, A1 1
unassigned_1;43_02G, G 1
unassigned_2;02_AG, 06_cpx 4
unassigned_2;02_AG, 09_cpx 2
unassigned_2;02_AG, A1 7
unassigned_2;02_AG, G 1
unassigned_2;06_cpx, 02_AG 8
unassigned_2;09_cpx, 45_cpx, 02_AG 1
unassigned_2;25_cpx, 02_AG, A1 1
unassigned_2;A1, 01_AE, 02_AG 1
unassigned_2;D, 02_AG 1
Pol subtype Pol sequence length (bp) Env subtype Env sequence length (bp)
Seq 1 unassigned;06_cpx, 02_AG 1248 02_AG 2380
Seq 2 unassigned;06_cpx, 02_AG 1248 02_AG 2387
Seq 3 unassigned;06_cpx, 02_AG 1248 06_cpx 1386
Seq 4 unassigned;06_cpx, 02_AG 1246 06_cpx 2227
Seq 5 unassigned;02_AG, 06_cpx 1248 06_cpx 2210
Seq 6 unassigned;06_cpx, 02_AG 1248 06_cpx 2280
Seq 7 unassigned;02_AG, 06_cpx 1248 unassigned;02_AG, 06_cpx 2368
Seq 8 unassigned;06_cpx, 02_AG 1248 unassigned;02_AG, 06_cpx, 09_cpx 1575
Seq 9 unassigned;06_cpx, 02_AG 1248 unassigned;06_cpx, 02_AG 2027
Seq 10 unassigned;02_AG, 06_cpx 1248 unassigned;06_cpx, 02_AG 2297
Seq 11 unassigned;02_AG, 06_cpx 1248 unassigned;06_cpx, 02_AG, G 1381
Seq 12 unassigned;06_cpx, 02_AG 1248 unassigned;06_cpx, 02_AG, G 2370
Potential CRF02_AG/CRF06_cpx recombinants
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6.3.3 Transmitted drug resistance 
288 sequences were submitted to the Calibrated Population Resistance tool (Gifford, Liu et 
al. 2009), to detect the presence of any drug resistance mutations listed on the World Health 
Organization 2009 Mutation List. Mutations detected were verified by checking the original 
electropherogram traces. Among 271 RT sequences suitable for analysis, 4 (1.5%) and 5 
(1.8%) showed NRTI and NNRTI drug resistance associated mutations, respectively. There 
were two subjects (0.7%) with resistance to both drug classes. 271 sequences were suitable 
for analysis of protease, with 1 (0.4%) sequence having a drug resistance associated mutation. 
In total, 8/271 (3.0%) of patients in the cohort had a drug resistance mutation in their HIV-1 
RT and protease sequence. Overall the results were consistent with drug availability in 
Ghana, comprising primarily NRTIs and NNRTIs (Table 6.4). 
 
 
Table 6.4. Drug resistant mutations by year of patient diagnosis. 
  
Year diagnosed NRTI NNRTI PI
Patient A 2008 D67N
Patient B 2008 D67N
Patient C 2009 V106A, G190A
Patient D 2010 K103N
Patient E 2011 I85V
Patient F 2011 K101E
Patient G 2011 M184V K103N
Patient H 2011 M184V K103N, Y181C
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6.3.4 Transmission clusters 
288 patients had their HIV-1 pol consensus sequences subjected to phylogenetic analysis 
using PhyML3.0. Four pairs of sequences were identified as potential transmission clusters 
on the basis of having ≥95% bootstrap support and maximum intra-cluster pairwise genetic of 
≤0.045 (Fig 6.1. and Table 6.5.). Consensus sequencing of the envelope region was carried 
out for all 8 patients to see if there was additional support for relatedness of the sequences. 
Percentage identity between env sequences within each pair was 93.1% or more (Table 6.4.), 
compared to a mean pairwise genetic identity of 88.0% when the pairwise distances between 
non-related pairs were used as a control. In all pairs there was good agreement between pol 
and env subtypes between the individuals in the pair and between regions within each 
individual. 
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Figure 6.1. Phylogenetic tree showing four putative transmission clusters in red, as 
defined by ≥95% bootstrap and ≤0.045 intra-cluster pairwise genetic distance. Scale bar 
is 0.06 nucleotide substitutions per site.  
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Table 6.5. Table showing clinical characteristics of the eight individuals involved in four 
putative transmission clusters.  
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6.3.4.1 Nucleotide ambiguity cut-off 
The proportion of ambiguous nucleotides was calculated as previously described (section 
2.12.2) for all 288 patients with pol sequence available to see if it could be a useful marker of 
infection length when correlated with avidity indices. After removing DRAM associated 
codons (Bennett, Camacho et al. 2009), 17/274 (6.2%) patients had 0.00% nucleotide 
ambiguities in their DRAM codon stripped pol sequence (14 patients removed due to 
sequence length <800bp, minimum length required for 0.00% cut-off), 37/288 (12.8%) 
patients had ≤0.17% nucleotide ambiguities in their pol sequence (as per the cut-off 
developed on a UK cohort of new diagnosis patients – see chapter 3). As advanced HIV 
disease is associated with a reduction in intra-patient quasi-species diversity (Shankarappa, 
Margolick et al. 1999), the nucleotide ambiguity analysis was repeated removing patients 
potentially diagnosed with late stage disease, using CD4
+
 cell count as a proxy marker. In a 
similar procedure to the avidity indices analysis above, patients were ordered by avidity 
indices, and individuals with avidity indices ≤0.75 were filtered on the basis of CD4+ cell 
counts <150 and <100 cells/mm
3
. 17/267 (6.4%) and 17/272 (6.3%) had 0.00% ambiguous 
nucleotides using the <150 and <100 cells/mm
3
 filters respectively (with sequences <800bp 
in length removed). 37/281 (13.2%) and 37/286 (12.9%) individuals had a percentage of 
ambiguous nucleotides <0.17% using the <150 and <100 cells/mm
3
 filters respectively. 
Extending the CD4
+
 cell count filter upwards to <250 and <350 cells/mm
3
 did not change the 
results for either cut-off in a significant way (Table 6.6). 
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Table 6.6. Table showing the effect of CD4
+
 cell count filter on proportion of Kumasi 
cohort defined as recently infected using the nucleotide ambiguity cut-off (both the 
0.00% cut-off and the 0.17% cut-off). 
 
The ambiguous nucleotide percentages of the individuals with avidity indices ≤0.75 
was compared to those of the population of individuals with avidity indices >0.75 using the 
Mann-Whitney test. The median percentage of ambiguous nucleotides for individuals with 
avidity indices ≤0.75 vs. >0.75 avidity was 0.54 vs. 0.80 (z = 3.71258, p-value <0.001) 
(14/288 patients with pol sequence did not have avidity results available). When patients with 
<150 CD4
+
 cells/mm
3
 were removed from the group of individuals with avidity indices 
≤0.75, the median percentage of ambiguous nucleotides for individuals with avidity indices 
≤0.75 vs. >0.75 was 0.46 vs. 0.80 (z = 3.98748, p-value <0.001, two-tailed test). When 
removing patients with <100 CD4
+
 cells/mm
3
 the respective values were 0.46 vs. 0.80 (z = 
3.9925, p-value <0.001, two-tailed test). When nucleotide ambiguity was used to order 
patients, a nucleotide ambiguity cut-off of 0.63% was found to maximise the difference 
between the median avidity index of patients below this cut-off when compared to patients 
above this cut-off (0.77 vs. 0.91, z = 5.46769, p-value < 0.001, two-tailed test). 
Correlation of avidity indices with nucleotide ambiguity score was poor regardless of 
removal of individuals with low CD4
+
 cell count (<350 cells/mm
3
: R
2
 = 0.055; <250 
CD4 cut-off 0.00% 0.17%
100 17/272 (6.3) 37/286 (12.9)
150 17/267 (6.4) 37/281 (13.2)
200 17/263 (6.5) 37/277 (13.4)
250 17/260 (6.5) 33/260 (12.7)
300 17/254 (6.7) 33/254 (13.0)
350 17/247 (6.9) 30/247 (12.1)
Nucleotide ambiguity cut-off
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cells/mm
3
: R
2
 = 0.052; <150 cells/mm
3
: R
2
 = 0.037; All: R
2
 = 0.035). When avidity index 
≤0.75 was used as the definition of recent infection, application of the nucleotide ambiguity 
cut-off produced positive predictive values (PPVs) across the four CD4
+
 cell count filtering 
categories of <350 cells/mm
3
: 0.38; <250 cells/mm
3
: 0.46, <150 cells/mm
3
: 0.48 and All: 
0.48 (Table 6.7.). 
 
Table 6.7. Sensitivity and specificity of the nucleotide ambiguity cut-off, using the 
guanidine-based avidity assay as the reference marker for recent infection. Each of the 
four panels reflects use of a different CD4
+
 cell count cut-off to remove individuals from 
the recent infection group (as classified by an avidity index ≤0.75) in order to assess the 
possible impact of individuals diagnosed with advanced HIV. Positive predictive value 
≤ 0.75 > 0.75 ≤ 0.75 > 0.75
≤ 0.17 12 13 25 ≤ 0.17 12 13 25
> 0.17 37 108 145 > 0.17 32 108 140
49 121 170 44 121 165
Sensitivity 0.24 Sensitivity 0.27
Specificity 0.89 Specificity 0.89
PPV 0.48 PPV 0.48
NPV 0.74 NPV 0.77
≤ 0.75 > 0.75 ≤ 0.75 > 0.75
≤ 0.17 11 13 24 ≤ 0.17 8 13 21
> 0.17 26 108 134 > 0.17 19 108 127
37 121 158 27 121 148
Sensitivity 0.30 Sensitivity 0.30
Specificity 0.89 Specificity 0.89
PPV 0.46 PPV 0.38
NPV 0.81 NPV 0.85
All < 150 cells/mm3 removed
< 250 cells/mm3 removed < 350 cells/mm3 removed
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(PPV) and negative predictive values (NPV) are also shown, and were calculated as 
described in (Altman and Bland 1994). 
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6.4 Discussion 
This study investigated a cohort of patients newly diagnosed with HIV-1 in Kumasi, Ghana, a 
resource limited, generalised HIV epidemic setting. It set out to investigate four main aspects 
of the HIV-1 epidemic: i) a simple assessment of subtype distribution in this region of Ghana; 
ii) the role of transmission clusters in the formation of the epidemic within the environs of 
Kumasi, Ghana’s second largest city; iii) assessment of the level of drug resistance 
circulating within the patient population; and iv) the performance of a guanidine-based 
avidity assay and a pol consensus sequence nucleotide ambiguity cut-off in identifying 
patients in early stages of infection. 
 The results of the first part of the study fits well with previous more limited studies of 
populations elsewhere in Ghana: CRF02_AG was found to be the most prevalent form of the 
virus in the population, at 78.1% of sequences, followed by CRF06_cpx, at 4.9% (Fischetti, 
Opare‐Sem et al. 2004; Sagoe, Dwidar et al. 2009). Both of these forms are known to be 
prevalent in this region, together with subtypes A and G. In comparison to other studies from 
Accra and the eastern region of Ghana (Delgado, Ampofo et al. 2008), the proportion of 
potential URFs of complex structure detected in this study is slightly lower. This may 
indicate that in and around Kumasi there are fewer individuals dually infected with HIV-1 of 
different forms, perhaps through lower levels of partner exchange or limited import of non-
standard genetic forms of the virus compared to what might be occurring in the capital city or 
along particular trade routes. However, without larger sample numbers, more widespread 
population sampling, and full-genome sequencing, it may be futile to speculate in too much 
depth, and it should be noted that methodology and reference sequence sets (and how these 
reference sequences were themselves subtyped) can also have an impact on subtype analysis 
where complex genome structures are involved. As an example, the COMET subtyping tool 
uses a Prediction by Partial Match (ppm) algorithm with a reference set of 201 HIV-1 
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genomes, including CRFs 1-49, whereas the REGA HIV subtyping tool v2.0 (De Oliveira, 
Deforche et al. 2005) uses bootscanning, and has 48 reference sequences covering CRFs 1-
14; consequently when the results for the 288 pol sequences for COMET were compared to 
REGA there were discordant results. The region of the genome submitted for analysis can 
also have a major impact on subtyping, as regions of a CRF that are exclusively of one 
subtype may disguise the true complexity of the genome (Sagoe, Dwidar et al. 2009), for 
example, in CRF02_AG the C2V3 region of env is exclusively subtype A, and so reliance 
solely on this region alone for subtyping is likely to lead to misclassification (Brandful, 
Ampofo et al. 1998). From the 31 potential URFs identified in this study, the fact that 12 of 
them have evidence of recombination between CRF02_AG and CRF06_cpx is not 
unexpected given that these are the major forms circulating in the region. However, if any 
particular URFs are found to be circulating in significant numbers, it may be interesting to 
perform whole-genome sequencing to map breakpoints and identify which segments of the 
genome have been retained from which parental strains, as this could point to important 
genetic factors involved in the evolution of HIV-1 in this population, i.e. factors that have an 
influence on transmission, or pathogenesis. It is important to note that in this cohort HIV is 
diagnosed using a rapid test that detects both HIV-1 and HIV-2 antibodies, but routine 
follow-up tests to differentiate between the two viruses are not performed. This means that 
samples that did not produce sequence may have been HIV-1 viruses of novel structure, with 
sequence that did not allow the reverse transcription primer to bind efficiently during the RT-
PCR, or could have been HIV-2, which would not be amplified by the primers used in this 
study. The prevalence of HIV-2 in this cohort will need to be determined in order to more 
fully address this issue. 
 The second aspect of the study investigated the extent to which HIV-1 infections in 
the cohort cluster into groups of highly related viruses, which may indicate the existence of 
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transmission chains within the wider local epidemic. In any setting, caution must be taken 
when trying to identify transmission patterns within an epidemic, as sampling depth (i.e. the 
proportion of infected individuals captured within the study) and time taken for 
epidemiologically linked individuals to infect one another, and subsequently be diagnosed, 
can have major impacts upon results. In this study, only transmission pairs were identified, 
and although it is impossible to rule the involvement of additional individuals not captured by 
the clinic (indeed, such individuals must exist for one partner to have become infected in the 
first place), the epidemiological data for 3 of the pairs is strongly suggestive of transmissions 
within heterosexual partnerships. The patients involved in the remaining pair are both 
females and were diagnosed several years apart, with one possible scenario that could 
account for this being that a third individual, a male, could have either infected both females, 
or been infected by one female and then went on to transmit to the second female. For two of 
the four transmission pairs the date of diagnosis and date of sample were within 30 days, but 
both avidity indices and nucleotide ambiguity scores suggested both partners in each pair 
were unlikely to have had recent infection at diagnosis. The remaining two pairs had 
diagnosis dates and sample dates too far apart to allow for a valid application of either 
biomarker. Returning to the overall transmission cluster analysis, there do not appear to be 
large clusters of transmission in this cohort, which in other settings can be associated with 
high risk sexual or injecting drug use behaviour (Mathers, Degenhardt et al. 2008; Brenner, 
Roger et al. 2011). 
 The third aim of the study was to assess the prevalence of drug resistance within the 
ART-naive HIV-1 infected population. There is evidence of increasing prevalence of 
transmitted drug resistance in African countries where ART roll-out was commenced early 
last decade (Frentz, Boucher et al. 2012; Gupta, Jordan et al. 2012; Stadeli and Richman 
2013). Antiretroviral therapy has been available in Ghana since 2003, but other recent studies 
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specifically in Ghanaian populations have not found high levels of drug resistance in 
treatment naive individuals (Delgado, Ampofo et al. 2008; Nii-Trebi, Ibe et al. 2013). The 
finding that 3.0% of individuals harbouring a drug resistance associated mutation in this 
cohort is in line with other countries in the region, and lower than is found in other settings 
(U.K. Collaborative Group on HIV Drug Resistance 2012; Bonney, Addo et al. 2013). 
Although ongoing population level monitoring is likely to be warranted given continuing use 
of ART and lack of routine virological monitoring, and the limited options available for first-
line therapy in Ghana (National HIV/AIDS/STI Control Programme 2010), the level of drug 
resistance found in this treatment naive population, together with the lack of evidence of 
substantial clustering of infections, suggests transmitted drug resistance is not currently a 
major issue in this context. Instead, it may be more pertinent to focus on the treatment 
adherence of those who have already commenced therapy, as an earlier study of the Kumasi 
HIV infected population on treatment found that whilst most patients sampled (95.6%) were 
on triple therapy, as per national guidelines, self-reported adherence levels were 80.6%, and 
just over half of participants found the cost of the therapy unaffordable (Ohene and Forson 
2009). Likely to be linked to these issues, evidence from a more recent study suggests that 
drug resistance in patients experiencing virological failure in this population is high (Nii-
Trebi, Ibe et al. 2013). 
 The final aspect of this study aimed to investigate how two biomarkers of recent HIV-
1 infection performed within a population who may have very different virus and host 
characteristics to the population the biomarkers were developed on. The biomarkers in 
question were a guanidine-based avidity assay, that measures the strength of HIV antigen-
antibody affinity, and which was developed on a mixed subtype panel of infections in the 
United Kingdom (Chawla, Murphy et al. 2007), and a measure based upon the proportion of 
ambiguous nucleotides in pol consensus sequence, developed on a primarily Caucasian 
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population infected with HIV-1 subtype B (chapter 3). The proportion of patients diagnosed 
with recent infection based upon the avidity assay results (34.0%) was greater than the 
proportion predicted by both the 0.00% and 0.17% nucleotide ambiguity cut-off (6.2% and 
12.8% respectively). Although the linear correlation between the two markers was poor, the 
statistically significant difference in median nucleotide ambiguity between patients above and 
below the 0.75 avidity index cut-off definition of recent infection is encouraging. Further, the 
fact that adjustment of the nucleotide ambiguity cut-off enabled two patient groups with a 
strong statistical difference in their avidity indices to be defined, indicates that the two 
markers do co-segregate well, and that both are able to detect some underlying substructure 
to the Kumasi cohort. The overall estimate of the proportion of recent infections in the cohort 
produced by the avidity assay compares with similar enzyme-immuno assays used in other 
African settings, however, these studies argue that such assays may overestimate the 
proportion of recent infections in a population (Karita, Price et al. 2007; Sakarovitch, Rouet 
et al. 2007; Braunstein, van de Wijgert et al. 2009; Kim, McDougal et al. 2010; Kim, Hallett 
et al. 2011). In comparison to the proportion suggested by the nucleotide ambiguity cut-off, 
this is the case (12.8% using the 0.17% cut-off), but further validation of both assays against 
a panel of known Ghanaian seroconverters is required to determine which assay is the more 
accurate and robust, and to determine sensitivity, specificity and positive predictive values. It 
may be that additional biomarkers of early infection, such as a combination of HIV antibody 
and p24 antigen tests (Fiscus, Pilcher et al. 2007), could be useful in combination with an 
enzyme-immuno assay, or that other sequencing-based infection length estimation 
methodologies, enabled by collection of dried blood or plasma spots, will soon prove 
tractable for cross-sectional surveillance purposes (Giorgi, Funkhouser et al. 2010; Ji, Li et al. 
2011; Poon, McGovern et al. 2011; Dudley, Chin et al. 2012). 
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 In conclusion, this study represents one of the largest analyses of the Human 
Immunodeficiency Virus in Ghana to date. Results of pol consensus sequence analysis 
confirms the broad distribution of HIV-1 genetic forms that have been found elsewhere in the 
country, over several years, and suggests an evolutionary status quo in terms of the 
predominant forms circulating, with a continuing turnover of novel recombination events 
occurring in a small proportion of individuals. Molecular epidemiological analysis of this 
cohort suggests that within this large peri-urban setting, there is not a major issue with high 
risk behaviour generating large chains of transmission, assuming reasonable sampling of the 
HIV infected population has been achieved by the clinic. The study also suggests that while 
transmitted drug resistance in treatment naive individuals does exist, it is at low levels, and 
resistance developed in individuals with virological breakthrough may therefore be more of 
an issue for clinicians, though this patient group was not a focus of this study. In terms of 
application of laboratory-based diagnostic assays designed to assess length of HIV-1 
infection, results obtained in this study do compare with other studies investigating similar 
assays, but further work is likely required to ensure cut-offs are suitable for different 
populations in different settings. 
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Chapter Seven 
 
General discussion 
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7 Discussion and future directions 
The overall aims of this thesis were to investigate the molecular epidemiology and evolution 
of HIV-1 among newly infected patients in high and low prevalence settings. In the context 
of this thesis, those settings were the United Kingdom and Ghana. The investigation aimed to 
develop a measure of the length of HIV-1 infection based upon the number of ambiguous 
nucleotides in Sanger pol consensus sequences, and to then apply this measure to viral 
sequences obtained from cohorts of newly diagnosed patients. The work assessed the extent 
to which individuals with recent infections contribute to transmission clusters, and the levels 
of transmitted drug resistant viruses within the treatment naive population in both settings. In 
terms of the Ghana molecular epidemiological exploration, in light of the relative paucity of 
recent data available for large cohorts, this investigation also provided the chance to obtain a 
broader picture of the overall HIV-1 epidemic taking place in and around the country’s 
second largest city, Kumasi. Finally, the investigation involved a more in-depth analysis of 
the intra-host dynamics of recent HIV-1 infection, using deep-sequencing to look beyond the 
limitations imposed by Sanger sequencing. 
 An initial step in the investigation was to develop a measure of HIV-1 infection length 
that could be used with viral sequences that are collected routinely as part of antiretroviral 
drug resistance surveillance programs in the UK and elsewhere. Collections of such 
sequences exist in clinics or central repositories in a variety of countries, and offer a useful 
resource for investigations into the evolution and continuation of the epidemic (Yerly, Kaiser 
et al. 1999; Lewis, Hughes et al. 2008; Brenner, Roger et al. 2011). Determining the main 
drivers of an epidemic has a clear impact on containment policies. In the case of HIV, three 
sources of onward transmission can be proposed:  
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i) Subjects with recent infection that may or not have been diagnosed at the time 
when they experience peak virus replication and infectivity. A prominent role 
would trigger interventions to increase access to HIV testing and promote 
awareness of risk in the community. 
ii) Subjects with established but untreated infection. A prominent role would trigger 
recommendations about earlier initiation of antiretroviral therapy as a public 
health measure 
iii) Subjects with established and treated infections that experience suboptimal HIV 
suppression. A prominent role would trigger monitoring and management 
interventions to promote improved use of and adherence to treatment.  
There is support from a number of studies that individuals with recent infections 
disproportionately drive the HIV epidemic in a variety of different settings compared to 
untreated individuals in the established, symptomless phase of their infection (Yerly, Vora et 
al. 2001; Brenner, Roger et al. 2007; Abu-Raddad and Longini Jr 2008; Hollingsworth, 
Anderson et al. 2008). These studies are necessarily carried out on cohorts of restricted size, 
as it is usually laboratory and/or clinical approaches that are used to assess the stage of 
infection of an individual, and as such there is a limitation on how many individuals such 
information can be collected for. A classifier that can be applied to nucleotide sequences 
taken routinely from diagnosed individuals provides a potential way of getting around this 
issue. In this study, two classifier cut-offs were investigated, one that was optimised to 
maximise both sensitivity and specificity, and one that aimed to maximise specificity for 
recent infection at the expense of sensitivity. The validation and overall performance of both 
classifiers seemed strongly influenced by sample size, with results being relatively poor for 
the smaller St Mary’s Hospital cohort, compared to the larger UK Register of HIV 
Seroconverters cohort. This is possibly an effect of the margin of error associated with 
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smaller sample sizes (Lohr 2009), and the fact that the prevalence of recent infection in these 
cohorts was relatively low, and so the number of false positive classifications may be inflated 
(Altman and Bland 1994). Comparison of the positive predictive values obtained for the 
0.17% and 0.00% ambiguity cut-offs suggests that the more stringent 0.00% cut-off may be 
more useful in terms of identification of recent infections. The performance of both classifiers 
on the UKHIVDRD treatment naive cohort produced estimates of the proportion of recent 
infections in the population consistent with different studies in European settings (Semaille, 
Barin et al. 2007; Yerly, Junier et al. 2009; Fisher, Pao et al. 2010). The closest match in 
terms of geographical setting and definition of recent infection actually comes from results of 
the Recent Infection Testing Algorithm obtained from across England, Wales and Northern 
Ireland (Aghaizu, Brown et al. 2013). The results are from a chronologically more recent 
cross-section of the population, but suggest that overall 16% of new diagnoses were from the 
4-6 month window post-infection. This result matches closely to the UKHIVDRD result of 
14% when the 0.00% cut-off was used, and therefore lends support to the use of this cut-off, 
and adds validity to the findings of the subsequent phylogenetic analyses that utilise the cut-
off results. 
The results of these subsequent phylogenetic analyses suggest that recent infections 
are more likely to be linked to transmission clusters than established infections, a finding that 
is supported by, but extends the scale of similar studies (Yerly, Vora et al. 2001; Pao, Fisher 
et al. 2005; Brenner, Roger et al. 2007; Brenner, Roger et al. 2008; Fisher, Pao et al. 2010). 
What the results of this investigation reveal are that this disproportionate linkage is seen 
across multiple subtypes, which are likely to represent different, compartmentalised sub-
epidemics within the UK (Fox, Castro et al. 2010; Abecasis, Wensing et al. 2013). The 
linkage was also observed across different cluster sizes, from pairs to clusters containing 10 
individuals or more. In terms of this disproportionate linkage of recent infections to clusters, 
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treatment of the results requires caution on two fronts. Firstly, there is evidence to suggest 
that clustering of recent infections in phylogenies may be a reflection of the method of 
identification of these clusters, whereby genetically closely related sequences are more likely 
to be linked together than genetically distant sequences (Volz, Koopman et al. 2012). Further 
to this, the process of contact tracing is found to be more efficient in more clustered networks 
(Eames and Keeling 2003; Kiss, Green et al. 2005), which may combine with increased 
probability of recall of previous sexual partners in individuals recently infected and thereby 
lead to preferential attachment of subsequent recent infections to clusters. Conversely, this 
effect may be countered by increased inability to recall previous partners if that number is 
large (Brewer, Garrett et al. 1999; Brewer and Garrett 2001), and so it is clear that there is 
scope for further investigation of this potential source of ascertainment bias. Secondly, as 
outlined in Brown et al. (Brown, Gifford et al. 2009), linkage of recent infections to clusters 
is not necessarily evidence for transmission from the recent phase of infection, as the period 
is by definition transient – individuals may have their virus sampled during the recent phase 
of their infection, but may not transmit for another half a year, and depending on the criteria 
used to identify clusters, they may still be identified as belonging to a transmission cluster 
(providing linked individuals have also been sampled). The thesis attempted to develop two 
proof-of-principle methods to illustrate how results from the nucleotide ambiguity classifier 
could be harnessed in overcoming this issue. Both methods aimed to allow a comparison of 
the contribution of recent infections to onward transmission between different cluster sizes, 
rather than an absolute figure for the proportion of infections coming from the recent 
infection phase. The results of the models, based on overlapping approaches, suggest that 
larger clusters seem to have a greater degree of overlap between the recent phase windows of 
infection, i.e. there appears to be a greater degree of transmission from the recent phase of 
infection. Whilst other studies have already concluded this, this is the first phylogeny-based 
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model that explicitly attempts to tackle the potentially misleading conflation of recent 
infection linkage to transmission clusters, and recent phase transmission. Future work is 
needed to disentangle these results from the potential ascertainment biases outlined above, to 
reveal if recent infections are really leading to a disproportionate number of onward 
infections, or they are just more likely to be diagnosed and to be linked in clusters through 
contact tracing and phylogenetic effects, but the models are a good example of how the 
nucleotide ambiguity classifier can be used in such large-scale analyses. Beyond this, it may 
be useful to investigate the usefulness of incorporating the classifier into recent infection 
testing algorithms as an additional biomarker of recent infection. 
The molecular epidemiological characterisation of the Kumasi cohort represents one 
of the largest studies of its kind in Ghana to date. Previous studies have found a broadly 
similar range of subtypes to the results in this thesis, with CRF02_AG and CRF06_cpx 
predominating, but these studies found a slightly greater proportion of unique recombinant 
forms (Fischetti, Opare‐Sem et al. 2004; Delgado, Ampofo et al. 2008; Sagoe, Dwidar et al. 
2009). As discussed in chapter 4, these differences can be influenced by methodology and 
reference sequences used for subtyping. What is clear from the results in this thesis, and the 
published data, is that CRF02_AG is the predominant form of the virus in multiple regions of 
Ghana, in line with the rest of west Africa, and there is evidence to support the hypothesis 
that CRF02_AG has higher replicative fitness compared to its parental strains, which may 
have assisted its spread through the region (Fischetti, Opare-Sem et al. 2004; Konings, Burda 
et al. 2006; Njai, Gali et al. 2006). Whilst this predominance of CRF02_AG seems to be 
stable, there is clearly ongoing recombination between CRF02_AG and other forms of the 
virus, such as CRF06_cpx, to form new unique recombinant forms (URFs) of the virus. We 
did not detect any putative new CRFs in the Kumasi cohort, although there is clear potential 
for spread of the multiple URFs detected by us and others. These results point to an overall 
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relatively stable picture of subtype and CRF distribution in the region, broadly in line with 
global trends leading up to the period during which these viral samples were obtained 
(Hemelaar, Gouws et al. 2011). 
The investigation of the Kumasi cohort also aimed to characterise the number of 
individuals that are diagnosed with recent infection in the region, using two approaches 
developed and used in the UK setting, the avidity assay and the nucleotide ambiguity 
classifier. There did not seem to be a strong correlation between the avidity index and 
proportion of nucleotide ambiguity in the cohort, but it is difficult to identify the causes of the 
discrepancies without additional measures of timing of infection. However, it is interesting to 
note the statistically significant difference in nucleotide ambiguity between patients with an 
avidity index ≤0.75, and patients with an avidity index >0.75, suggesting there is some 
relationship between the markers, and that a different cut-off for classifying infections as 
recent by the avidity assay may be needed in this population, as put forward elsewhere 
(Sakarovitch, Rouet et al. 2007; Kim, McDougal et al. 2010). It is important to appreciate that 
the cut-off of 0.75 was developed within Western cohorts of acute seroconverters 
predominantly infected with subtype B. There is published evidence that the avidity 
maturation curve is similar in at least some non-B subtypes, but the evidence is not extensive 
(Chawla, Murphy et al. 2007). As the Kumasi new diagnosis cohort was recruited cross-
sectionally, as opposed to prospectively, it was not possible to identify a panel of 
seroconverters of known infection date against which to validate the two methods in this 
geographical setting. These studies need to be performed if either of these approaches is 
intended to be rolled out as a surveillance tool in this or similar settings.  
The results of the phylogenetic analysis and transmission cluster identification in the 
Kumasi cohort suggests that in this cohort there is not a large degree of high risk sexual 
behaviours or use of injecting drugs, which can be drivers in the formation of transmission 
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clusters in other contexts (Mathers, Degenhardt et al. 2008; Brenner, Roger et al. 2011). One 
potential caveat to this is that there may be a higher degree of smaller clusters that are not 
being picked up due to the depth of sampling of the underlying epidemic that has been 
achieved in this thesis, however, this is difficult to ascertain with any degree of accuracy 
whilst estimates for the proportion of undiagnosed infections are absent in Ghana. 
 The final part of this thesis used a deep-sequencing approach to dissect HIV-1 quasi-
species dynamics close to the point of infection to reveal some important issues in relation to 
the use of the nucleotide ambiguity classifier in estimating length of HIV-1 infection. There 
were a number of individuals who appeared to have more than one subpopulation at their 
earliest time point, which manifested in Sanger sequencing of the pol gene as a high number 
of ambiguous nucleotides – these subjects would have been classified as having an 
established infection using the nucleotide ambiguity classifier. If the proportion of such 
individuals remained the same on the larger, national scale, this could lead to an 
underestimation of the number of individuals with recent infection using the nucleotide 
ambiguity classifier. On the other hand, it is also clear that genetic diversity can increase 
without an increase in subpopulation number, which presents an opposite problem when 
considering application of the nucleotide ambiguity classifier. These within subpopulation 
increases in diversity may not be large enough to register on a Sanger sequence 
electropherogram, and so will not be picked up as ambiguous nucleotides, potentially leading 
to individuals with established infection being falsely classed as having a recent infection. 
This problem is less likely to be an issue going forward, with application of deep-sequencing 
technologies (Giorgi, Funkhouser et al. 2010; Poon, McGovern et al. 2011). However, in 
order to utilise the vast amount of historical HIV-1 pol sequences available as part of national 
drug resistance surveillance programs, both the potential for false negative and false positive 
results based on nucleotide ambiguity need to be taken into account and further investigated, 
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in terms of potential ways to address these limitations, perhaps by looking for hyper-diversity 
at particular sites known to differ between subtypes, perhaps by incorporating other clinical 
markers where available. 
A further interesting aspect of HIV-1 molecular epidemiology revealed by analysis of 
the deep-sequencing data produced for this thesis is the identification and dissection of a 
transmission cluster within the patient cohort. Strong phylogenetic evidence connected 4 
individuals, and enabled examination of the possible complexity in transmission dynamics 
that can be missed with consensus Sanger sequencing, and sequencing of one region of the 
HIV-1 genome only. Three individuals were linked on the basis of Sanger sequencing of the 
virus pol region performed on their diagnosis sample. The deep-sequencing results made it 
clear that 21 weeks later, the primary and secondary subpopulations in one patient had 
switched, and that if pol Sanger sequencing had been carried out using this latter time point, 
one of the three patients would not have been identified as belonging to the transmission 
cluster. If HIV-1 superinfection is more common than previously thought (Redd, Mullis et al. 
2012; Redd, Quinn et al. 2013), and switches in primary and secondary/tertiary 
subpopulations occur on these timescales, the true structure of epidemics has hitherto been 
over-simplified. In the future, whole genome deep-sequencing, with an approach tailored to 
detect such infections, will be required for a more accurate understanding of the public health 
intervention approaches required to reduce transmissions. 
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Appendix 1: Table of primers for 454 deep-sequencing of HIV-1 pol and env 
Pol amplicon     
      
Primer A (LibA) MID Forward pol gene template specific option 1 
(NG_PinF2) 
CGTATCGCCTCCCTCGCGCCATCAG ACGAGTGCGT AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG ACGCTCGACA AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG AGACGCACTC AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG AGCACTGTAG AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG ATCAGACACG AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG ATATCGCGAG AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG CGTGTCTCTA AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG CTCGCGTGTC AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG TCTCTATGCG AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG TGATACGTCT AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG CATAGTAGTG AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG CGAGAGATAC AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG ATACGACGTA AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG TCACGTACTA AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG CGTCTAGTAC AGCATGACAAAAATCTTAGA 
CGTATCGCCTCCCTCGCGCCATCAG TCTACGTAGC AGCATGACAAAAATCTTAGA 
      
Primer B (LibA) MID Reverse pol gene template specific option 1 
(NG_PinR2) 
CTATGCGCCTTGCCAGCCCGCTCAG ACGAGTGCGT TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG ACGCTCGACA TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG AGACGCACTC TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG AGCACTGTAG TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG ATCAGACACG TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG ATATCGCGAG TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG CGTGTCTCTA TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG CTCGCGTGTC TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG TCTCTATGCG TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG TGATACGTCT TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG CATAGTAGTG TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG CGAGAGATAC TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG ATACGACGTA TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG TCACGTACTA TGCCARTTCTARYTCTGCTTC 
232 
 
CTATGCGCCTTGCCAGCCCGCTCAG CGTCTAGTAC TGCCARTTCTARYTCTGCTTC 
CTATGCGCCTTGCCAGCCCGCTCAG TCTACGTAGC TGCCARTTCTARYTCTGCTTC 
      
Primer A (LibA) MID Forward pol gene template specific option 2 
(JA323) 
CGTATCGCCTCCCTCGCGCCATCAG ACGAGTGCGT TGGAAAGGATCACCAGCRATA 
CGTATCGCCTCCCTCGCGCCATCAG ACGCTCGACA TGGAAAGGATCACCAGCRATA 
CGTATCGCCTCCCTCGCGCCATCAG AGACGCACTC TGGAAAGGATCACCAGCRATA 
CGTATCGCCTCCCTCGCGCCATCAG AGCACTGTAG TGGAAAGGATCACCAGCRATA 
      
Primer B (LibA) MID Reverse pol gene template specific option 2 
(JA332) 
CTATGCGCCTTGCCAGCCCGCTCAG ACGAGTGCGT GCTGTACTGTCCATTTRTCAGGATG 
CTATGCGCCTTGCCAGCCCGCTCAG ACGCTCGACA GCTGTACTGTCCATTTRTCAGGATG 
CTATGCGCCTTGCCAGCCCGCTCAG AGACGCACTC GCTGTACTGTCCATTTRTCAGGATG 
CTATGCGCCTTGCCAGCCCGCTCAG AGCACTGTAG GCTGTACTGTCCATTTRTCAGGATG 
   
Env amplicon     
      
Primer A (LibA) MID Forward env gene template specific option 
1 (6955FQ) 
CGTATCGCCTCCCTCGCGCCATCAG ACGAGTGCGT CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG ACGCTCGACA CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG AGACGCACTC CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG AGCACTGTAG CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG ATCAGACACG CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG ATATCGCGAG CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG CGTGTCTCTA CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG CTCGCGTGTC CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG TCTCTATGCG CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG TGATACGTCT CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG CATAGTAGTG CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG CGAGAGATAC CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG ATACGACGTA CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG TCACGTACTA CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG CGTCTAGTAC CAGTACAATGYACACATGG 
CGTATCGCCTCCCTCGCGCCATCAG TCTACGTAGC CAGTACAATGYACACATGG 
      
Primer B (LibA) MID Reverse env gene template specific option 1 
(NG_EinR2) 
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CTATGCGCCTTGCCAGCCCGCTCAG ACGAGTGCGT TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG ACGCTCGACA TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG AGACGCACTC TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG AGCACTGTAG TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG ATCAGACACG TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG ATATCGCGAG TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG CGTGTCTCTA TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG CTCGCGTGTC TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG TCTCTATGCG TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG TGATACGTCT TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG CATAGTAGTG TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG CGAGAGATAC TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG ATACGACGTA TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG TCACGTACTA TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG CGTCTAGTAC TAGAAAAATTCYCCTCYACAATTAAAR 
CTATGCGCCTTGCCAGCCCGCTCAG TCTACGTAGC TAGAAAAATTCYCCTCYACAATTAAAR 
      
Primer A (LibA) MID Forward env gene template specific option 
2 (Roz_sense) 
CGTATCGCCTCCCTCGCGCCATCAG ACGAGTGCGT TGGCAGTCTAGCAGAAGAAG 
CGTATCGCCTCCCTCGCGCCATCAG ACGCTCGACA TGGCAGTCTAGCAGAAGAAG 
CGTATCGCCTCCCTCGCGCCATCAG AGACGCACTC TGGCAGTCTAGCAGAAGAAG 
CGTATCGCCTCCCTCGCGCCATCAG AGCACTGTAG TGGCAGTCTAGCAGAAGAAG 
      
Primer B (LibA) MID Reverse env gene template specific option 2 
(Roz_anti) 
CTATGCGCCTTGCCAGCCCGCTCAG ACGAGTGCGT CTGGGTCCCCTCCTGAGG 
CTATGCGCCTTGCCAGCCCGCTCAG ACGCTCGACA CTGGGTCCCCTCCTGAGG 
CTATGCGCCTTGCCAGCCCGCTCAG AGACGCACTC CTGGGTCCCCTCCTGAGG 
CTATGCGCCTTGCCAGCCCGCTCAG AGCACTGTAG CTGGGTCCCCTCCTGAGG 
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Appendix 2: Perl scripts (available in electronic format on request) 
 
findclusterdistances.pl 
 
#!usr/bin/perl -w 
 
# Program for finding clusters with a support value greater than a specified amount and for finding the 
distances between all nodes in such clusters 
use Math::BigInt; 
use Math::BigFloat; 
use Bio::TreeIO; 
use Scalar::Util qw(looks_like_number); 
 
my $input_file; 
my $output_file; 
 
if (defined($ARGV[0])) { 
  chomp($tree_input_file = $ARGV[0]); 
} else { 
  print "Please enter a newick formatted tree file (with full path if not in this directory): "; 
  chomp($tree_input_file = <>); 
} 
 
if (defined($ARGV[1])) { 
  chomp($sequences_input_file = $ARGV[1]); 
} else { 
  print "Please enter a fasta formatted sequence file (with full path if not in this directory): "; 
  chomp($sequences_input_file = <>); 
} 
 
my $support_score = 0; 
my $lower_cluster_size_filter = 0; 
my $upper_cluster_size_filter = 2000; 
 
system ("rm -rf 
$sequences_input_file.$support_score.$lower_cluster_size_filter.$upper_cluster_size_filter.findclusteroutpu
t.txt"); 
system ("rm -rf $sequences_input_file.temp_R.txt"); 
system ("rm -rf $sequences_input_file.rscript.R"); 
system ("rm -rf $sequences_input_file.R_distances.txt"); 
system ("rm -rf $sequences_input_file.rscript.Rout"); 
 
print "\n\nLoading tree..."; 
 
my $input = Bio::TreeIO->new(-file => $tree_input_file, -format=>'newick'); 
 
################# CREATING LIST OF SEQUENCES INVOLVED IN CLUSTERS SECTION ################# 
 
my @nodearray; 
my $nodecount = 0; 
 
while($tree = $input->next_tree){ 
 print "\n\nProcessing nodes..."; 
 for my $node ($tree->get_nodes){ 
  if(!$node->is_Leaf){ 
   if(looks_like_number($node->id)){ 
    if($node->id >= ($support_score/100)){ 
     my @predistancearray; 
     @descendents = $node->get_all_Descendents; 
     my $descendentcount = 0; 
     foreach $descendent (@descendents){ 
      if($descendent->is_Leaf){ 
       # @predistancearray is an array to store all 
leaves in a particular cluster for future calculation of their distances from each other 
       $predistancearray[$descendentcount] = 
$descendent->id; 
       $descendentcount++; 
      } 
     } 
     # This if conditional is to filter out massive clusters 
     if (@predistancearray > $lower_cluster_size_filter && 
@predistancearray <= $upper_cluster_size_filter){ 
      # $nodearray is an array of references to arrays with 
all leaves from a particular cluster 
      $nodearray[$nodecount] = [@predistancearray]; 
      $nodecount++; 
     } 
    } 
   } 
  } 
 } 
} 
 
# Loop to remove duplicates from cluster list because some sequences will be in clusters within clusters 
my %unique_cluster_ids = (); 
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for $arrayref (@nodearray){ 
 for $id (@$arrayref){ 
  $unique_cluster_ids{$id} = 1; 
 } 
} 
 
################# SELECT SEQUENCES SECTION ################# 
 
open(SEQUENCES, $sequences_input_file); 
 
my @identifiers = keys %unique_cluster_ids; 
 
my %sequences; 
my $switch = "start"; 
my $identifier = ""; 
my $goodformat = "true"; 
my $index = 1; 
 
while(my $fileline = <SEQUENCES>){ 
 if($fileline =~ /^>(\S*)/ && $switch eq "start"){ 
  $identifier = $1; 
  $switch = "identifier";       
 }elsif($fileline =~ /^>(\S*)/ && $switch eq "sequence"){ 
  $identifier = $1; 
  $switch = "identifier";       
 }elsif($fileline !~ /^>\S*/ && $switch eq "identifier"){ 
  $sequences{$identifier} = $fileline; 
  $switch = "sequence"; 
 }else{ 
  $goodformat = "false"; 
  if($switch eq "start"){ 
   print "\nSequence file not in correct fasta format around line $index.\n"; 
  }else{ 
   print "\nSequence file not in correct fasta format around sequence 
$identifier.\n"; 
  } 
  die(); 
 } 
 $index++; 
} 
 
if($goodformat){ 
 print "\n\nInput sequence file in good fasta format...\n\n"; 
} 
 
for $i (0..$#nodearray){ 
 my $currentclustercount = $i+1; 
 print "processing cluster $currentclustercount of $nodecount\n"; 
 # get reference to the $ith array of leaf nodes, i.e. a particular cluster 
 $arrayref = $nodearray[$i]; 
 # get length of array, which is how many sequences are in the particular cluster - !!! REMEMBER 
that arrays start at 0, e.g. $n == 2 will pull out all clusters of size 3 NOT size 2 (0,1,2) !!! 
 $n = @$arrayref - 1; 
 open(OUTPUT, ">$sequences_input_file.temp_R.txt"); 
 # $j will be the element in the $ith array up to the length of $i array 
 for $j (0..$n){   
  #foreach my $array (@identifiers){ 
  if($sequences{$nodearray[$i][$j]}){ 
   print OUTPUT ">$nodearray[$i][$j]\n$sequences{$nodearray[$i][$j]}"; 
  }else{ 
   print "Sequence $nodearray[$i][$j] is not present in sequence file.\n"; 
  } 
 } 
 
 close OUTPUT; 
 
################# R DISTANCE CALCULATION SECTION ################# 
 
 open(RSCRIPT, ">$sequences_input_file.rscript.R"); 
 print RSCRIPT "library(ape)"."\n"; 
 print RSCRIPT "seqs<-read.dna('$sequences_input_file.temp_R.txt',format='fasta')"."\n"; 
 print RSCRIPT "dist<-dist.dna(seqs,model='raw',pairwise.deletion=T,as.matrix=T)"."\n"; 
 print RSCRIPT "write.table(dist,file='$sequences_input_file.R_distances.txt',quote=F)"."\n"; 
 close RSCRIPT; 
 
 system ("R CMD BATCH $sequences_input_file.rscript.R"); 
 
 
################# R DISTANCE MATRIX INPUT SECTION ################# 
 
 open(RSCRIPTINPUT, "$sequences_input_file.R_distances.txt"); 
 
 my @AoA = (); 
 
 # Loop to split each line of the distance matrix by " " and store in an array, then push this into 
an array of arrays 
 while(my $fileline = <RSCRIPTINPUT>){ 
  my @tmp = split(" ",$fileline); 
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  push(@AoA, [@tmp]); 
 } 
 
 my $count = 0; 
 my %hash_of_arrays = (); 
 my %hash_of_column_positions = (); 
 
 # This foreach loop stores the distances for one particular sequence to all other sequences in a 
hash array  
 # with the key the sequence name (which should always be the first position in the matrix output 
by R 
 # The hash_of_columns is to store the column that a particular sequence's distance will be from 
the sequence  
 # row being dealt with, i.e. the first sequence row is for x, and is a row of distances 
corresponding to the  
 # other sequences,y,z... the second row is for sequence y, and its first distance position will be 
for the  
 # distance to sequence x 
 foreach my $array(@AoA){ 
 
  #################################################################################### 
  # This line uses the first element in each array as the name of the sequence, only # 
  # to be employed when using write.table in R to write out a matrix. This will      # 
  # overwrite the first line of the matrix, which will just be a line of sequence    # 
  # identifiers - but $count will have already been incremented by one because of    # 
  # the first line of the R output                                                   # 
  #################################################################################### 
  $hash_of_arrays{@$array[0]} = [@$array]; 
  $hash_of_column_positions{@$array[0]} = $count; 
  $count++; 
 } 
 
 
 
################# AVERAGE PAIRWISE DISTANCE CALCULATION SECTION ################# 
 
 open(FINDCLUSTEROUTPUT, 
">>$sequences_input_file.$support_score.$lower_cluster_size_filter.$upper_cluster_size_filter.findclusterou
tput.txt"); 
 
 # The following variable is created for each cluster, and is a non-duplicate list of all nodes in 
the cluster - this is sorted below and used as a unique identifier for that cluster 
 my %unique_cluster_ids_hash = (); 
 my $sum_distances = 0; 
 # This variable is to account for some distances that are unmeasurable ("NA") in the matrix and 
cannot be summed (because they do not have overlapping sequence, i.e. one has gaps aligned to the other's 
sequence and vice versa) 
 my $unmeasurable_distances_count = 0; 
 for $j (0..$n){ 
  $m = $n - $j; 
  for $k (0..$m){ 
   $l = $k + $j; 
   my $node1 = $nodearray[$i][$j]; 
   my $node2 = $nodearray[$i][$l]; 
   my $distance = $hash_of_arrays{$node1}[$hash_of_column_positions{$node2}]; 
   print FINDCLUSTEROUTPUT "Distance between node $node1 and node $node2 is 
$distance\n"; 
   if(looks_like_number($distance)){ 
    $sum_distances += $distance; 
   }else{ 
    # Add a count to $unmeasurable_distances_count to reduce nCr by one 
because one pairwise distance was unmeasurable ("NA") - this happens when two sequences do not overlap at 
all in alignedsequences.fas 
    $unmeasurable_distances_count++; 
   } 
   $unique_cluster_ids_hash{$node1} = 1; 
   $unique_cluster_ids_hash{$node2} = 1; 
  } 
 } 
 # Use bcom subroutine to use factorials to calculate nCr 
 my $nCr = bcomb(($n+1), 2); 
 # Reduce nCr by the number of pairwise distances that were unmeasurable above 
 $nCr = $nCr-$unmeasurable_distances_count; 
 # Use divide subroutine to divide with BigFloat 
 $mean_distances = divide($sum_distances, $nCr); 
 print FINDCLUSTEROUTPUT "mean of cluster = $mean_distances:"; 
 foreach $unique_cluster_id (sort(keys %unique_cluster_ids_hash)){ 
  print FINDCLUSTEROUTPUT " "."$unique_cluster_id"; 
 } 
 print FINDCLUSTEROUTPUT "\n\n"; 
 close FINDCLUSTEROUTPUT; 
 
 system ("rm -rf $sequences_input_file.temp_R.txt"); 
 system ("rm -rf $sequences_input_file.rscript.R"); 
 system ("rm -rf $sequences_input_file.R_distances.txt"); 
 system ("rm -rf $sequences_input_file.rscript.Rout"); 
} 
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print "\n\nSee 
$sequences_input_file.$support_score.$lower_cluster_size_filter.$upper_cluster_size_filter.findclusteroutpu
t.txt for cluster average pairwise genetic distances.\n\n"; 
 
sub divide{ 
 my ($nom, $denom) = @_; 
 $nom = Math::BigFloat->new($nom); 
 return $nom->copy()->bdiv($denom); 
} 
 
sub bcomb{ 
 my ($n, $r) = @_; 
 $n = Math::BigInt->new($n); 
 $r = Math::BigInt->new($r); 
 my $k = $n - $r; 
 return $n->bfac()/($r->bfac()*$k->bfac()); 
} 
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recentestablishedsorter_adapted_for_infector_assignment.pl 
 
#!usr/bin/perl -w 
 
use strict; 
use warnings; 
use List::Util qw(shuffle); 
 
# 
# File to find number of recent and established infections within a cluster that could have seeded other 
cluster infections 
# 
 
if (defined($ARGV[0])) { 
  open(INPUT1, $ARGV[0]); 
} else { 
  print 'No recent/established status file of the form "sequenceId sampleDate recent/establishedStatus"\n';   
 my $input = <>; 
  open(INPUT1, $input); 
} 
 
if (defined($ARGV[1])) { 
  open(INPUT2, $ARGV[1]); 
} else { 
  print "No treatment experience file, please enter one:\n";   
 my $input = <>; 
  open(INPUT2, $input); 
} 
 
if (defined($ARGV[2])) { 
  open(INPUT3, $ARGV[2]); 
} else { 
  print "No clusters file, please enter one:\n";   
 my $input = <>; 
  open(INPUT3, $input); 
} 
 
my $min_analysis_size; 
if (defined($ARGV[3])) { 
  if($ARGV[3] =~ /\d+/){ 
    $min_analysis_size = $ARGV[3]-1; 
  } else { 
    die ("No minimum cluster size specified\n"); 
  } 
} else { 
   die ("No minimum cluster size specified\n"); 
} 
 
my $recent_phase_length; 
if (defined($ARGV[4])) { 
  if($ARGV[4] =~ /\d+/){ 
    $recent_phase_length = $ARGV[4]; 
  } else { 
    die ("No recent phase length specified as final argument\n"); 
  } 
} else { 
   die ("No recent phase length specified as final argument\n"); 
} 
 
#my $output = "recentestablishedsorter_random.txt"; 
#open(OUTPUT, ">$output"); 
 
my %sequence_infection_status_hash = (); 
my %sequence_sampledate_hash = (); 
my %sequence_therapy_status_hash = (); 
my %sequence_drug_resistance_status_hash = (); 
my %hash_of_cluster_arrays = (); 
my %hash_of_cluster_lengths = (); 
my %hash_upper_dates = (); 
my %hash_lower_dates = (); 
my %duplicate_recents_infection_dates = (); 
my %duplicate_recents_infection_dates_experienced = (); 
my %duplicate_recents_infection_dates_notclassified = (); 
my %duplicate_recents_infection_dates_naive = (); 
 
my $infection_window_for_recents = $recent_phase_length; 
 
while(my $fileline = <INPUT1>){ 
 chomp($fileline); 
 # INPUT1 should be a tab delimited list of sequence id followed by dbsample date as a number 
followed by recent or established status followed by drug resistance (D for drug resistance, S for drug 
sensitive) 
 my @fileline = split(/\t/,$fileline); 
 # Use sequence id as key, and status as value 
 if(!$sequence_infection_status_hash{$fileline[0]}){ 
  $sequence_sampledate_hash{$fileline[0]} = $fileline[1]; 
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  $sequence_infection_status_hash{$fileline[0]} = $fileline[2]; 
  $sequence_drug_resistance_status_hash{$fileline[0]} = $fileline[3]; 
 }else{ 
  die "Sequence $fileline[0] used more than once!\n"; 
 } 
} 
 
while(my $fileline = <INPUT2>){ 
 chomp($fileline); 
 # INPUT2 should be a tab delimited list of sequence id followed by therapy status 
 my @fileline = split(/,/,$fileline); 
 # Use sequence id as key, and status as value 
 if(!$sequence_therapy_status_hash{$fileline[0]}){ 
  $sequence_therapy_status_hash{$fileline[0]} = $fileline[1]; 
 }else{ 
  die "Sequence $fileline[0] used more than once!\n"; 
 } 
} 
 
while(my $fileline = <INPUT3>){ 
 if($fileline =~ /^\s\d/){ 
  chomp($fileline); 
  # USE // WITH split() NOT '' with this form of cluster id - using // means first element 
is empty, because there's a space at the beginning of the line e.g. " 101253 112376 113698" 
  my @clusterarray = split(/\s/, $fileline); 
  splice(@clusterarray,0,1); 
  $hash_of_cluster_arrays{$fileline} = [@clusterarray]; 
  $hash_of_cluster_lengths{$fileline} = @clusterarray; 
 } 
} 
 
##Loop to filter out non-recents 
my %hash_of_recents_cluster_arrays = (); 
my $number_of_suitable_clusters = 0; 
foreach my $unique_cluster_id (sort keys %hash_of_cluster_arrays){ 
 my @recents_array = (); 
 
############################################################ 
# Added in a filter to select for treatment naive patients # 
############################################################ 
 
 foreach my $sequence1 (@{$hash_of_cluster_arrays{$unique_cluster_id}}){ 
  if($sequence_infection_status_hash{$sequence1} eq "recent" && 
$sequence_therapy_status_hash{$sequence1} eq '"Naive"'){ 
   push @recents_array, $sequence1; 
  } 
 } 
 #Must be more than a specified number of recents in the cluster for the ordersorter section to 
work 
 if(scalar @recents_array > $min_analysis_size){ 
  $number_of_suitable_clusters++; 
  $hash_of_recents_cluster_arrays{$unique_cluster_id} = [@recents_array]; 
 } 
} 
 
my $iterations = 10; 
my $count = 0; 
my @temp_array = (); 
my @recents_in_cluster_array = (); 
my @cluster_number_of_recents_array = (); 
my @cluster_number_of_experienced_recents_array = (); 
my @cluster_number_of_naive_recents_array = (); 
my @cluster_number_of_notclassified_recents_array = (); 
my @cluster_number_of_drug_resistance_recents_array = (); 
my @cluster_number_of_experienced_drug_resistance_recents_array = (); 
my @cluster_number_of_naive_drug_resistance_recents_array = (); 
my @cluster_number_of_notclassified_drug_resistance_recents_array = (); 
my @cluster_number_of_establisheds_array = (); 
my @cluster_number_of_experienced_establisheds_array = (); 
my @cluster_number_of_naive_establisheds_array = (); 
my @cluster_number_of_notclassified_establisheds_array = (); 
my @cluster_number_of_drug_resistance_establisheds_array = (); 
my @cluster_number_of_experienced_drug_resistance_establisheds_array = (); 
my @cluster_number_of_naive_drug_resistance_establisheds_array = (); 
my @cluster_number_of_notclassified_drug_resistance_establisheds_array = (); 
my $recents_in_cluster_array = 0; 
my $cluster_number_of_recents_array = 0; 
my $cluster_number_of_experienced_recents_array = 0; 
my $cluster_number_of_naive_recents_array = 0; 
my $cluster_number_of_notclassified_recents_array = 0; 
my $cluster_number_of_drug_resistance_recents_array = 0; 
my $cluster_number_of_experienced_drug_resistance_recents_array = 0; 
my $cluster_number_of_naive_drug_resistance_recents_array = 0; 
my $cluster_number_of_notclassified_drug_resistance_recents_array = 0; 
my $cluster_number_of_establisheds_array = 0; 
my $cluster_number_of_experienced_establisheds_array = 0; 
my $cluster_number_of_naive_establisheds_array = 0; 
my $cluster_number_of_notclassified_establisheds_array = 0; 
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my $cluster_number_of_drug_resistance_establisheds_array = 0; 
my $cluster_number_of_experienced_drug_resistance_establisheds_array = 0; 
my $cluster_number_of_naive_drug_resistance_establisheds_array = 0; 
my $cluster_number_of_notclassified_drug_resistance_establisheds_array = 0; 
 
if(keys %hash_of_recents_cluster_arrays > 0){ 
 my $random1 = 0; 
 my $random2 = 0; 
 my $ordered1 = 0; 
 my $ordered2 = 0; 
 my $fake1 = 0; 
 my $fake2 = 0; 
 my $fake_random1 = 0; 
 my $fake_random2 = 0; 
 ##Loop to randomly assign infectors to infectees 
 while($count < $iterations){ 
  foreach my $unique_cluster_id (sort keys %hash_of_recents_cluster_arrays){ 
   my %random_infector_hash = (); 
   #Date order sequences in cluster to see if there is more than one sequence with 
the earliest date (i.e. the same date) 
   my %dbsample_dates_hash = (); 
   foreach my $sequence1 (@{$hash_of_recents_cluster_arrays{$unique_cluster_id}}){ 
    $dbsample_dates_hash{$sequence1} = $sequence_sampledate_hash{$sequence1}; 
   } 
   my @cluster_members_sorted_by_dbsample_date = (); 
   @cluster_members_sorted_by_dbsample_date = sort{$dbsample_dates_hash{$a} cmp 
$dbsample_dates_hash{$b}} keys %dbsample_dates_hash; 
   %random_infector_hash = 
random_infector_assignment(\@cluster_members_sorted_by_dbsample_date, \%dbsample_dates_hash, 
$unique_cluster_id); 
   @temp_array = 
@{ordersorter($unique_cluster_id,\%random_infector_hash,\%sequence_sampledate_hash)}; 
   push @recents_in_cluster_array, $temp_array[0]; 
   push @cluster_number_of_recents_array, $temp_array[1]; 
   push @cluster_number_of_experienced_recents_array, $temp_array[2]; 
   push @cluster_number_of_naive_recents_array, $temp_array[3]; 
   push @cluster_number_of_notclassified_recents_array, $temp_array[4]; 
   push @cluster_number_of_drug_resistance_recents_array, $temp_array[5]; 
   push @cluster_number_of_experienced_drug_resistance_recents_array, 
$temp_array[6]; 
   push @cluster_number_of_naive_drug_resistance_recents_array, $temp_array[7]; 
   push @cluster_number_of_notclassified_drug_resistance_recents_array, 
$temp_array[8]; 
   push @cluster_number_of_establisheds_array, $temp_array[9]; 
   push @cluster_number_of_experienced_establisheds_array, $temp_array[10]; 
   push @cluster_number_of_naive_establisheds_array, $temp_array[11]; 
   push @cluster_number_of_notclassified_establisheds_array, $temp_array[12]; 
   push @cluster_number_of_drug_resistance_establisheds_array, $temp_array[13]; 
   push @cluster_number_of_experienced_drug_resistance_establisheds_array, 
$temp_array[14]; 
   push @cluster_number_of_naive_drug_resistance_establisheds_array, 
$temp_array[15]; 
   push @cluster_number_of_notclassified_drug_resistance_establisheds_array, 
$temp_array[16]; 
   $recents_in_cluster_array = $recents_in_cluster_array + $temp_array[0]; 
   $cluster_number_of_recents_array = $cluster_number_of_recents_array + 
$temp_array[1]; 
   $cluster_number_of_experienced_recents_array = 
$cluster_number_of_experienced_recents_array + $temp_array[2]; 
   $cluster_number_of_naive_recents_array = $cluster_number_of_naive_recents_array + 
$temp_array[3]; 
   $cluster_number_of_notclassified_recents_array = 
$cluster_number_of_notclassified_recents_array + $temp_array[4]; 
   $cluster_number_of_drug_resistance_recents_array = 
$cluster_number_of_drug_resistance_recents_array + $temp_array[5]; 
   $cluster_number_of_experienced_drug_resistance_recents_array = 
$cluster_number_of_experienced_drug_resistance_recents_array + $temp_array[6]; 
   $cluster_number_of_naive_drug_resistance_recents_array = 
$cluster_number_of_naive_drug_resistance_recents_array + $temp_array[7]; 
   $cluster_number_of_notclassified_drug_resistance_recents_array = 
$cluster_number_of_notclassified_drug_resistance_recents_array + $temp_array[8]; 
   $cluster_number_of_establisheds_array = $cluster_number_of_establisheds_array + 
$temp_array[9]; 
   $cluster_number_of_experienced_establisheds_array = 
$cluster_number_of_experienced_establisheds_array + $temp_array[10]; 
   $cluster_number_of_naive_establisheds_array = 
$cluster_number_of_naive_establisheds_array + $temp_array[11]; 
   $cluster_number_of_notclassified_establisheds_array = 
$cluster_number_of_notclassified_establisheds_array + $temp_array[12]; 
   $cluster_number_of_drug_resistance_establisheds_array = 
$cluster_number_of_drug_resistance_establisheds_array + $temp_array[13]; 
   $cluster_number_of_experienced_drug_resistance_establisheds_array = 
$cluster_number_of_experienced_drug_resistance_establisheds_array + $temp_array[14]; 
   $cluster_number_of_naive_drug_resistance_establisheds_array = 
$cluster_number_of_naive_drug_resistance_establisheds_array + $temp_array[15]; 
   $cluster_number_of_notclassified_drug_resistance_establisheds_array = 
$cluster_number_of_notclassified_drug_resistance_establisheds_array + $temp_array[16]; 
  } 
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  $count++; 
 } 
 
 $random1 = $recents_in_cluster_array/$iterations; 
 print "random:total_of_recent_infection_events_in_clusters:$random1;"; 
 $random2 = $cluster_number_of_recents_array/$iterations; 
 print "random:total_of_recent_phase_infections:$random2;"; 
 
 ##Loop to date order assign infectors to infectees 
 @temp_array = (); 
 @recents_in_cluster_array = (); 
 @cluster_number_of_recents_array = (); 
 @cluster_number_of_experienced_recents_array = (); 
 @cluster_number_of_naive_recents_array = (); 
 @cluster_number_of_notclassified_recents_array = (); 
 @cluster_number_of_drug_resistance_recents_array = (); 
 @cluster_number_of_experienced_drug_resistance_recents_array = (); 
 @cluster_number_of_naive_drug_resistance_recents_array = (); 
 @cluster_number_of_notclassified_drug_resistance_recents_array = (); 
 @cluster_number_of_establisheds_array = (); 
 @cluster_number_of_experienced_establisheds_array = (); 
 @cluster_number_of_naive_establisheds_array = (); 
 @cluster_number_of_notclassified_establisheds_array = (); 
 @cluster_number_of_drug_resistance_establisheds_array = (); 
 @cluster_number_of_experienced_drug_resistance_establisheds_array = (); 
 @cluster_number_of_naive_drug_resistance_establisheds_array = (); 
 @cluster_number_of_notclassified_drug_resistance_establisheds_array = (); 
 $recents_in_cluster_array = 0; 
 $cluster_number_of_recents_array = 0; 
 $cluster_number_of_experienced_recents_array = 0; 
 $cluster_number_of_naive_recents_array = 0; 
 $cluster_number_of_notclassified_recents_array = 0; 
 $cluster_number_of_drug_resistance_recents_array = 0; 
 $cluster_number_of_experienced_drug_resistance_recents_array = 0; 
 $cluster_number_of_naive_drug_resistance_recents_array = 0; 
 $cluster_number_of_notclassified_drug_resistance_recents_array = 0; 
 $cluster_number_of_establisheds_array = 0; 
 $cluster_number_of_experienced_establisheds_array = 0; 
 $cluster_number_of_naive_establisheds_array = 0; 
 $cluster_number_of_notclassified_establisheds_array = 0; 
 $cluster_number_of_drug_resistance_establisheds_array = 0; 
 $cluster_number_of_experienced_drug_resistance_establisheds_array = 0; 
 $cluster_number_of_naive_drug_resistance_establisheds_array = 0; 
 $cluster_number_of_notclassified_drug_resistance_establisheds_array = 0; 
 ##Ordered assignment section 
 foreach my $unique_cluster_id (sort(keys %hash_of_recents_cluster_arrays)){ 
  my %ordered_infector_hash = (); 
  my %dbsample_dates_hash = (); 
  foreach my $sequence1 (@{$hash_of_recents_cluster_arrays{$unique_cluster_id}}){ 
   $dbsample_dates_hash{$sequence1} = $sequence_sampledate_hash{$sequence1}; 
  } 
  my @cluster_members_sorted_by_dbsample_date = (); 
  @cluster_members_sorted_by_dbsample_date = sort{$dbsample_dates_hash{$a} cmp 
$dbsample_dates_hash{$b}} keys %dbsample_dates_hash; 
  my $array_count = 0; 
  foreach (@cluster_members_sorted_by_dbsample_date){ 
   if($array_count < scalar @cluster_members_sorted_by_dbsample_date && $array_count 
> 0){ 
   
 $ordered_infector_hash{$cluster_members_sorted_by_dbsample_date[$array_count]} = 
$cluster_members_sorted_by_dbsample_date[$array_count - 1]; 
   } 
   $array_count++; 
  } 
  @temp_array = 
@{ordersorter($unique_cluster_id,\%ordered_infector_hash,\%sequence_sampledate_hash)}; 
  push @recents_in_cluster_array, $temp_array[0]; 
  push @cluster_number_of_recents_array, $temp_array[1]; 
  push @cluster_number_of_experienced_recents_array, $temp_array[2]; 
  push @cluster_number_of_naive_recents_array, $temp_array[3]; 
  push @cluster_number_of_notclassified_recents_array, $temp_array[4]; 
  push @cluster_number_of_drug_resistance_recents_array, $temp_array[5]; 
  push @cluster_number_of_experienced_drug_resistance_recents_array, $temp_array[6]; 
  push @cluster_number_of_naive_drug_resistance_recents_array, $temp_array[7]; 
  push @cluster_number_of_notclassified_drug_resistance_recents_array, $temp_array[8]; 
  push @cluster_number_of_establisheds_array, $temp_array[9]; 
  push @cluster_number_of_experienced_establisheds_array, $temp_array[10]; 
  push @cluster_number_of_naive_establisheds_array, $temp_array[11]; 
  push @cluster_number_of_notclassified_establisheds_array, $temp_array[12]; 
  push @cluster_number_of_drug_resistance_establisheds_array, $temp_array[13]; 
  push @cluster_number_of_experienced_drug_resistance_establisheds_array, $temp_array[14]; 
  push @cluster_number_of_naive_drug_resistance_establisheds_array, $temp_array[15]; 
  push @cluster_number_of_notclassified_drug_resistance_establisheds_array, $temp_array[16]; 
  $recents_in_cluster_array = $recents_in_cluster_array + $temp_array[0]; 
  $cluster_number_of_recents_array = $cluster_number_of_recents_array + $temp_array[1]; 
  $cluster_number_of_experienced_recents_array = 
$cluster_number_of_experienced_recents_array + $temp_array[2]; 
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  $cluster_number_of_naive_recents_array = $cluster_number_of_naive_recents_array + 
$temp_array[3]; 
  $cluster_number_of_notclassified_recents_array = 
$cluster_number_of_notclassified_recents_array + $temp_array[4]; 
  $cluster_number_of_drug_resistance_recents_array = 
$cluster_number_of_drug_resistance_recents_array + $temp_array[5]; 
  $cluster_number_of_experienced_drug_resistance_recents_array = 
$cluster_number_of_experienced_drug_resistance_recents_array + $temp_array[6]; 
  $cluster_number_of_naive_drug_resistance_recents_array = 
$cluster_number_of_naive_drug_resistance_recents_array + $temp_array[7]; 
  $cluster_number_of_notclassified_drug_resistance_recents_array = 
$cluster_number_of_notclassified_drug_resistance_recents_array + $temp_array[8]; 
  $cluster_number_of_establisheds_array = $cluster_number_of_establisheds_array + 
$temp_array[9]; 
  $cluster_number_of_experienced_establisheds_array = 
$cluster_number_of_experienced_establisheds_array + $temp_array[10]; 
  $cluster_number_of_naive_establisheds_array = $cluster_number_of_naive_establisheds_array 
+ $temp_array[11]; 
  $cluster_number_of_notclassified_establisheds_array = 
$cluster_number_of_notclassified_establisheds_array + $temp_array[12]; 
  $cluster_number_of_drug_resistance_establisheds_array = 
$cluster_number_of_drug_resistance_establisheds_array + $temp_array[13]; 
  $cluster_number_of_experienced_drug_resistance_establisheds_array = 
$cluster_number_of_experienced_drug_resistance_establisheds_array + $temp_array[14]; 
  $cluster_number_of_naive_drug_resistance_establisheds_array = 
$cluster_number_of_naive_drug_resistance_establisheds_array + $temp_array[15]; 
  $cluster_number_of_notclassified_drug_resistance_establisheds_array = 
$cluster_number_of_notclassified_drug_resistance_establisheds_array + $temp_array[16]; 
 } 
 
 $ordered1 = $recents_in_cluster_array; 
 print "ordered:total_of_recent_infection_events_in_clusters:$ordered1;"; 
 $ordered2 = $cluster_number_of_recents_array; 
 print "ordered:total_of_recent_phase_infections:$ordered2;"; 
 
 my @fake_dbsample_dates_temp_array = (); 
 my @fake_dbsample_dates_recents_in_cluster_array = (); 
 my @fake_dbsample_dates_cluster_number_of_recents_array = (); 
 my @fake_dbsample_dates_cluster_number_of_experienced_recents_array = (); 
 my @fake_dbsample_dates_cluster_number_of_naive_recents_array = (); 
 my @fake_dbsample_dates_cluster_number_of_notclassified_recents_array = (); 
 my @fake_dbsample_dates_cluster_number_of_drug_resistance_recents_array = (); 
 my @fake_dbsample_dates_cluster_number_of_experienced_drug_resistance_recents_array = (); 
 my @fake_dbsample_dates_cluster_number_of_naive_drug_resistance_recents_array = (); 
 my @fake_dbsample_dates_cluster_number_of_notclassified_drug_resistance_recents_array = (); 
 my @fake_dbsample_dates_cluster_number_of_establisheds_array = (); 
 my @fake_dbsample_dates_cluster_number_of_experienced_establisheds_array = (); 
 my @fake_dbsample_dates_cluster_number_of_naive_establisheds_array = (); 
 my @fake_dbsample_dates_cluster_number_of_notclassified_establisheds_array = (); 
 my @fake_dbsample_dates_cluster_number_of_drug_resistance_establisheds_array = (); 
 my @fake_dbsample_dates_cluster_number_of_experienced_drug_resistance_establisheds_array = (); 
 my @fake_dbsample_dates_cluster_number_of_naive_drug_resistance_establisheds_array = (); 
 my @fake_dbsample_dates_cluster_number_of_notclassified_drug_resistance_establisheds_array = (); 
 my $fake_dbsample_dates_temp_array = 0; 
 my $fake_dbsample_dates_recents_in_cluster_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_recents_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_experienced_recents_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_naive_recents_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_notclassified_recents_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_drug_resistance_recents_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_experienced_drug_resistance_recents_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_naive_drug_resistance_recents_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_notclassified_drug_resistance_recents_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_establisheds_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_experienced_establisheds_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_naive_establisheds_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_notclassified_establisheds_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_drug_resistance_establisheds_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_experienced_drug_resistance_establisheds_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_naive_drug_resistance_establisheds_array = 0; 
 my $fake_dbsample_dates_cluster_number_of_notclassified_drug_resistance_establisheds_array = 0; 
  
 my @fake_random_dbsample_dates_temp_array = (); 
 my @fake_random_dbsample_dates_recents_in_cluster_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_recents_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_experienced_recents_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_naive_recents_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_notclassified_recents_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_drug_resistance_recents_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_experienced_drug_resistance_recents_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_naive_drug_resistance_recents_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_notclassified_drug_resistance_recents_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_establisheds_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_experienced_establisheds_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_naive_establisheds_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_notclassified_establisheds_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_drug_resistance_establisheds_array = (); 
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 my @fake_random_dbsample_dates_cluster_number_of_experienced_drug_resistance_establisheds_array = 
(); 
 my @fake_random_dbsample_dates_cluster_number_of_naive_drug_resistance_establisheds_array = (); 
 my @fake_random_dbsample_dates_cluster_number_of_notclassified_drug_resistance_establisheds_array 
= (); 
 my $fake_random_dbsample_dates_temp_array = 0; 
 my $fake_random_dbsample_dates_recents_in_cluster_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_recents_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_experienced_recents_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_naive_recents_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_notclassified_recents_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_drug_resistance_recents_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_experienced_drug_resistance_recents_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_naive_drug_resistance_recents_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_notclassified_drug_resistance_recents_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_establisheds_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_experienced_establisheds_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_naive_establisheds_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_notclassified_establisheds_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_drug_resistance_establisheds_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_experienced_drug_resistance_establisheds_array = 
0; 
 my $fake_random_dbsample_dates_cluster_number_of_naive_drug_resistance_establisheds_array = 0; 
 my $fake_random_dbsample_dates_cluster_number_of_notclassified_drug_resistance_establisheds_array 
= 0; 
 
 #Section to generate fake dbsample dated clusters 
 my $count2 = 0; 
 while($count2 < $iterations){ 
  #Must initially use the clusters stored in the recents hash, because these are a subset of 
all clusters as determined by the size selection step when setting up the recents aray hash... 
  foreach my $unique_cluster_id (sort keys %hash_of_recents_cluster_arrays){ 
   my %dbsample_dates_hash = (); 
   my %fake_ordered_infector_hash = (); 
   my %fake_random_infector_hash = (); 
   #...but then, for these clusters, you must get all members (not just recents) to 
set up your fake clusters 
   foreach my $sequence1 (@{$hash_of_cluster_arrays{$unique_cluster_id}}){ 
    $dbsample_dates_hash{$sequence1} = $sequence_sampledate_hash{$sequence1}; 
   } 
   #This variable covers the overall cluster timespan, not just recents 
   my @overall_cluster_members_sorted_by_dbsample_date = (); 
   @overall_cluster_members_sorted_by_dbsample_date = sort{$dbsample_dates_hash{$a} 
cmp $dbsample_dates_hash{$b}} keys %dbsample_dates_hash; 
   #Section to assign random infection dates to infections to compare to scenarios 
above 
   #Get timespan of cluster... 
   my $earliest_cluster_date = 
$sequence_sampledate_hash{$overall_cluster_members_sorted_by_dbsample_date[0]}; 
   my $latest_cluster_date = 
$sequence_sampledate_hash{$overall_cluster_members_sorted_by_dbsample_date[@overall_cluster_members_sorted_
by_dbsample_date-1]}; 
   my $cluster_timespan = $latest_cluster_date - $earliest_cluster_date; 
   #print 
"earliest_cluster_date:$earliest_cluster_date;latest_cluster_date:$latest_cluster_date;timespan:$cluster_ti
mespan\n"; 
   #Then assign each infection a new 'fake' dbsample date based on random selection 
of date within timespan... 
   my %fake_dbsample_dates_hash = (); 
   my $this_count = 0; 
   #This loop goes through members of the original cluster in dbsample order until 
the number matches the number of recents in the real cluster, these sequences, that have essentialy been 
designated recent (but not randomly), then get assigned a random date of infection between the upper and 
lower dbsample dates of the original cluster - thereby introducing the stochastic randoom element into the 
model (i.e. essentially it doesn't matter what sequences are designated recent, as long as their infection 
dates are randomised 
   foreach my $seq_id (@overall_cluster_members_sorted_by_dbsample_date){ 
    if($this_count < scalar 
@{$hash_of_recents_cluster_arrays{$unique_cluster_id}}){ 
     #This recent infection gets a random date assigned 
     $fake_dbsample_dates_hash{$seq_id} = $earliest_cluster_date + 
int(rand($cluster_timespan)); 
    } 
    $this_count++; 
   } 
   my @fake_dbsample_dates_sorted_by_dbsample_date = (); 
   @fake_dbsample_dates_sorted_by_dbsample_date = sort{$fake_dbsample_dates_hash{$a} 
cmp $fake_dbsample_dates_hash{$b}} keys %fake_dbsample_dates_hash; 
   my $array_count2 = 0; 
   foreach (@fake_dbsample_dates_sorted_by_dbsample_date){ 
    if($array_count2 < scalar @fake_dbsample_dates_sorted_by_dbsample_date && 
$array_count2 > 0){ 
    
 $fake_ordered_infector_hash{$fake_dbsample_dates_sorted_by_dbsample_date[$array_count2]} = 
$fake_dbsample_dates_sorted_by_dbsample_date[$array_count2 - 1]; 
    } 
    $array_count2++; 
   } 
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   @fake_dbsample_dates_temp_array = 
@{ordersorter($unique_cluster_id,\%fake_ordered_infector_hash,\%fake_dbsample_dates_hash)}; 
   push @fake_dbsample_dates_recents_in_cluster_array, 
$fake_dbsample_dates_temp_array[0]; 
   push @fake_dbsample_dates_cluster_number_of_recents_array, 
$fake_dbsample_dates_temp_array[1]; 
   push @fake_dbsample_dates_cluster_number_of_experienced_recents_array, 
$fake_dbsample_dates_temp_array[2]; 
   push @fake_dbsample_dates_cluster_number_of_naive_recents_array, 
$fake_dbsample_dates_temp_array[3]; 
   push @fake_dbsample_dates_cluster_number_of_notclassified_recents_array, 
$fake_dbsample_dates_temp_array[4]; 
   push @fake_dbsample_dates_cluster_number_of_drug_resistance_recents_array, 
$fake_dbsample_dates_temp_array[5]; 
   push 
@fake_dbsample_dates_cluster_number_of_experienced_drug_resistance_recents_array, 
$fake_dbsample_dates_temp_array[6]; 
   push @fake_dbsample_dates_cluster_number_of_naive_drug_resistance_recents_array, 
$fake_dbsample_dates_temp_array[7]; 
   push 
@fake_dbsample_dates_cluster_number_of_notclassified_drug_resistance_recents_array, 
$fake_dbsample_dates_temp_array[8]; 
   push @fake_dbsample_dates_cluster_number_of_establisheds_array, 
$fake_dbsample_dates_temp_array[9]; 
   push @fake_dbsample_dates_cluster_number_of_experienced_establisheds_array, 
$fake_dbsample_dates_temp_array[10]; 
   push @fake_dbsample_dates_cluster_number_of_naive_establisheds_array, 
$fake_dbsample_dates_temp_array[11]; 
   push @fake_dbsample_dates_cluster_number_of_notclassified_establisheds_array, 
$fake_dbsample_dates_temp_array[12]; 
   push @fake_dbsample_dates_cluster_number_of_drug_resistance_establisheds_array, 
$fake_dbsample_dates_temp_array[13]; 
   push 
@fake_dbsample_dates_cluster_number_of_experienced_drug_resistance_establisheds_array, 
$fake_dbsample_dates_temp_array[14]; 
   push 
@fake_dbsample_dates_cluster_number_of_naive_drug_resistance_establisheds_array, 
$fake_dbsample_dates_temp_array[15]; 
   push 
@fake_dbsample_dates_cluster_number_of_notclassified_drug_resistance_establisheds_array, 
$fake_dbsample_dates_temp_array[16]; 
   $fake_dbsample_dates_recents_in_cluster_array = 
$fake_dbsample_dates_recents_in_cluster_array + $fake_dbsample_dates_temp_array[0]; 
   $fake_dbsample_dates_cluster_number_of_recents_array = 
$fake_dbsample_dates_cluster_number_of_recents_array + $fake_dbsample_dates_temp_array[1]; 
   $fake_dbsample_dates_cluster_number_of_experienced_recents_array = 
$fake_dbsample_dates_cluster_number_of_experienced_recents_array + $fake_dbsample_dates_temp_array[2]; 
   $fake_dbsample_dates_cluster_number_of_naive_recents_array = 
$fake_dbsample_dates_cluster_number_of_naive_recents_array + $fake_dbsample_dates_temp_array[3]; 
   $fake_dbsample_dates_cluster_number_of_notclassified_recents_array = 
$fake_dbsample_dates_cluster_number_of_notclassified_recents_array + $fake_dbsample_dates_temp_array[4]; 
   $fake_dbsample_dates_cluster_number_of_drug_resistance_recents_array = 
$fake_dbsample_dates_cluster_number_of_drug_resistance_recents_array + $fake_dbsample_dates_temp_array[5]; 
   $fake_dbsample_dates_cluster_number_of_experienced_drug_resistance_recents_array 
= $fake_dbsample_dates_cluster_number_of_experienced_drug_resistance_recents_array + 
$fake_dbsample_dates_temp_array[6]; 
   $fake_dbsample_dates_cluster_number_of_naive_drug_resistance_recents_array = 
$fake_dbsample_dates_cluster_number_of_naive_drug_resistance_recents_array + 
$fake_dbsample_dates_temp_array[7]; 
  
 $fake_dbsample_dates_cluster_number_of_notclassified_drug_resistance_recents_array = 
$fake_dbsample_dates_cluster_number_of_notclassified_drug_resistance_recents_array + 
$fake_dbsample_dates_temp_array[8]; 
   $fake_dbsample_dates_cluster_number_of_establisheds_array = 
$fake_dbsample_dates_cluster_number_of_establisheds_array + $fake_dbsample_dates_temp_array[9]; 
   $fake_dbsample_dates_cluster_number_of_experienced_establisheds_array = 
$fake_dbsample_dates_cluster_number_of_experienced_establisheds_array + 
$fake_dbsample_dates_temp_array[10]; 
   $fake_dbsample_dates_cluster_number_of_naive_establisheds_array = 
$fake_dbsample_dates_cluster_number_of_naive_establisheds_array + $fake_dbsample_dates_temp_array[11]; 
   $fake_dbsample_dates_cluster_number_of_notclassified_establisheds_array = 
$fake_dbsample_dates_cluster_number_of_notclassified_establisheds_array + 
$fake_dbsample_dates_temp_array[12]; 
   $fake_dbsample_dates_cluster_number_of_drug_resistance_establisheds_array = 
$fake_dbsample_dates_cluster_number_of_drug_resistance_establisheds_array + 
$fake_dbsample_dates_temp_array[13]; 
  
 $fake_dbsample_dates_cluster_number_of_experienced_drug_resistance_establisheds_array = 
$fake_dbsample_dates_cluster_number_of_experienced_drug_resistance_establisheds_array + 
$fake_dbsample_dates_temp_array[14]; 
   $fake_dbsample_dates_cluster_number_of_naive_drug_resistance_establisheds_array = 
$fake_dbsample_dates_cluster_number_of_naive_drug_resistance_establisheds_array + 
$fake_dbsample_dates_temp_array[15]; 
  
 $fake_dbsample_dates_cluster_number_of_notclassified_drug_resistance_establisheds_array = 
$fake_dbsample_dates_cluster_number_of_notclassified_drug_resistance_establisheds_array + 
$fake_dbsample_dates_temp_array[16]; 
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   %fake_random_infector_hash = 
random_infector_assignment(\@fake_dbsample_dates_sorted_by_dbsample_date, \%fake_dbsample_dates_hash, 
$unique_cluster_id); 
   @fake_random_dbsample_dates_temp_array = 
@{ordersorter($unique_cluster_id,\%fake_random_infector_hash,\%fake_dbsample_dates_hash)}; 
   push @fake_random_dbsample_dates_recents_in_cluster_array, 
$fake_random_dbsample_dates_temp_array[0]; 
   push @fake_random_dbsample_dates_cluster_number_of_recents_array, 
$fake_random_dbsample_dates_temp_array[1]; 
   push @fake_random_dbsample_dates_cluster_number_of_experienced_recents_array, 
$fake_random_dbsample_dates_temp_array[2]; 
   push @fake_random_dbsample_dates_cluster_number_of_naive_recents_array, 
$fake_random_dbsample_dates_temp_array[3]; 
   push @fake_random_dbsample_dates_cluster_number_of_notclassified_recents_array, 
$fake_random_dbsample_dates_temp_array[4]; 
   push @fake_random_dbsample_dates_cluster_number_of_drug_resistance_recents_array, 
$fake_random_dbsample_dates_temp_array[5]; 
   push 
@fake_random_dbsample_dates_cluster_number_of_experienced_drug_resistance_recents_array, 
$fake_random_dbsample_dates_temp_array[6]; 
   push 
@fake_random_dbsample_dates_cluster_number_of_naive_drug_resistance_recents_array, 
$fake_random_dbsample_dates_temp_array[7]; 
   push 
@fake_random_dbsample_dates_cluster_number_of_notclassified_drug_resistance_recents_array, 
$fake_random_dbsample_dates_temp_array[8]; 
   push @fake_random_dbsample_dates_cluster_number_of_establisheds_array, 
$fake_random_dbsample_dates_temp_array[9]; 
   push 
@fake_random_dbsample_dates_cluster_number_of_experienced_establisheds_array, 
$fake_random_dbsample_dates_temp_array[10]; 
   push @fake_random_dbsample_dates_cluster_number_of_naive_establisheds_array, 
$fake_random_dbsample_dates_temp_array[11]; 
   push 
@fake_random_dbsample_dates_cluster_number_of_notclassified_establisheds_array, 
$fake_random_dbsample_dates_temp_array[12]; 
   push 
@fake_random_dbsample_dates_cluster_number_of_drug_resistance_establisheds_array, 
$fake_random_dbsample_dates_temp_array[13]; 
   push 
@fake_random_dbsample_dates_cluster_number_of_experienced_drug_resistance_establisheds_array, 
$fake_random_dbsample_dates_temp_array[14]; 
   push 
@fake_random_dbsample_dates_cluster_number_of_naive_drug_resistance_establisheds_array, 
$fake_random_dbsample_dates_temp_array[15]; 
   push 
@fake_random_dbsample_dates_cluster_number_of_notclassified_drug_resistance_establisheds_array, 
$fake_random_dbsample_dates_temp_array[16]; 
   $fake_random_dbsample_dates_recents_in_cluster_array = 
$fake_random_dbsample_dates_recents_in_cluster_array + $fake_random_dbsample_dates_temp_array[0]; 
   $fake_random_dbsample_dates_cluster_number_of_recents_array = 
$fake_random_dbsample_dates_cluster_number_of_recents_array + $fake_random_dbsample_dates_temp_array[1]; 
   $fake_random_dbsample_dates_cluster_number_of_experienced_recents_array = 
$fake_random_dbsample_dates_cluster_number_of_experienced_recents_array + 
$fake_random_dbsample_dates_temp_array[2]; 
   $fake_random_dbsample_dates_cluster_number_of_naive_recents_array = 
$fake_random_dbsample_dates_cluster_number_of_naive_recents_array + 
$fake_random_dbsample_dates_temp_array[3]; 
   $fake_random_dbsample_dates_cluster_number_of_notclassified_recents_array = 
$fake_random_dbsample_dates_cluster_number_of_notclassified_recents_array + 
$fake_random_dbsample_dates_temp_array[4]; 
   $fake_random_dbsample_dates_cluster_number_of_drug_resistance_recents_array = 
$fake_random_dbsample_dates_cluster_number_of_drug_resistance_recents_array + 
$fake_random_dbsample_dates_temp_array[5]; 
  
 $fake_random_dbsample_dates_cluster_number_of_experienced_drug_resistance_recents_array = 
$fake_random_dbsample_dates_cluster_number_of_experienced_drug_resistance_recents_array + 
$fake_random_dbsample_dates_temp_array[6]; 
   $fake_random_dbsample_dates_cluster_number_of_naive_drug_resistance_recents_array 
= $fake_random_dbsample_dates_cluster_number_of_naive_drug_resistance_recents_array + 
$fake_random_dbsample_dates_temp_array[7]; 
  
 $fake_random_dbsample_dates_cluster_number_of_notclassified_drug_resistance_recents_array = 
$fake_random_dbsample_dates_cluster_number_of_notclassified_drug_resistance_recents_array + 
$fake_random_dbsample_dates_temp_array[8]; 
   $fake_random_dbsample_dates_cluster_number_of_establisheds_array = 
$fake_random_dbsample_dates_cluster_number_of_establisheds_array + 
$fake_random_dbsample_dates_temp_array[9]; 
   $fake_random_dbsample_dates_cluster_number_of_experienced_establisheds_array = 
$fake_random_dbsample_dates_cluster_number_of_experienced_establisheds_array + 
$fake_random_dbsample_dates_temp_array[10]; 
   $fake_random_dbsample_dates_cluster_number_of_naive_establisheds_array = 
$fake_random_dbsample_dates_cluster_number_of_naive_establisheds_array + 
$fake_random_dbsample_dates_temp_array[11]; 
   $fake_random_dbsample_dates_cluster_number_of_notclassified_establisheds_array = 
$fake_random_dbsample_dates_cluster_number_of_notclassified_establisheds_array + 
$fake_random_dbsample_dates_temp_array[12]; 
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   $fake_random_dbsample_dates_cluster_number_of_drug_resistance_establisheds_array 
= $fake_random_dbsample_dates_cluster_number_of_drug_resistance_establisheds_array + 
$fake_random_dbsample_dates_temp_array[13]; 
  
 $fake_random_dbsample_dates_cluster_number_of_experienced_drug_resistance_establisheds_array = 
$fake_random_dbsample_dates_cluster_number_of_experienced_drug_resistance_establisheds_array + 
$fake_random_dbsample_dates_temp_array[14]; 
  
 $fake_random_dbsample_dates_cluster_number_of_naive_drug_resistance_establisheds_array = 
$fake_random_dbsample_dates_cluster_number_of_naive_drug_resistance_establisheds_array + 
$fake_random_dbsample_dates_temp_array[15]; 
  
 $fake_random_dbsample_dates_cluster_number_of_notclassified_drug_resistance_establisheds_array = 
$fake_random_dbsample_dates_cluster_number_of_notclassified_drug_resistance_establisheds_array + 
$fake_random_dbsample_dates_temp_array[16]; 
  } 
  $count2++; 
 } 
  
 $fake1 = $fake_dbsample_dates_recents_in_cluster_array/$iterations; 
 print "fake:total_of_recent_infection_events_in_clusters:$fake1;"; 
 $fake2 = $fake_dbsample_dates_cluster_number_of_recents_array/$iterations; 
 print "fake:total_of_recent_phase_infections:$fake2;"; 
 
 my $temp_fake = $fake1-$fake2; 
 
 system ("rm -rf fisher.rscript.R"); 
 system ("rm -rf fisher.Rout.txt"); 
 system ("rm -rf fisher.rscript.Rout"); 
 
 my $temp_random = $random1-$random2; 
 open(RSCRIPT, ">fisher.rscript.R"); 
 print RSCRIPT "x <- matrix(c($random2,$temp_random,$fake2,$temp_fake),nc=2)\n"; 
 print RSCRIPT "y <- fisher.test(x)\n"; 
 print RSCRIPT "write.table(print(c(y\$p.value,y\$estimate,y\$conf.int)), file='fisher.Rout.txt', 
quote=F, row.names=F, col.names=F, eol='\\n')\n"; 
 close RSCRIPT; 
 
 system ("R CMD BATCH fisher.rscript.R"); 
 
 open(RSCRIPTINPUT, "fisher.Rout.txt"); 
 
 my $counter1 = 0; 
 my @fisher_array1; 
 while(my $fileline = <RSCRIPTINPUT>){ 
  chomp($fileline); 
  $fisher_array1[$counter1] = $fileline; 
  $counter1++; 
 } 
 print "random_vs_fake;p-
value;$fisher_array1[0];odds_ratio;$fisher_array1[1];95pc_lower_conf_int;$fisher_array1[2];95pc_upper_conf_
int;$fisher_array1[3];"; 
  
 system ("rm -rf fisher.rscript.R"); 
 system ("rm -rf fisher.Rout.txt"); 
 system ("rm -rf fisher.rscript.Rout"); 
 
 $fake_random1 = $fake_random_dbsample_dates_recents_in_cluster_array/$iterations; 
 print "fake_random:total_of_recent_infection_events_in_clusters:$fake_random1;"; 
 $fake_random2 = $fake_random_dbsample_dates_cluster_number_of_recents_array/$iterations; 
 print "fake_random:total_of_recent_phase_infections:$fake_random2;"; 
 
 my $temp_fake_random = $fake_random1-$fake_random2; 
 open(RSCRIPT, ">fisher.rscript.R"); 
 print RSCRIPT "x <- matrix(c($random2,$temp_random,$fake_random2,$temp_fake_random),nc=2)\n"; 
 print RSCRIPT "y <- fisher.test(x)\n"; 
 print RSCRIPT "write.table(print(c(y\$p.value,y\$estimate,y\$conf.int)), file='fisher.Rout.txt', 
quote=F, row.names=F, col.names=F, eol='\\n')\n"; 
 close RSCRIPT; 
 
 system ("R CMD BATCH fisher.rscript.R"); 
 
 open(RSCRIPTINPUT, "fisher.Rout.txt"); 
 
 my $counter2 = 0; 
 my @fisher_array2; 
 while(my $fileline = <RSCRIPTINPUT>){ 
  chomp($fileline); 
  $fisher_array2[$counter2] = $fileline; 
  $counter2++; 
 } 
 print "random_vs_fake_random;p-
value;$fisher_array2[0];odds_ratio;$fisher_array2[1];95pc_lower_conf_int;$fisher_array2[2];95pc_upper_conf_
int;$fisher_array2[3];"; 
  
 system ("rm -rf fisher.rscript.R"); 
 system ("rm -rf fisher.Rout.txt"); 
 system ("rm -rf fisher.rscript.Rout"); 
247 
 
 
 my $temp_ordered = $ordered1-$ordered2; 
 open(RSCRIPT, ">fisher.rscript.R"); 
 print RSCRIPT "x <- matrix(c($ordered2,$temp_ordered,$fake2,$temp_fake),nc=2)\n"; 
 print RSCRIPT "y <- fisher.test(x)\n"; 
 print RSCRIPT "write.table(print(c(y\$p.value,y\$estimate,y\$conf.int)), file='fisher.Rout.txt', 
quote=F, row.names=F, col.names=F, eol='\\n')\n"; 
 close RSCRIPT; 
 
 system ("R CMD BATCH fisher.rscript.R"); 
 
 open(RSCRIPTINPUT, "fisher.Rout.txt"); 
 
 my $counter3 = 0; 
 my @fisher_array3; 
 while(my $fileline = <RSCRIPTINPUT>){ 
  chomp($fileline); 
  $fisher_array3[$counter3] = $fileline; 
  $counter3++; 
 } 
 print "ordered_vs_fake;p-
value;$fisher_array3[0];odds_ratio;$fisher_array3[1];95pc_lower_conf_int;$fisher_array3[2];95pc_upper_conf_
int;$fisher_array3[3];"; 
 
}else{ 
 print "#!!# No clusters to process given the current criteria for numbers of recents #!!#;"; 
} 
 
print "iterations:$iterations;"; 
  
print "number_of_suitable_clusters:$number_of_suitable_clusters\n"; 
 
close INPUT1; 
close INPUT2; 
close INPUT3; 
#close OUTPUT; 
 
sub random_infector_assignment{ 
 my @same_first_date_array = (); 
 my ($cluster_members_sorted_by_dbsample_date_ref, $dbsample_dates_hash_ref, $unique_cluster_id) = 
@_; 
 my @cluster_members_sorted_by_dbsample_date = @{$cluster_members_sorted_by_dbsample_date_ref}; 
 my %dbsample_dates_hash = %{$dbsample_dates_hash_ref}; 
 foreach my $temp_key (@cluster_members_sorted_by_dbsample_date){ 
  if($temp_key != $cluster_members_sorted_by_dbsample_date[0] && 
$dbsample_dates_hash{$temp_key} == $dbsample_dates_hash{$cluster_members_sorted_by_dbsample_date[0]}){ 
   push @same_first_date_array, $temp_key; 
  } 
 } 
 ##Random assignment section 
 my %random_infector_hash = (); 
 foreach my $sequence1 (@cluster_members_sorted_by_dbsample_date){ 
  my @potential_infector_array; 
  foreach my $sequence2 (@cluster_members_sorted_by_dbsample_date){ 
   if($sequence1 != $sequence2 && $sequence_sampledate_hash{$sequence2} < 
$sequence_sampledate_hash{$sequence1}){ 
    push @potential_infector_array, $sequence2; 
   } 
  } 
  my $random_array_element; 
  if(scalar @potential_infector_array > 0){ 
   $random_infector_hash{$sequence1} = $potential_infector_array[rand 
@potential_infector_array]; 
  } 
 } 
 #Check you have two or more seqs with same date that is the oldest date in the cluster recents, if 
so then make the original one from above ordering the random infector of the others, as they all have same 
date, sothen just add the first sequence with the same first date to all the subsequent ones, to make sure 
you have them all 
 if(scalar @same_first_date_array > 0){ 
  #first add in the original oldest sequence from above, so you have all of them 
  push @same_first_date_array, $cluster_members_sorted_by_dbsample_date[0]; 
  my @shuffled_same_first_date_array = shuffle(@same_first_date_array); 
  my $array_count = 0; 
  foreach (@shuffled_same_first_date_array){ 
   if($array_count < scalar @shuffled_same_first_date_array && $array_count > 0){ 
    $random_infector_hash{$shuffled_same_first_date_array[$array_count]} = 
$shuffled_same_first_date_array[$array_count - 1]; 
   } 
   $array_count++; 
  } 
 } 
 return %random_infector_hash; 
} 
 
sub ordersorter{ 
 my ($unique_cluster_id, $infector_hash_ref, $temp_dbsample_date_hash_ref) = @_; 
 my %infector_hash = %{$infector_hash_ref}; 
248 
 
 my %temp_dbsample_date_hash = %{$temp_dbsample_date_hash_ref}; 
 my $recents_in_cluster = scalar keys %infector_hash; 
 my $recent = 0; 
 my $experienced_recent = 0; 
 my $naive_recent = 0; 
 my $notclassified_recent = 0; 
 my $drug_resistance_recent = 0; 
 my $experienced_drug_resistance_recent = 0; 
 my $naive_drug_resistance_recent = 0; 
 my $notclassified_drug_resistance_recent = 0; 
 
 my $established = 0; 
 my $experienced_established = 0; 
 my $naive_established = 0; 
 my $notclassified_established = 0; 
 my $drug_resistance_established = 0; 
 my $experienced_drug_resistance_established = 0; 
 my $naive_drug_resistance_established = 0; 
 my $notclassified_drug_resistance_established = 0; 
 
 foreach my $sequence1 (sort keys %infector_hash){ 
  #print "$sequence1 $temp_dbsample_date_hash{$sequence1} $infector_hash{$sequence1} 
$temp_dbsample_date_hash{$infector_hash{$sequence1}}\n"; 
  # This foreach goes through each sequence, and then the inner while compares each outer 
sequence to all the other cluster members 
  #$recents_in_cluster++; 
  if($temp_dbsample_date_hash{$sequence1} - $infection_window_for_recents < 
$temp_dbsample_date_hash{$infector_hash{$sequence1}}){ 
   $recent++; 
   if($sequence_therapy_status_hash{$infector_hash{$sequence1}} eq '"Experienced"'){ 
    $experienced_recent++; 
    if($sequence_drug_resistance_status_hash{$infector_hash{$sequence1}} eq 
"D"){ 
     $drug_resistance_recent++; 
     $experienced_drug_resistance_recent++; 
    } 
   }elsif($sequence_therapy_status_hash{$infector_hash{$sequence1}} eq '"Naive"'){ 
    $naive_recent++; 
    if($sequence_drug_resistance_status_hash{$infector_hash{$sequence1}} eq 
"D"){ 
     $drug_resistance_recent++; 
     $naive_drug_resistance_recent++; 
    } 
   }elsif($sequence_therapy_status_hash{$infector_hash{$sequence1}} eq '"Not 
classified"'){ 
    $notclassified_recent++; 
    if($sequence_drug_resistance_status_hash{$infector_hash{$sequence1}} eq 
"D"){ 
     $drug_resistance_recent++; 
     $notclassified_drug_resistance_recent++; 
    } 
   } 
  }else{ 
   $established++; 
   if($sequence_therapy_status_hash{$infector_hash{$sequence1}} eq '"Experienced"'){ 
    $experienced_established++; 
    if($sequence_drug_resistance_status_hash{$infector_hash{$sequence1}} eq 
"D"){ 
     $drug_resistance_established++; 
     $experienced_drug_resistance_established++; 
    } 
   }elsif($sequence_therapy_status_hash{$infector_hash{$sequence1}} eq '"Naive"'){ 
    $naive_established++; 
    if($sequence_drug_resistance_status_hash{$infector_hash{$sequence1}} eq 
"D"){ 
     $drug_resistance_established++; 
     $naive_drug_resistance_established++; 
    } 
   }elsif($sequence_therapy_status_hash{$infector_hash{$sequence1}} eq '"Not 
classified"'){ 
    $notclassified_established++; 
    if($sequence_drug_resistance_status_hash{$infector_hash{$sequence1}} eq 
"D"){ 
     $drug_resistance_established++; 
    $notclassified_drug_resistance_established++; 
    } 
   } 
  } 
 } 
 
 my @array_of_results = ($recents_in_cluster, $recent, $experienced_recent, $naive_recent, 
$notclassified_recent, $drug_resistance_recent, $experienced_drug_resistance_recent, 
$naive_drug_resistance_recent, $notclassified_drug_resistance_recent, $established, 
$experienced_established, $naive_established, $notclassified_established, $drug_resistance_established, 
$experienced_drug_resistance_established, $naive_drug_resistance_established, 
$notclassified_drug_resistance_established); 
 return \@array_of_results; 
}  
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genetic_distance_model.pl 
 
#!usr/bin/perl -w 
 
use strict; 
use warnings; 
 
# 
# File to find number of recent and established infections within a cluster that could have seeded other 
cluster infections 
# 
 
if (defined($ARGV[0])) { 
  open(INPUT1, $ARGV[0]); 
} else { 
  print 'No recent/established status file of the form "sequenceId sampleDate recent/establishedStatus"\n';   
 my $input = <>; 
  open(INPUT1, $input); 
} 
 
if (defined($ARGV[1])) { 
  open(INPUT2, $ARGV[1]); 
} else { 
  print "No treatment experience file, please enter one:\n";   
 my $input = <>; 
  open(INPUT2, $input); 
} 
 
if (defined($ARGV[2])) { 
  open(INPUT3, $ARGV[2]); 
 
} else { 
  print "No clusters file, please enter one:\n";   
 my $input = <>; 
  open(INPUT3, $input); 
} 
 
#Input4 is a file that has been preprocessed by an awk command such as: awk '($9 !~ /NA/ && $9 <= 0.03) && 
$0 !~ /^mean/' 
/home/virology/Perl/re_doing/REGA_subtype_subsets/DRAM_subsets/findcluster94.5/REGA_b_subtype_subset_non_du
plicate_DRAM_sequences.94.5.0.2000.findclusteroutput.txt  > testing_short_distances 
#In other words, it is a list of pairwise distances generated by the findclusterdistances.pl script - but 
this can be easily adapted 
if (defined($ARGV[3])) { 
  open(INPUT4, $ARGV[3]); 
} else { 
  print "No pairwise distances file, please enter one:\n";   
 my $input = <>; 
  open(INPUT4, $input); 
} 
#my $output = "genetic_distance_model_output"; 
#open(OUTPUT, ">$output"); 
 
my %sequence_infection_status_hash = (); 
my %sequence_sampledate_hash = (); 
my %sequence_therapy_status_hash = (); 
my %sequence_drug_resistance_status_hash = (); 
my %hash_of_cluster_arrays = (); 
my %hash_of_cluster_lengths = (); 
my %hash_of_pairwise_distances = (); 
my %hash_of_recent_phase = (); 
my $infection_window_for_recents = 125; 
while(my $fileline = <INPUT1>){ 
 chomp($fileline); 
 # INPUT1 should be a tab delimited list of sequence id followed by dbsample date as a number 
followed by recent or established status followed by drug resistance (D for drug resistance, S for drug 
sensitive) 
 my @fileline = split(/\t/,$fileline); 
 # Use sequence id as key, and status as value 
 if(!$sequence_infection_status_hash{$fileline[0]}){ 
  $sequence_sampledate_hash{$fileline[0]} = $fileline[1]; 
  $sequence_infection_status_hash{$fileline[0]} = $fileline[2]; 
  $sequence_drug_resistance_status_hash{$fileline[0]} = $fileline[3]; 
 }else{ 
  die "Sequence $fileline[0] used more than once!\n"; 
 } 
} 
while(my $fileline = <INPUT2>){ 
 chomp($fileline); 
 # INPUT2 should be a tab delimited list of sequence id followed by therapy status 
 my @fileline = split(/,/,$fileline); 
 # Use sequence id as key, and status as value 
 if(!$sequence_therapy_status_hash{$fileline[0]}){ 
  $sequence_therapy_status_hash{$fileline[0]} = $fileline[1]; 
 }else{ 
  die "Sequence $fileline[0] used more than once!\n"; 
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 } 
} 
while(my $fileline = <INPUT3>){ 
 if($fileline =~ /^\s\d/){ 
  chomp($fileline); 
  # USE // WITH split() NOT '' with this form of cluster id - using // means first element 
is empty, because there's a space at the beginning of the line e.g. " 101253 112376 113698" 
  my @clusterarray = split(/\s/, $fileline); 
  splice(@clusterarray,0,1); 
  $hash_of_cluster_arrays{$fileline} = [@clusterarray]; 
  $hash_of_cluster_lengths{$fileline} = @clusterarray; 
 } 
} 
while(my $fileline = <INPUT4>){ 
 chomp($fileline); 
 if($fileline =~ /Distance between node (\d+) and node (\d+) is (\d+\.\d+)/){ 
  #This just generates a unique key of the form largestSequenceId_smallestSequenceId 
  if($1 > $2){ 
   my $key = $1."_".$2; 
   $hash_of_pairwise_distances{$key} = $3; 
  }else{ 
   my $key = $2."_".$1; 
   $hash_of_pairwise_distances{$key} = $3; 
  } 
 } 
} 
foreach my $unique_cluster_id (sort keys %hash_of_cluster_arrays){ 
 my %hash_of_pairwise_distances_done = (); 
 my %hash_to_check_overcount = (); 
 my @temp_array = (); 
 foreach my $sequence1 (@{$hash_of_cluster_arrays{$unique_cluster_id}}){ 
  foreach my $sequence2 (@{$hash_of_cluster_arrays{$unique_cluster_id}}){ 
   my $key = 0; 
   if($sequence1 != $sequence2){ 
    if($sequence1 > $sequence2){ 
     $key = $sequence1."_".$sequence2; 
    }else{ 
     $key = $sequence2."_".$sequence1; 
    } 
   } 
   if($hash_of_pairwise_distances{$key} && !$hash_of_pairwise_distances_done{$key}){ 
    $hash_of_pairwise_distances_done{$key} = 1; 
    my @temp_nodes_array = split(/_/,$key); 
     
    if(($sequence_infection_status_hash{$temp_nodes_array[0]} eq "recent") && 
($sequence_infection_status_hash{$temp_nodes_array[1]} eq "recent")){ 
     if(abs($sequence_sampledate_hash{$temp_nodes_array[0]} - 
$sequence_sampledate_hash{$temp_nodes_array[1]}) <= $infection_window_for_recents){ 
      #This checks that you don't overcount transmission 
because of something like A-B, A-C and B-C: one of these is excluded by the other two (if you do not count 
super-infection!) 
      if($hash_to_check_overcount{$temp_nodes_array[0]} && 
$hash_to_check_overcount{$temp_nodes_array[1]}){ 
       print "overcount: $temp_nodes_array[0], 
$temp_nodes_array[1]\n"; 
      }else{ 
       $hash_to_check_overcount{$temp_nodes_array[0]} 
= 1; 
       $hash_to_check_overcount{$temp_nodes_array[1]} 
= 1; 
       push @temp_array, 
$temp_nodes_array[0]."_".$temp_nodes_array[1]; 
      } 
     } 
    } 
   } 
  } 
 } 
 if(scalar(@temp_array) > 0){ 
  $hash_of_recent_phase{$unique_cluster_id} = \@temp_array; 
 } 
} 
 
foreach my $unique_cluster_id (sort keys %hash_of_recent_phase){ 
 print "\n$unique_cluster_id\n"; 
 my @array = @{$hash_of_recent_phase{$unique_cluster_id}}; 
 foreach my $pair (@array){ 
  print "$pair\n"; 
 } 
} 
 
close INPUT1; 
close INPUT2; 
close INPUT3; 
close INPUT4; 
#close OUTPUT; 
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nucleotide_type_counter.pl 
 
#!usr/bin/perl -w 
 
# Program for taking sequences and converting them into a IUPAC containing consensus sequence 
use Bio::SimpleAlign; 
use Bio::AlignIO; 
use Bio::SeqIO; 
use Bio::PopGen::Utilities; 
use Bio::Tools::Run::StandAloneBlast; 
use Data::Dumper; 
 
if (defined($ARGV[0])) {$sequences_input_file = $ARGV[0]} else {die "Missing file";} 
if (defined($ARGV[1])) {$sanger_pol_seqs_file = $ARGV[1]} else {die "Missing file";} 
 
my $sample_name = $sequences_input_file; 
$sample_name =~ s/_usearch_primerstripped_pol_f_and_r_main_orf390_aligned_degapped\.fasta3//g; 
 
my $aln_obj = Bio::AlignIO->new(-file => $sequences_input_file); 
my $seq_obj = Bio::SeqIO->new(-file => $sanger_pol_seqs_file, -format => 'fasta'); 
 
my %all_sanger_pols_hash = (); 
my $pol_sanger_seq_obj; 
my $temp_sample_name = $sample_name."_sanger"; 
while (my $seq = $seq_obj->next_seq()){ 
 if($seq->display_id eq ($temp_sample_name)){ 
  $pol_sanger_seq_obj = $seq; 
 } 
} 
 
my $aln = $aln_obj->next_aln(); 
 
my $pop = Bio::PopGen::Utilities->aln_to_population(-alignment=>$aln, -include_monomorphic => 1); 
my @marker_names = $pop->get_marker_names; 
my %predominant_variant_hash = (); 
foreach $marker_name (@marker_names){ 
 my $variant_count = 0; 
 my %temp_allele_hash = (); 
# print "marker_name:$marker_name\t"; 
 my $marker = $pop->get_Marker($marker_name); 
 my %allele_freqs = $marker->get_Allele_Frequencies; 
 foreach my $allele (keys %allele_freqs){ 
  #get any allele above a minimum threshold and store it in a temporary hash 
  if($allele_freqs{$allele} >= 0.02){ 
   $variant_count++; 
   $temp_allele_hash{$allele} = $allele_freqs{$allele}; 
  } 
 } 
 my $switch = 0; 
 my $position = 0; 
 foreach my $allele_ordered (sort {$temp_allele_hash{$b} <=> $temp_allele_hash{$a}} (keys 
%temp_allele_hash)){ 
#  print "$allele_ordered\t$temp_allele_hash{$allele_ordered}\t"; 
  #this switch is just to generate a 'consensus' sequence with the most predomiant allele at 
each position 
  if(!$switch){ 
   $position = $marker_name; 
   #convert marker name to number by removing prefix 
   $position =~ s/Site-//g; 
   $predominant_variant_hash{$position} = $allele_ordered; 
   $switch = 1; 
  } 
 } 
# print "\n"; 
} 
my $counter = 0; 
my $predominant_variant; 
foreach my $key (sort {$a <=> $b} (keys %predominant_variant_hash)){ 
 $predominant_variant .= $predominant_variant_hash{$key}; 
} 
 
my $predominant_variant_seq_obj = new Bio::Seq->new(-display_id => $sample_name, -seq => 
$predominant_variant); 
 
my $blast_factory = Bio::Tools::Run::StandAloneBlast->new(-outfile => 'bl2seq.out', -program => "blastn"); 
my $blast_report = $blast_factory->bl2seq($predominant_variant_seq_obj,$pol_sanger_seq_obj); 
$align_obj = Bio::AlignIO->new(-file => 'bl2seq.out', -format => 'bl2seq'); 
 
my $hsp = $blast_report->next_result->next_hit->next_hsp; 
#print Dumper($hsp); 
my $predom_start = $hsp->{'QUERY_START'}; 
my $pol_start = $hsp->{'HIT_START'}; 
 
my $pairwise_alignment = $align_obj->next_aln(); 
 
my $mapping_from_unaligned_predominant_variant_seq_to_aligned_predominant_variant_seq = $predom_start - 1; 
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my @reduced_marker_names; 
#correct a copy of the original marker names with the mapping info 
my $index = $mapping_from_unaligned_predominant_variant_seq_to_aligned_predominant_variant_seq; 
#print "index:$index\n"; 
my @copy_marker_names = @marker_names; 
@reduced_marker_names = splice(@copy_marker_names, $index); 
 
my @aligned_seq_array = (); 
my $array_count = 0; 
foreach my $aligned_seq ($pairwise_alignment->each_seq()){ 
 if($aligned_seq->display_id =~ /sanger/){ 
  $pol_sanger_seq_aligned = $aligned_seq; 
 }else{ 
  $predominant_variant_aligned = $aligned_seq; 
 } 
} 
 
#print $predominant_variant_aligned->seq."\n"; 
#print $pol_sanger_seq_aligned->seq."\n"; 
 
my @predominant_variant_aligned_array = split("", $predominant_variant_aligned->seq); 
my @pol_sanger_seq_aligned = split("", $pol_sanger_seq_aligned->seq); 
 
$length = scalar @predominant_variant_aligned_array; 
my $predom_gaps = 0; 
my $acgt_agreements = 0; 
my $iupac_agreements = 0; 
my $disagreements = 0; 
my $second_most_abundant_variant_agreements = 0; 
my $gap_disagreements = 0; 
for($i=0; $i<$length; $i++){ 
 if($predominant_variant_aligned_array[$i] eq $pol_sanger_seq_aligned[$i]){ 
#  print "agree:\t$predominant_variant_aligned_array[$i]\t$pol_sanger_seq_aligned[$i]\n"; 
  $acgt_agreements++; 
 }else{ 
   
  $disagreements++; 
  if($predominant_variant_aligned_array[$i] eq "-"){ 
   $gap_disagreements++; 
   $predom_gaps++; 
  }else{ 
   my $temp_marker_name = $reduced_marker_names[$i-$predom_gaps]; 
   my $temp_marker = $pop->get_Marker($temp_marker_name); 
   my %temp_allele_freqs = $temp_marker->get_Allele_Frequencies; 
   my @temp_alleles_array = (); 
   my $temp_alleles_string = (); 
   my $temp_variant_count = 0; 
   foreach my $temp_allele (sort {$temp_allele_freqs{$b} <=> $temp_allele_freqs{$a}} 
(keys %temp_allele_freqs)){ 
    #get any allele above a minimum threshold and store it in a temporary 
hash - this cut-off can be something to do with when mixed base peaks start appearing, e.g.20-30% - but 
actually I have seen that there is better iupac agreement with lower cut-offs, e.g. there are a few 
instances where the ~11% minority variant still appears to contribute to the ambiguity in sanger (e.g. 
Pool1_TC10) 
    print 
"disag$i:\t$predominant_variant_aligned_array[$i]\t$pol_sanger_seq_aligned[$i]\t$temp_allele 
$temp_allele_freqs{$temp_allele}\n"; 
     if($temp_allele_freqs{$temp_allele} >= 0.02){ 
#     print "\t$temp_allele $temp_allele_freqs{$temp_allele}"; 
     $temp_allele =~ tr/A-Z/a-z/; 
     push(@temp_alleles_array, $temp_allele); 
     $temp_alleles_string .= $temp_allele; 
     $temp_variant_count++; 
    } 
   } 
   $temp_alleles_string =~ tr/uU/tT/; 
   if($temp_alleles_string =~ /a/ && $temp_alleles_string =~ /g/ && 
$temp_variant_count == 2){ 
    if($pol_sanger_seq_aligned[$i] eq "r"){ 
#     print "\tiupac_agrees:\tr\t$pol_sanger_seq_aligned[$i]"; 
     $iupac_agreements++; 
    }else{ 
#     print "\tiupac_disagrees:\tr\t$pol_sanger_seq_aligned[$i]"; 
     if($temp_alleles_array[1] eq $pol_sanger_seq_aligned[$i]){ 
      $second_most_abundant_variant_agreements++; 
     } 
    } 
   }elsif($temp_alleles_string =~ /c/ && $temp_alleles_string =~ /t/ && 
$temp_variant_count == 2){ 
    if($pol_sanger_seq_aligned[$i] eq "y"){ 
#     print "\tiupac_agrees:\ty\t$pol_sanger_seq_aligned[$i]"; 
     $iupac_agreements++; 
    }else{ 
#     print "\tiupac_disagrees:\ty\t$pol_sanger_seq_aligned[$i]"; 
     if($temp_alleles_array[1] eq $pol_sanger_seq_aligned[$i]){ 
      $second_most_abundant_variant_agreements++; 
     } 
253 
 
    } 
   }elsif($temp_alleles_string =~ /c/ && $temp_alleles_string =~ /a/ && 
$temp_variant_count == 2){ 
    if($pol_sanger_seq_aligned[$i] eq "m"){ 
#     print "\tiupac_agrees:\tm\t$pol_sanger_seq_aligned[$i]"; 
     $iupac_agreements++; 
    }else{ 
#     print "\tiupac_disagrees:\tm\t$pol_sanger_seq_aligned[$i]"; 
     if($temp_alleles_array[1] eq $pol_sanger_seq_aligned[$i]){ 
      $second_most_abundant_variant_agreements++; 
     } 
    } 
   }elsif($temp_alleles_string =~ /t/ && $temp_alleles_string =~ /g/ && 
$temp_variant_count == 2){ 
    if($pol_sanger_seq_aligned[$i] eq "k"){ 
#     print "\tiupac_agrees:\tk\t$pol_sanger_seq_aligned[$i]"; 
     $iupac_agreements++; 
    }else{ 
#     print "\tiupac_disagrees:\tk\t$pol_sanger_seq_aligned[$i]"; 
     if($temp_alleles_array[1] eq $pol_sanger_seq_aligned[$i]){ 
      $second_most_abundant_variant_agreements++; 
     } 
    } 
   }elsif($temp_alleles_string =~ /t/ && $temp_alleles_string =~ /a/ && 
$temp_variant_count == 2){ 
    if($pol_sanger_seq_aligned[$i] eq "w"){ 
#     print "\tiupac_agrees:\tw\t$pol_sanger_seq_aligned[$i]"; 
     $iupac_agreements++; 
    }else{ 
#     print "\tiupac_disagrees:\tw\t$pol_sanger_seq_aligned[$i]"; 
     if($temp_alleles_array[1] eq $pol_sanger_seq_aligned[$i]){ 
      $second_most_abundant_variant_agreements++; 
     } 
    } 
   }elsif($temp_alleles_string =~ /c/ && $temp_alleles_string =~ /g/ && 
$temp_variant_count == 2){ 
    if($pol_sanger_seq_aligned[$i] eq "s"){ 
#     print "\tiupac_agrees:\ts\t$pol_sanger_seq_aligned[$i]"; 
     $iupac_agreements++; 
    }else{ 
#     print "\tiupac_disagrees:\ts\t$pol_sanger_seq_aligned[$i]"; 
     if($temp_alleles_array[1] eq $pol_sanger_seq_aligned[$i]){ 
      $second_most_abundant_variant_agreements++; 
     } 
    } 
   }elsif($temp_alleles_string =~ /c/ && $temp_alleles_string =~ /t/ && 
$temp_alleles_string =~ /g/ && $temp_variant_count == 3){ 
    if($pol_sanger_seq_aligned[$i] eq "b"){ 
#     print "\tiupac_agrees:\tb\t$pol_sanger_seq_aligned[$i]"; 
     $iupac_agreements++; 
    }else{ 
#     print "\tiupac_disagrees:\tb\t$pol_sanger_seq_aligned[$i]"; 
     if($temp_alleles_array[1] eq $pol_sanger_seq_aligned[$i]){ 
      $second_most_abundant_variant_agreements++; 
     } 
    } 
   }elsif($temp_alleles_string =~ /a/ && $temp_alleles_string =~ /t/ && 
$temp_alleles_string =~ /g/ && $temp_variant_count == 3){ 
    if($pol_sanger_seq_aligned[$i] eq "d"){ 
#     print "\tiupac_agrees:\td\t$pol_sanger_seq_aligned[$i]"; 
     $iupac_agreements++; 
    }else{ 
#     print "\tiupac_disagrees:\td\t$pol_sanger_seq_aligned[$i]"; 
     if($temp_alleles_array[1] eq $pol_sanger_seq_aligned[$i]){ 
      $second_most_abundant_variant_agreements++; 
     } 
    } 
   }elsif($temp_alleles_string =~ /a/ && $temp_alleles_string =~ /t/ && 
$temp_alleles_string =~ /c/ && $temp_variant_count == 3){ 
    if($pol_sanger_seq_aligned[$i] eq "h"){ 
#     print "\tiupac_agrees:\th\t$pol_sanger_seq_aligned[$i]"; 
     $iupac_agreements++; 
    }else{ 
#     print "\tiupac_disagrees:\th\t$pol_sanger_seq_aligned[$i]"; 
     if($temp_alleles_array[1] eq $pol_sanger_seq_aligned[$i]){ 
      $second_most_abundant_variant_agreements++; 
     } 
    } 
   }elsif($temp_alleles_string =~ /a/ && $temp_alleles_string =~ /c/ && 
$temp_alleles_string =~ /g/ && $temp_variant_count == 3){ 
    if($pol_sanger_seq_aligned[$i] eq "v"){ 
#     print "\tiupac_agrees:\tv\t$pol_sanger_seq_aligned[$i]"; 
     $iupac_agreements++; 
    }else{ 
#     print "\tiupac_disagrees:\tv\t$pol_sanger_seq_aligned[$i]"; 
     if($temp_alleles_array[1] eq $pol_sanger_seq_aligned[$i]){ 
      $second_most_abundant_variant_agreements++; 
     } 
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    } 
   }elsif($temp_alleles_string =~ /a/ && $temp_alleles_string =~ /c/ && 
$temp_alleles_string =~ /g/ && $temp_alleles_string =~ /t/ && $temp_variant_count == 4){ 
    if($pol_sanger_seq_aligned[$i] eq "n"){ 
#     print "\tiupac_agrees:\tn\t$pol_sanger_seq_aligned[$i]"; 
     $iupac_agreements++; 
    }else{ 
#     print "\tiupac_disagrees:\tn\t$pol_sanger_seq_aligned[$i]"; 
     if($temp_alleles_array[1] eq $pol_sanger_seq_aligned[$i]){ 
      $second_most_abundant_variant_agreements++; 
     } 
    } 
   }else{ 
#    print 
"\tstill_does_not_agree:$temp_alleles_string\t$pol_sanger_seq_aligned[$i]"; 
   } 
  } 
#  print "\n"; 
 } 
} 
 
#print "acgt_agreements:$acgt_agreements, iupac_agreements:$iupac_agreements, disagreements:$disagreements, 
second_most_abundant_variant_agreements:$second_most_abundant_variant_agreements, 
gap_disagreements:$gap_disagreements\n"; 
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Appendix 3: Subtype and read abundance for each time point for each patient with 
multiple time points available.  Percentages may not sum to 100% if not all reads 
mapped to the subpopulations present at >1%. 
 
Patient
Time 
point
Weeks post-
diagnosis COMET subtype % abundance COMET subtype % abundance
Patient 1 T0 14 B 98.8 B 52.7
B 17.9
B 14.5
B 11.0
T1 27 B 96.0 B 53.9
B 3.4 B 6.5
B 3.3
B 2.0
B 3.0
B 2.7
B 5.7
B 5.5
B 8.0
T2 39 B 97.7 B 20.8
B 10.0
B 3.3
B 9.9
B 2.7
B 9.3
B 19.9
B 2.3
B 6.2
B 1.8
T3 53 B 89.2 B 65.3
B 7.8 B 2.1
B 2.6
B 6.8
B 3.4
B 3.4
B 5.0
T4 71 B 97.4 B 52.7
B 2.5 B 3.3
B 6.9
B 3.0
B 14.2
B 3.0
B 1.8
B 8.5
Patient 2 T0 8 B 98.0 B 98.4
T1 19 B 99.5 B 97.1
T2 30 B 89.0 B 95.7
B 5.5 B 2.7
T3 33 B 99.2 B 96.8
B 1.9
Pol Env
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Patient
Time 
point
Weeks post-
diagnosis COMET subtype % abundance COMET subtype % abundance
Patient 4 T0 3 B 96.5 B 92.2
B 1.7 B 6.0
T1 8 B 57.6 B 76.7
B 34.8 B 19.5
B 2.5 B 2.4
T2 11 B 54.5 B 67.7
B 20.3 B 24.3
B 19.5 B 6.0
B 4.5
T3 19 B 56.9 B 40.6
B 2.7 B 26.9
B 31.3 B 19.3
B 5.7 B 8.6
T4 28 B 57.1 B 60.3
B 20.9 B 10.0
B 11.0 B 8.0
D 1.9 B 9.3
B 6.3
B 3.4
T5 33 B 49.5 B 50.1
B 11.3 B 24.2
B 34.0 B 2.4
B 8.0
B 2.1
B 3.6
B 1.8
B 3.6
Patient 8 T0 21 B 80.5 B 96.2
B 16.7 A1 2.5
T1 26 B 90.8 B (check for 15_01B) 88.4
B 2.4 A1 6.9
A1 (check for 02_AG) 3.9
T2 30 B 98.3 B (check for 15_01B) 68.7
unassigned_1;D, A1 30.8
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Patient
Time 
point
Weeks post-
diagnosis COMET subtype % abundance COMET subtype % abundance
Patient 9 T0 18 02_AG 95.4 A1 (check for 02_AG) 34.9
02_AG 4.5 A1 (check for 02_AG) 2.1
A1 (check for 02_AG) 7.9
A1 (check for 02_AG) 7.0
A1 (check for 02_AG) 1.7
A1 (check for 02_AG) 1.8
A1 (check for 02_AG) 4.7
02_AG 6.8
A1 (check for 02_AG) 3.3
A1 (check for 02_AG) 3.3
02_AG 5.3
A1 (check for 02_AG) 5.3
A1 (check for 02_AG) 2.0
T1 27 02_AG 95.2 A1 (check for 02_AG) 45.1
A1 (check for 02_AG) 2.0
A1 (check for 02_AG) 3.4
A1 (check for 02_AG) 8.7
A1 (check for 02_AG) 5.5
A1 (check for 02_AG) 5.5
A1 (check for 02_AG) 6.0
A1 (check for 02_AG) 1.6
A1 (check for 02_AG) 1.8
A1 (check for 02_AG) 2.6
A1 (check for 02_AG) 2.8
A1 (check for 02_AG) 3.2
A1 (check for 02_AG) 3.0
T2 40 02_AG 69.1 A1 (check for 02_AG) 53.1
02_AG 23.2 02_AG 2.8
A1 (check for 02_AG) 3.2
A1 (check for 02_AG) 1.7
A1 (check for 02_AG) 2.6
A1 (check for 02_AG) 3.5
A1 (check for 02_AG) 7.8
A1 (check for 02_AG) 2.4
02_AG 2.1
A1 (check for 02_AG) 2.0
A1 (check for 02_AG) 3.5
A1 (check for 02_AG) 2.9
T3 62 02_AG 92.0 A1 (check for 02_AG) 53.3
A1 (check for 02_AG) 1.8
A1 (check for 02_AG) 10.6
A1 (check for 02_AG) 2.0
A1 (check for 02_AG) 3.4
A1 (check for 02_AG) 10.5
A1 (check for 02_AG) 4.7
Pol Env
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Patient
Time 
point
Weeks post-
diagnosis COMET subtype % abundance COMET subtype % abundance
Patient 13 T0 0 B 91.9 B 85.7
B 3.2
B 3.8
B 7.0
T1 1 B 84.9 B 73.8
B 6.2 B (check for 15_01B) 12.8
B 3.3 B 2.3
B 2.6 B 8.1
B 2.4
T2 3 B 85.7 B 75.6
B 3.7 B 4.3
B 5.2 B 7.3
B 4.1 B 4.1
B 6.8
T3 10 B 90.5 B 70.9
B 3.0 B 5.4
B 1.7 B 3.1
B 1.7 B 7.2
B 2.1
B 3.1
T4 14 B 82.3 B 38.8
B 2.8 B 3.6
B 4.7 B 9.6
B 3.5 B 4.8
B 3.2
B 6.2
B 8.3
B 3.9
B 1.8
B 1.6
B 2.5
B 5.5
B 1.9
T5 16 B 83.5 B 31.8
B 3.5 B 2.8
B 3.5 B 3.3
B 2.8 B 2.9
B 1.8
B 5.5
B 12.8
B 7.9
B 4.5
B 3.2
B 5.8
B 5.8
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Patient
Time 
point
Weeks post-
diagnosis COMET subtype % abundance COMET subtype % abundance
Patient 23 T0 0 B 99.5 B 94.8
B (check for 29_BF) 3.0
T1 0 B 99.8 B 97.5
T2 10 B 98.9 B 99.0
Patient 35 T0 0 B 99.1 B 99.2
T1 1 B 97.3 B 95.0
T2 3 B 99.8 B 99.2
Patient 36 T0 1 B (check for 29_BF) 99.4 B 99.9
T1 7 B (check for 29_BF) 83.6 B 55.1
B (check for 12_BF) 11.1 A1 44.2
T2 25 B (check for 29_BF) 57.3 A1 75.3
B (check for 29_BF) 3.2 F1 16.0
B (check for 29_BF) 15.6 F1 5.1
B (check for 29_BF) 3.4 A1 2.5
D (check for 17_BF) 3.2
T3 37 B (check for 29_BF) 60.7 A1 (check for 02_AG) 94.1
B (check for 29_BF) 19.5 B 5.0
B 2.1
B 3.0
B 2.0
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